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Abstract 
 
Background:  Epilepsy is a common and very heterogeneous neurologic disorder which shows a 
predilection towards the pediatric population.  Idiopathic epilepsy (IE) refers to cases with no 
known underlying etiology other than a presumed genetic predisposition.  IE accounts for 
approximately half of all cases of epilepsy.  Newfoundland and Labrador has a tertiary referral 
center for pediatric neurology patients where virtually all children living on the Avalon 
Peninsula are treated.  The current study aims to determine the clinical and genetic 
epidemiologic characteristics in this population. 
 
Purpose:  To describe the incidence, genetic and clinical epidemiology of pediatric IE in the 
province of Newfoundland and Labrador. 
 
Methods:  All children < 15 years of age with IE were ascertained through the provincial 
pediatric neurology clinic at the Janeway Child Health Centre.  Family history, medical history 
and blood samples were obtained from affected children and their family members.  All blood 
samples were screened for mutations in the seven candidate genes (SCN1A, SCN2A, SCN1B, 
KCNQ2, GABRA1, GABRG2 and KCNQ3) of highest priority, based on previously reported 
phenotype-genotype relationships, by direct bidirectional Sanger DNA sequencing. 
 
Results:  The mean annual incidence of IE for the population of children living on the Avalon 
region of Newfoundland from 2000 to 2004 was 107 per 100 000.  This rate is approximately 
three-fold greater than comparable populations in other developed countries.  Incidence was 
similar in males and females.  Multiple different epilepsy phenotypes were identified between 
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and amongst families. Of 117 families with IE eligible for study, 86 (74%) provided detailed 
pedigree data. Fifty-five families (64%) had a positive family history.  Eight (9%) of these had 
family histories compatible with autosomal dominant (AD) inheritance and these families lived 
in five different geographic isolates.  DNA was obtained from 79 individuals in 21 families.  
Seven genes previously associated with childhood epilepsy were sequenced and excluded in all 
but one family which had a pathogenic mutation in SCN1A.  This gene encodes a sodium channel 
subunit and a novel missense mutation (c.1162T>C, p.Tyr388His) was identified in a multiplex 
family segregating a severe, clinically novel form of autosomal dominant generalized epilepsy 
with febrile seizures plus (GEFS+).  The phenotype was consistent with GEFS+, with a variable 
phenotype that included mood and anxiety disorders, as well as ataxia – thereby expanding the 
phenotypic spectrum of GEFS+ to include neuropsychiatric disease.  
 
Conclusions:  The incidence of IE in the Avalon Peninsula of Newfoundland is three times 
higher than comparison populations and the rate of familial disease is high throughout the 
province of Newfoundland and Labrador.  The distribution of familial and AD IE in different 
geographic isolates, together with the clinical heterogeneity of disease, suggests substantial 
genetic heterogeneity.  A novel SCN1A mutation and phenotype was identified.   
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Chapter 1 
 
Introduction and Overview 
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1 Introduction 
1.1 Rationale 
Epilepsy is a common, chronic neurological disorder marked by disturbed electrical 
rhythms of the central nervous system and typically manifested by recurrent convulsive attacks 
known as seizures.  It creates a significant burden for the affected individual, their family and 
society.  The lifetime prevalence of all epilepsies is 2-5% (Shorvon 1990; Hauser, Annegers et 
al. 1996) and the average incidence is approximately 40 to 80 per 100 000 children (Blom, 
Heijbel et al. 1978; Camfield, Camfield et al. 1996; Olafsson, Hauser et al. 1996; Zarrelli, Beghi 
et al. 1999; Freitag, May et al. 2001; Forsgren, Beghi et al. 2005; Theodore, Spencer et al. 2006).  
The heritability of epilepsy, as measured by the concordance rate between twin pairs, has been 
estimated to be 70-88%; that is, 70-88% of the liability to develop epilepsy can be accounted for 
by genetic factors (Kjeldsen, Kyvik et al. 2001).  Family studies have shown a risk to the sibling 
of an affected person with epilepsy is approximately 2.5 to 4 fold greater than the general 
population risk (Annegers, Rocca et al. 1996).  
Worldwide, the epilepsies are the second most common neurologic disorder, second only 
to headaches.  In developing countries, the epilepsies are the most common neurologic disorder.  
In the United States, the epilepsies are second only to cerebrovascular disease and stroke.  Of the 
40 to 100 million persons with epilepsy worldwide, approximately 50% have generalized 
seizures.  Among the generalized epilepsies, the most common are juvenile myoclonus epilepsy 
(JME) with 10% to 30% of cases, childhood absence epilepsy (CAE) with 5% to 15% of cases, 
and tonic-clonic seizures on awakening with 22% to 37% of cases (Delgado-Escueta, Medina et 
al. 1999).  Moreover, certain types of seizures are unique to children, including absence, JME 
seizures, and most febrile seizures.  Age-specific incidence studies of epilepsy have 
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demonstrated that the highest peak occurs in childhood (Kotsopoulos, van Merode et al. 2002). 
Thus, a disproportionately large number of children are burdened by epilepsy disorders. 
The prognosis of patients with childhood epilepsy varies widely, depending on the type, 
frequency and severity of the individual’s seizures or syndrome, as well as the patient’s response 
to treatment, environmental factors and the severity of any underlying etiology.  Many children 
with epilepsy respond well to treatment, achieve seizure control and experience no long term 
psychomotor deficits.  However, there are also many cases of childhood epilepsy with intractable 
seizures despite various treatment regimens, as well as devastating long term cognitive and 
motor impairments, and even, in rare cases, death.  
Although epilepsy research over the last two decades has uncovered many important 
findings into the molecular genetic basis of the common epilepsies, the prevalence and incidence 
have not decreased, and there is no known cure for the epilepsies.  Researchers in the field of 
epilepsy are now cognizant that identifying mutations for the idiopathic generalized epilepsies 
could lead to curative treatment and eventual elimination of 25% to 35% of all epilepsies (Baulac 
and Baulac 2009; Michelucci, Pasini et al. 2012; Pandolfo 2012).  Much research attention has 
begun to focus on mapping, positional cloning, and mutation analyses of the common 
generalized and partial epilepsies. 
 
1.2 Objectives 
1) To describe the incidence of pediatric IE on the Avalon Peninsula of Newfoundland, over 
a five year period. 
2) To classify cases of pediatric IE based on clinical manifestations. 
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3) To determine the geographical distribution of pediatric IE, in the province of 
Newfoundland and Labrador.  
4)  To identify families likely to have a monogenic form of IE and to determine the 
underlying genetic etiology of these families. 
   
1.3 Classification of epilepsy 
Epilepsies are a diverse group of disorders with both shared and distinct features.  
Classification allows a coherent, systematic approach and serves as a universal language between 
physicians and health care providers all over the world.  Classifying and describing seizure 
disorders with shared clinical and EEG (electroencephalography) features, plays an important 
role in the field of epilepsy research.  Increasingly, classification systems are being refined as 
new information becomes available and our understanding of the etiology and presentation of 
each syndrome widens.  Advances in neuroimaging and neurogenetics have been particularly 
important and are likely to fundamentally change our concepts of syndrome classification.  
 
1.3.1 Seizure and epilepsy classification systems 
The International League Against Epilepsy (ILAE) is a worldwide association of 
physicians and other health professionals which disseminates research findings on epilepsy and 
related seizure disorders through periodic publications interpreting relevant data pertaining to 
concepts and organizational systems to guide classification of seizures and epilepsies.  In 1981 
and 1989, respectively, the ILAE published guidelines for seizure and epilepsy classification and 
terminology.  They recommended a system which classifies epilepsy syndromes according to 
presumed localization (partial, generalized, undetermined) and etiology (idiopathic, cryptogenic, 
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symptomatic).  This became the most widely accepted and utilized classification system used 
worldwide (ILAE 1981; ILAE 1989).   
The classification system divides seizures into those of partial onset and those of 
generalized onset, depending on whether the initial clinical manifestations indicate that one 
cortical region or both hemispheres are involved at the onset of the seizure.  The undetermined 
group includes patients in which localization was not possible (ILAE 1989; Commission 1993; 
Engel 2006).  A seizure is considered to be generalized when the EEG finding is consistent with 
a generalized pattern and when assessment of clinical symptoms provides no indication of an 
anatomic localization and no clinical evidence of partial onset.   
When possible, three main generalized seizure subtypes are recognized: 
 Generalized convulsive seizures with predominantly tonic, clonic, or tonic-clonic features; 
 Generalized nonconvulsive seizures represented by absence seizures; 
 Myoclonic seizures (Commission 1993). 
In patients who have experienced several types of generalized seizures, each seizure type must 
be categorized. 
Partial seizures are divided into simple partial seizures, in which a fully conscious state is 
retained, or complex partial seizures, in which consciousness is impaired.  A seizure should be 
classified as partial when there is evidence of a clinical partial onset, regardless of whether the 
seizure is secondarily generalized.  The first clinical signs of a seizure have a highly localizing 
value and result from the anatomic or functional neuronal activation of part of one hemisphere.  
When alertness and ability to interact appropriately with the environment is maintained, the 
seizure is classified as a simple partial seizure.  When impairment of consciousness, amnesia, or 
confusion during or after a seizure is reported, the seizure is classified as a complex partial 
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seizure.  When the distinction between simple and complex partial seizure cannot be made, from 
information provided by history or medical records, the seizure is classified as partial epileptic 
seizure of unknown type.  When a patient has several types of partial seizures, each should be 
separately categorized.  When a patient becomes secondarily generalized, the seizure is classified 
as a partial seizure, secondarily generalized (simple or complex) (ILAE 1989; Commission 1993; 
Commission 1993).  This system has the advantage that seizures can be classified relatively 
easily and choice of an antiepileptic drug (AED) is dictated by seizure type. 
Within the generalized and localized groups, there are further subdivisions into 
idiopathic, cryptogenic or symptomatic.  Idiopathic epilepsies are generally genetic, and while 
many such syndromes have been described, advances in molecular genetics will undoubtedly 
reveal many more syndromes in the near future.  Cryptogenic epilepsies are those in which an 
underlying environmental or somatic cause is suspected, but the etiology remains unknown.  
Epilepsies for which there is an underlying structural cause or major metabolic derangement are 
considered symptomatic (Edwards 2001).  This classification is complex and many syndromes 
are not adequately defined.  At initial presentation, it may not be possible to identify the 
syndrome.  Only a small proportion of patients easily fit into specific syndromes while a large 
proportion fall into non-specific categories.  
Prior to the guidelines published by the ILAE, international classification of seizure 
disorders relied on the use of clinical and EEG criteria.  However, EEG is often unavailable or 
impractical.  Such is the case in many field surveys, population polls, and in rural or 
undeveloped regions, worldwide.  Therefore, in 1981, the ILAE established these classification 
criteria based predominantly on clinical data.  The criteria was later revised in subsequent papers 
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published in 1989, 1993, and 2004 (Okuma 2004).  Each subsequent article was meant to 
supplement the previous classification system. 
In clinical practice, these guidelines are often useful to conceptualize epilepsy syndromes 
according to their usual age at presentation, which greatly facilitates syndrome identification in 
new patients and recognizes the age-related expression of many childhood epilepsies.  However, 
classification problems exist for many pediatric epilepsy syndromes, particularly the epileptic 
encephalopathies of early infancy, the benign epilepsies of infancy and childhood, the myoclonic 
epilepsies of infancy and early childhood, and the idiopathic generalized epilepsies of childhood 
and adolescence (Duchowny and Harvey 1996).  The clinical manifestation of epileptic seizures 
may vary widely from patient to patient, depending on the region of the brain involved.  It is 
likely that further input from the fields of molecular genetics and neuroimaging will enable the 
classification of epilepsies to become more etiologically oriented and disease specific.  Presently, 
classification of epilepsy diagnosis according to seizure phenotype is complex due to the 
diversity of clinical manifestations and the heterogeneity of seizures and other clinical 
manifestations within and between individuals and families.  
There have been several attempts to update the concepts as new research findings 
emerged, but no new proposal was implemented until 2010 when the ILAE made several 
changes to the system (ILAE 1989; Engel 2006).  These changes reflect the modifications to 
modern neuroimaging and our improved understanding of the molecular biology of epilepsy 
(Berg, Berkovic et al. 2010).  As science progresses, health care professionals and researchers 
must evolve as well, in order to facilitate these advances.  However, the retrospective design of 
the current study limited the ability for adaptation of new concepts and terminology.  It would 
create significant selection bias to alter the inclusion and diagnostic criteria toward the end of the 
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study and apply these concepts to patients that have been previously enrolled, diagnosed, and 
classified.  As a result, the modifications made by the ILAE in 2010 were considered to be 
additive to our current knowledge of epilepsy concepts, but we did not use the modifications 
suggested to alter the sample set.  Figure 1 provides an overview of the primary classifications, 
including the traditional system, along with the recent modifications. 
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Figure 1. Overview of epilepsy classification systems.  Modifications made by the ILAE in 
2010 are shown in brackets.  
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1.3.2 Defining epilepsy and epileptic seizures 
Defining the term epilepsy has been met with some disagreement due to the fact that 
epilepsy is not a singular disease entity but rather a variety of disorders reflecting underlying 
brain dysfunction resulting from multiple different causes.  However, establishing definitions 
that can be broadly agreed upon is important for communication among medical professionals as 
well as determining parameters for those involved in legislation, disability benefits, driving 
regulations, workplace safety, education, etc.  Consensus discussions amongst representatives of 
the ILAE have resulted in a definition of epilepsy that encompasses three elements; (1) history of 
at least one seizure, (2) enduring alteration in the brain that increases the likelihood of future 
seizures and (3) associated neurobiologic, cognitive, psychological, and social disturbances.  
These elements are articulated in the following definition; “epilepsy is a disorder of the brain 
characterized by an enduring predisposition to generate epileptic seizures and by the 
neurobiologic, cognitive, psychological, and social consequences of this condition.  The 
definition of epilepsy requires the occurrence of at least one epileptic seizure.” (Fisher, van 
Emde Boas et al. 2005). 
ILAE representatives also agreed upon a definition of epileptic seizure that encompasses 
three elements; (1) the mode of onset and termination, (2) clinical manifestations and (3) 
abnormal enhanced synchrony.  The resulting definition is as follows; “an epileptic seizure is a 
transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous 
neuronal activity in the brain”.  The clinical manifestation consists of sudden and transitory 
abnormal phenomena which may include alterations of consciousness, motor, sensory, 
autonomic, or psychic events, perceived by the patient or an observer (Commission 1993).   
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It is important to note that during an epileptic seizure, firing of neurons may involve inhibition as 
well as excitation.  Thus, the key feature of neuronal networks generating an epileptic seizure 
involves abnormal enhanced synchrony of neurons, not simply excessive neuronal activity as 
once thought (Fisher, van Emde Boas et al. 2005). 
However, as indicated by the definition of epilepsy, all seizures do not indicate epilepsy.  
Specifically, an individual may experience a seizure(s) but not fit the diagnostic criteria for 
epilepsy for multiple reasons.  For example, an individual will not be diagnosed with epilepsy if 
they only experience one seizure, if they experience multiple seizures but they occur within the 
same 24-hour period, or if the seizures are provoked by some cause such as fever or some 
precipitating event, such as head trauma or a seizure-related disorder other than epilepsy.   
The ILAE defines idiopathic seizures as unprovoked seizures occurring in the absence 
of a historical insult demonstrated to increase the risk of unprovoked seizures.  The presence of 
an unexplained localized abnormality on neurologic examination (i.e. a reflex asymmetry) or 
identified in the diagnostic workup (i.e. focal slowing or focal spike on EEG examination, 
lesions of uncertain etiology identified on computed tomography or magnetic resonance 
imaging) are not excluded from this category.  The ILAE reserves the term “idiopathic” for cases 
of presumed genetic origin.  Thus, most cases in the idiopathic category would be further 
classified as cryptogenic upon assessment of neurological exams and/or sophisticated testing 
(Hauser, Annegers et al. 1991). 
 
1.4 Pathophysiology of an epileptic seizure 
An epileptic seizure is an episode of neurologic dysfunction in which abnormal neuronal 
firing is manifest clinically by changes in motor control, sensory perception, behavior, and/or 
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autonomic function.  Epilepsy is the condition of recurrent spontaneous seizures arising from 
aberrant electrical activity within the brain.  While anyone can experience a seizure under the 
appropriate pathophysiological conditions, epilepsy suggests an enduring alteration of brain 
function that facilitates seizure recurrence.  Epileptogenesis is the process by which the normal 
brain becomes prone to epilepsy.  The aberrant electrical activity that underlies epilepsy is the 
result of biochemical processes at the cellular level promoting neuronal hyperexcitability and 
neuronal hypersynchrony.  However, a single neuron, discharging abnormally, is insufficient to 
produce a clinical seizure, which occurs only in the context of large neuronal networks.  Cortical 
and several key subcortical structures are involved in generating a seizure.  At a basic cellular 
level, an epileptic seizure may be understood to represent an imbalance between excitatory and 
inhibitory currents within neural circuits of the brain.  A seizure occurs when a burst of electrical 
impulses (excitatory) in the brain exceed the threshold for normal functionality.  The burst then 
spreads to neighbouring areas of the brain and creates an uncontrolled “storm” of electrical 
activity within the cortical nerve cells.  These electrical impulses may be transmitted to the 
muscles causing twitching and/or convulsions. 
 
1.5 Diagnosing epilepsy 
A diagnosis of epilepsy is typically made after a patient is evaluated following one or 
more suspected seizures.  Although the diagnostic techniques vary based upon the resources 
available, diagnosis for the current study was made following a thorough clinical work up 
involving family, medical, and seizure histories, and neurological examinations including 
electroencephalography (EEG) and magnetic resonance imaging (MRI).   
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1.5.1 Electroencephalography 
Electroencephalography is a method of measuring electrical activity along the scalp.  It 
uses an electroencephalograph to measure voltage fluctuations resulting from ionic current flows 
within the neurons of the brain and provide a record of the brain’s ongoing electrical activity.  
Apart from the patient history and the neurological exam, the EEG is the most influential tool in 
the diagnosis of seizures and epilepsy.  EEGs were first conducted in the latter parts of the 19th 
century.  At this time they were utilized by just a few researchers, who performed their 
experiments on animal brains.  It wasn’t until the 1920s that the first EEG was conducted on a 
human subject.  Since then, the EEG has been critical in both the research and clinical settings 
for assessments relating to the diagnosis of comas, brain tumours, stroke and encephalopathies; 
for the use in studying sleep and sleep disorders and particularly in neurology for diagnosing 
epilepsy (Swartz and Goldensohn 1998).   
Simply stated, an EEG measures the electrical activity of the brain.  However, this 
measurement is usually confined to the brain activity adjacent to the scalp, as EEG is not 
efficient at measuring the electric activity beneath the surface (cortex) of the brain.  In other 
words, it has poor spatial resolution.  Since neurons are electrically charged, particularly at the 
cortex, and many millions of neurons fire synchronously, an EEG can detect the electric potential 
of these cells.  The EEG can identify the oscillations at different frequencies, that can be 
characteristic of particular types of brain activity (e.g. during walking or sleeping) or irregular 
activity (e.g. during seizures).  These oscillations can have certain frequency ranges and spatial 
distributions.  These differing outputs are highly informative as they not only indicate a seizure 
but may also provide insight regarding the type of seizure and particular form of epilepsy.  The 
EEG tracing, with its record of electrical discharge, provides a record of activity in key areas of 
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the brain during the period of the test.  Excessive discharge (of the type that may cause a seizure) 
may show up as a sharp spike or series of spikes; some patterns (such as the 3-per-second spike 
and wave of absence seizures) are unique to particular forms of epilepsy.   
The encephalographer may try to evoke a seizure in order to obtain an EEG recording 
during the episode.  Through photic stimulation, a flashing light is used to assess whether the 
patient is photosensitive, that is, if he or she will have a seizure in response to the stimulus of a 
flashing light.  Hyperventilation (rapid over breathing) is another common trigger for seizures 
and is also a feature of an EEG assessment.  Almost all patients with typical absence seizures 
who are not receiving antiepilepsy medication will have the characteristic 3-per-second spike 
wave EEG pattern during hyperventilation. Patients may be asked to go to sleep during the test 
because EEG abnormalities are more likely to show up during sleep.  Various ictal (seizure) and 
interictal (between seizure) EEG patterns correspond to specific seizure types and types of 
epilepsy, although the correlation varies.  While the EEG is almost always abnormal during a 
seizure, it may be normal between seizures.  Thus, lack of interictal EEG abnormalities does not 
exclude a diagnosis of epilepsy.  However, at some time, most epilepsy patients have abnormal 
EEG discharges.  In contrast, some persons with EEGs that show epilepsy-like activity never 
have seizures.  Thus physicians interpret EEG results within the context of other information 
they are gathering.  See Figure 2 for a normal EEG pattern (A) and an EEG recording taken 
during an absence seizure showing the characteristic 3-per-second spike wave pattern (B). 
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(A)  
(B)  
Figure 2. Normal and abnormal EEG recordings. (A) EEG recording of a normal brain 
showing no unusual activity (B) EEG recording of an absence seizure showing the 
distinctive 3-per-second spike and wave discharge. (www.epilepsy.com/EEG). Signal 
intensity measured in microvolts. 
 
In neurology, EEG has also been particularly useful for distinguishing epileptic seizures 
from other types of events such as migraines, movement disorders and non-epileptic seizures.  It 
can also be useful to characterize seizures for the purposes of treatment and to localize the part of 
the brain that is being affected by seizures, which is helpful for phenotyping or when brain 
surgery is warranted.  The patient undergoing an EEG has electrodes placed on their scalp, which 
can be fastened in the form of individual electrodes or electrodes placed within a net or cap.  The 
placement and names of electrodes is very specific and is specified by an international system in 
order to standardize between labs and clinics.  The display of the EEG, mostly read by 
neurologists, represents the differences between two electrodes.  As there are numerous 
electrodes (approximately 19 in low density arrays and several hundred in high-density arrays) 
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there are many possible representations of the EEG channels.  The manner in which the 
encephalographer sets up the EEG is referred to as a montage.  There are a number of standard 
montages, including sequential, referential and average reference (Lagerlund 2000).   
Although the EEG is a very old technology and relatively primitive compared to other 
brain diagnostic technologies, such as fMRI (functional magnetic resonance imaging), PET 
(positron emission tomography), MEG (magnetoencephalography), or MRS (magnetic resonance 
spectroscopy), it remains very important in the clinical setting.  It has the advantage of being 
relatively inexpensive to use and is highly mobile.  Most importantly, it has a very high temporal 
resolution, meaning that it can measure on the order of milliseconds rather than seconds.  As 
well, EEG measures brain electrical activity directly unlike the other techniques mentioned 
above which measure blood flow and metabolic activity which is an indirect marker of brain 
electrical activity.  From a safety point of view, it is relatively non-invasive and does not involve 
exposure to high-density magnetic fields or radioligands.  It has been, and continues to be, the 
“bread and butter” technology of clinical neurologists.  Of course, there are numerous limitations 
of EEG too.  As mentioned above, it has low spatial density and cannot identify specific parts of 
the brain where particular events of interest may be taking place and ultimately the signal-to-
noise ratio is low, therefore sophisticated data analysis and interpretation is often needed (Swartz 
and Goldensohn 1998).  However, for the current study design it was the most suitable method to 
determine brain activity patterns in our cohort of epileptic patients. 
The Janeway neurology clinic utilizes a modern digital encephalogram which allows for 
use of any montage on any section of the EEG.  The neurologists order EEGs for all suspected 
seizure patients.  Photic stimulation and hyperventilation are routine and sleep deprived EEGs 
are done if the routine EEG is normal.  Other forms of provocation are rare. 
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1.5.1.1  EEG characteristics 
Frequency 
Frequency refers to rhythmic repetitive activity (in Hz). The frequency of EEG activity 
can have different properties including: rhythmic (waves of approximately constant frequency), 
arrhythmic (no stable rhythms are present), and dysrhythmic (rhythms and/or patterns that 
characteristically appear in patient groups and rarely seen in healthy subjects).  The primary 
human EEG wave patterns are delta, theta, alpha and beta (see Figure 3); 
Delta has a frequency of 3 Hz or below.  It tends to be the highest in amplitude and the slowest 
waves.  It is normal as the dominant rhythm in infants up to one year and in stages 3 and 4 of 
sleep.  It may occur focally with subcortical lesions and in general distribution with diffuse 
lesions, metabolic encephalopathy hydrocephalus or deep midline lesions.  It is usually most 
prominent frontally in adults (e.g. FIRDA - Frontal Intermittent Rhythmic Delta) and posteriorly 
in children (e.g. OIRDA - Occipital Intermittent Rhythmic Delta). 
Theta has a frequency of 3.5 to 7.5 Hz and is classified as "slow" activity.  It is perfectly normal 
in children up to 13 years and in adults while sleeping but abnormal in awake adults.  It can be 
seen as a manifestation of focal subcortical lesions.  It can also be seen in generalized 
distribution in diffuse disorders such as metabolic encephalopathy or some instances of 
hydrocephalus. 
Alpha has a frequency between 7.5 and 13 Hz.  It is usually best seen in the posterior regions of 
the head on each side, being higher in amplitude on the dominant side.  It appears when closing 
the eyes and relaxing, and disappears when opening the eyes or alerting by any mechanism 
(thinking, calculating).  It is the major rhythm seen in normal relaxed adults.  It is present during 
most of life especially after the age of thirteen. 
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Beta activity is "fast" activity.  It has a frequency of 14 and greater Hz. It is usually seen on both 
sides in symmetrical distribution and is most evident frontally.  It is accentuated by sedative-
hypnotic drugs especially the benzodiazepines and the barbiturates.  It may be absent or reduced 
in areas of cortical damage.  It is generally regarded as a normal rhythm. It is the dominant 
rhythm in patients who are alert or anxious and have their eyes open. 
 
 
Figure 3. Representation of EEG recording showing the four main frequency patterns of 
human brain wave activity. (www.epilepsy.com) 
 
Voltage 
Voltage refers to the average voltage or peak voltage of EEG activity. Voltage values in 
an EEG are small and are measured in microvolts (µV).  Descriptive terms associated with EEG 
voltage include: attenuation (reduction of amplitude resulting from decreased voltage), 
hypersynchrony (increase in voltage and regularity of rhythmic activity, or within the alpha, beta, 
or theta range), and paroxysmal (activity that emerges from the background with a rapid onset, 
reaching quite high voltage and ending with an abrupt return to lower voltage activity). 
 
1.5.2 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) has been a mainstay of radiological diagnoses and 
disease staging for over 20 years.  Based on using strong magnetic fields and radiowaves, an 
19 
 
MRI scanner forms a strong magnetic field around the area being imaged.  By creating an 
oscillating magnetic field and then by using a beam of radio waves, the scanner excites hydrogen 
atoms in the cells of tissues that contain water.  These hydrogen atoms in turn emit a radio signal 
that is detected by the scanner, which in turn is translated into an image by the computer.  The 
contrast between different tissues is determined by the rate at which excited atoms return to the 
equilibrium state.  By using a contrast agent that is administered into the blood stream, the image 
from the scanner can be enhanced.  The importance of the MRI in medicine was highlighted 
when two scientists, Sir Peter Mansfield and Paul Lauterbur, were given the Nobel Prize in 
Physiology or Medicine in 2003, for their discoveries concerning MRI.  Often MRI is used as an 
alternative for CT because it is more sensitive in determining small irregularities (e.g. tumours) 
and also because it is a safer alternative.   
While the classification of seizure type still relies primarily on clinical history, 
observation and possibly EEG, MRI has been particularly valuable in detecting the abnormalities 
that cause specific types of epilepsy.  Due to the sensitivity of MRI, it can identify scar tissue, 
areas of brain dysplasia, small brain tumours, blood vessel abnormalities and changes in white 
matter.  Such abnormalities are often the cause of epileptic seizures.  As well, MRI can help 
diagnose an epileptic syndrome.  For example, if an MRI shows a structural lesion that is the 
likely source of the seizures, then a classification as partial in nature can be made.  This often 
helps in determining the best treatment modality.  However, some epilepsy syndromes, such as 
benign rolandic epilepsy, cannot be diagnosed with MRI because it is not linked to damage to the 
structure of the brain.  In addition, an MRI can be informative for evaluating the likelihood that 
surgery would be effective in controlling seizures.  It can identify mesial temporal sclerosis or 
cavernous angioma, which carry a favorable surgical prognosis, and malformations of cortical 
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development, which have a less favorable prognosis for postoperative seizure control.  Finally, 
MRI can help identify the volume of tissue that needs to be removed during surgery. 
In the present study, MRI was used to identify or rule out any underlying cortical 
abnormalities causing epilepsy in our study patients.  Since some generalized EEG patterns are 
presumed to have an underlying genetic etiology, not all epilepsy patients have MRIs.  At the 
Janeway neurology clinic, MRIs are ordered by neurologists if a focal feature is present on the 
EEG, even if benign rolandic epilepsy is suspected.  Those with an identifiable cause on MRI 
were excluded from the idiopathic epilepsy group.  As stated in the study inclusion criteria, 
patients must present with no known underlying cause of seizures aside from the presumed 
genetic predisposition.  
 
1.6 Childhood Idiopathic Epilepsy Syndrome Classification: 
Upon diagnosis of childhood idiopathic epilepsy, specific features of the clinical 
examination should help categorize patients into one of the following epileptic syndromes; 
 
a) Idiopathic Generalized Epilepsies: 
Primary generalized epilepsy (PGE) is a form of epilepsy characterized by generalized 
seizures with no apparent cause.  Generalized seizures, as opposed to partial seizures, are a type 
of seizure that impairs consciousness and distorts the electrical activity of the whole or a larger 
portion of the brain which can be seen on EEG.  Primary generalized epilepsy is the originally 
diagnosed condition, as opposed to secondary epilepsy, which occurs as a symptom of a known, 
diagnosed condition.  PGEs typically have distinct patterns on EEG which are unique and 
provide evidence for the neurologist to presume there is no underlying etiology (ie. idiopathic).  
21 
 
 
Childhood absence epilepsy (CAE) is an idiopathic generalized epilepsy which occurs in 
otherwise normal children.  The age of onset is between four and 10 years with peak age between 
five and seven years.  Children with CAE have absence seizures which, although brief 
(approximately 4-20 seconds), they occur frequently, sometimes hundreds per day.  The absence 
seizures of CAE involve abrupt and severe impairment of consciousness.  Mild automatisms 
(repetitive unconscious gestures such as lip smacking, chewing, or swallowing) are frequent, but 
major motor involvement early in the course excludes this diagnosis.  EEG recordings 
demonstrate characteristic 3Hz spike-wave discharges.  Prognosis is excellent in well-defined 
cases of CAE with most patients out-grow their epilepsy by adolescence (Crunelli and Leresche 
2002). 
 
Juvenile absence epilepsy (JAE) is a relatively uncommon childhood seizure disorder with 
absence seizure onset typically occurring between 10 and 17 years of age.  All patients 
experience absence seizures and many also experience GTCS (Generalized tonic-clonic seizures) 
and myoclonic attacks (Trinka, Baumgartner et al. 2004).  Patients have normal intelligence and 
neurologic function.  EEG recordings show generalized spike and wave discharges with normal 
background activity.  Brain CT and MRI scans appear normal (Trinka, Baumgartner et al. 2004). 
  
Juvenile myoclonic epilepsy (JME), also known as Janz syndrome, is a fairly common form 
of idiopathic generalized epilepsy, representing 5-10% of all epilepsies.  It is characterized by the 
presence of absence seizures, myoclonic seizures and generalized tonic-clonic seizures.  The 
hallmark characteristic of JME is the presence of myoclonic jerks that occur upon awakening.  
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These myoclonic jerks are the most prominent seizure type.  This disorder typically first 
manifests itself between the ages of 12 and 18 with myoclonus occurring early in the morning.  
Patients typically do not out-grow this condition as it persists throughout life.  Most patients also 
have tonic-clonic seizures and many also have absence seizures (Syvertsen, Markhus et al. 
2012).   
 
Generalized epilepsy with febrile seizures plus (GEFS+) is a diagnostic label coined by 
Scheffer and Berkovic in 1997 to describe a dominantly inherited epilepsy disorder associated 
with febrile and afebrile seizures.  The phenotype is variable and can range from febrile seizures 
to severe intractable epilepsy with developmental delay in affected individuals within the same 
family.  The prognosis also varies widely from seizure cessation with no long term deficits to 
intractable seizures with developmental delay (Scheffer and Berkovic 1997; Fujiwara, Sugawara 
et al. 2003). 
 
Severe myoclonic epilepsy of infancy (SMEI), also called Dravet syndrome, is considered to 
be a genetic epileptic encephalopathy.  This severe form of epilepsy appears during the first year 
of life (usually at around six months of age) with the onset of frequent febrile seizures.  Beyond 
one year of age, other types of seizures typically arise, including absence, partial, atonic and 
often myoclonic seizures (involuntary muscle spasms).  Status epilepticus (one continuous 
unremitting seizure lasting longer than 30 minutes or recurrent seizures without regaining 
consciousness between seizures for greater than 30 minutes) may also occur.  Early development 
is normal, with slowing and regression after one to two years of age.  Children with Dravet 
syndrome typically experience an unfavorable prognosis with poor development of language and 
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motor skills, hyperactivity, and difficulty relating to others (Scheffer 2003; Dravet 2011; Dravet 
2011 B). 
 
Myoclonic astatic epilepsy (MAE) is a generalized idiopathic epilepsy characterized by the 
development of myoclonic seizures and/or myoclonic astatic seizures.  Onset occurs between the 
ages of two and five.  EEG recordings show regular and irregular bilaterally synchronous 2- to 3-
Hz spike-waves and polyspike patterns with a 4- to 7-Hz background.  The majority (84%) of 
affected children show normal development prior to seizures; the remainder show moderate 
psychomotor retardation mainly affecting speech.  Boys (74%) are more often affected than girls 
(Doose and Baier 1987).  
 
Benign myoclonic epilepsy in infancy (BMEI) is a form of idiopathic generalized epilepsy 
characterized by myoclonic seizures in the first three years of life in otherwise normal infants, 
and the lack of other seizure types except for rare simple febrile seizures.  Myoclonic jerks 
(singular or clusters) occur in all cases while febrile seizures occur in approximately 10% of 
cases.  Consciousness remains intact during seizures but mild clouding may occur during cluster 
of jerks.  Males (at 66%) are more frequently affected than females (Ito, Oguni et al. 2012). 
 
b) Idiopathic Partial Epilepsies: 
Complex partial seizures (CPS) are epileptic seizures associated with bilateral cerebral 
hemisphere involvement and causes impairment of awareness or responsiveness, i.e. loss of 
consciousness.  CPSs may arise from any lobe of the brain (Murro 2006) but most commonly 
arise from the mesial temporal lobe, particularly the amygdala, hippocampus, 
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and neocortical regions (Wolf 2008).  CPSs occur when excessive and synchronous electrical 
brain activity causes impaired awareness and responsiveness and the abnormal electrical activity 
may or may not spread to the rest of the brain and cause a secondary generalized tonic-clonic 
seizure.  
 
Benign rolandic epilepsy (BRE) is named after the rolandic area of the brain, which controls 
facial movement.  BRE is the most common form of partial epilepsy in children, affecting both 
boys and girls, but is slightly more prevalent in boys.  It usually starts between the ages of three 
and 12 years, and often stops around puberty (14-18 years of age).  First presentation is typically 
a partial seizure with tonic-clonic activity of the lower face associated with drooling and 
impaired speech.  Seizures commonly occur at night and may become secondarily generalized.  
The long-term prognosis for children with BRE is excellent with essentially all children entering 
remission by mid-adolescence; although, in some cases, specific difficulties with reading and 
language may persist.  EEG recordings are typically easily recognizable with characteristic high-
voltage sharp waves in the centrotemporal regions, which are activated with drowsiness and 
sleep (Wirrell 1998).  
 
Benign epilepsy of childhood with occipital paroxysms (BECOP) / Panayiotopoulous 
syndrome describes benign partial epilepsies with focal origin and includes a subset of two 
syndromes: benign childhood epilepsy with centrotemporal spikes (BCECTS) and childhood 
epilepsy with occipital paroxysms (CEOP).  Age of onset usually occurs in middle childhood 
(five to 11 years of age) but seizures can begin at any age from 15 months to 17 years.  EEG 
recordings reveal abnormalities in the occipital region of the brain.  About one third of children 
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have a family history of epilepsy and many have febrile seizures prior to BECOP onset.  A 15-
year follow-up prospective study indicated an excellent prognosis for most patients.  The 
majority of children with this condition have normal neurological and learning abilities and brain 
scans appear normal (Panayiotopoulos 1989). 
 
Benign Familial Neonatal Convulsions (BFNC) occur in otherwise healthy infants and are 
characterized most often by generalized or partial tonic-clonic seizures, normally within the first 
seven days of life and spontaneously remitting within the first two-three months.  Other findings 
are a seizure-free interval between birth and the onset of seizures; normal physical examination 
and laboratory tests prior to, between, and after seizures; and absence of specific EEG findings.  
Approximately 50% to 70% of infants have a normal interictal EEG; about 25% demonstrate a 
specific EEG pattern known as theta pointu alternant; and a small percentage have focal, often 
rolandic, discharges or spikes.  The EEG is usually normal by age 24 months.  Psychomotor 
development is usually normal.  About 10%-15% of individuals with BFNC develop epileptic 
seizures later in life (Bjerre and Corelius 1968; Mulley, Scheffer et al. 2003). 
In the mid-1990s, a Newfoundland family with autosomal dominant BFNC was studied 
and the genetic investigation of their DNA eventually led to one of the first novel epilepsy gene 
discoveries.  A gene that encodes a potassium channel subunit, KCNQ2, was first identified in 
this family in 1998 (Singh, Charlier et al. 1998).   
 
Benign partial epilepsy in infancy (BPEI) is defined as epilepsies with complex partial 
seizures (CPS) or secondary generalized seizures (SGS), or both, compatible with the following 
characteristics: normal development before and after onset, no underlying disorders, normal 
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interictal EEGs, and good response to treatment (Okumura, Hayakawa et al. 1996).  Seizure 
onset occurs in the first two years of life with an average age at onset of 5.9 months.  Seizures 
typically persist for approximately three months and cease thereafter (Okumura, Hayakawa et al. 
1996). 
 
West Syndrome, also known as Infantile Spasms (IS), are one of the most common and 
important epileptic encephalopathies of childhood.  Onset of this syndrome occurs in infancy and 
consists of a unique seizure type (infantile spasms), a specific and characteristic EEG pattern 
(hypsarrhythmia), and psychomotor arrest or delay.  IS is considered to be a “catastrophic 
epilepsy” due not only to the difficulty in attaining seizure control and in achieving 
normalization of the EEG, but primarily because, if untreated, affected infants almost uniformly 
deteriorate and develop severe developmental delay and mental retardation.  However, early 
identification and aggressive treatment can potentially translate into a good prognosis and allow 
for a good neurodevelopmental outcome (Watemberg 2012).  In an Icelandic epidemiological 
study of 214 patients diagnosed with infantile spasms, 31% died, 45% were retarded (IQ of 68-
84), and 24% had a reasonably favorable outcome with an IQ of 85 or greater (Riikonen 2001).  
 
1.7 Differential diagnosis 
 The differential diagnosis of epileptic and non-epileptic seizures or non-seizure episodes 
presents a number of challenges as the process of identifying the cause of seizures is quite 
diverse and complex.  The occurrence of epileptiform EEG recordings in children without 
epilepsy has been well documented for decades.  These patterns have been observed in patients 
with Cerebral Palsy (Gibbs, Gibbs et al. 1963), mental retardation (Trojaborg 1966), psychiatric 
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diseases (Zivin and Marsan 1968), behavioral disturbances (Lairy 1965), vegetative disturbances 
(Fois, Borgheresi et al. 1967), visual deficits (Jeavons 1964), and perceptive or praxic deficits 
(Berges, Harrison et al. 1968).  There have also been documented correlations between EEG 
abnormalities and clinical disturbances.  However, conclusions regarding the occurrence of such 
findings have remained difficult to draw as similar EEG findings have also been detected in 
subjects in which no clinical abnormalities can be found.  In other words, these patients are 
considered completely normal from a clinical perspective, despite abnormal EEG recordings.  An 
Italian study published in 1980 recorded EEG readings for 3726 children (aged 6-13 years) who 
were neurologically normal with no history of epileptic seizures and detected epileptiform 
abnormalities in 131 cases (3.5%).  Follow-up studies were conducted on these patients with 
abnormal EEGs for a period of nine years.  Spontaneous disappearance of EEG abnormalities by 
adolescence occurred in all but seven patients who developed epileptic seizures (Cavazzuti, 
Cappella et al. 1980).  Using modern epidemiological methods, this data could be interpreted as a 
relative risk increase of developing seizures by adolescence of 1.05 (or 5.5%), given an abnormal 
EEG recording in childhood.  This increase is not significantly greater than the population 
lifetime risk of 3-5%.  Thus, EEG as a pre-symptomatic tool for diagnosis would drastically 
over-estimate the rate of children predisposed to seizures as it is highly sensitive but not highly 
specific resulting in a high false positive rate.  
 Furthermore, different diagnostic techniques for epilepsy provide different clues to the 
most probable diagnosis and each technique is not readily available in all areas.  For example, 
long-term EEG monitoring with video recording (video EEG) is the strongest differential 
diagnostic tool available but it is also complex, costly and not available in all areas.  Several 
other diagnostic techniques are regularly utilized in conjunction with or alternatively to video 
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EEG including; routine EEG, medical history variables, seizure semiology, provocative testing, 
and psychological and neuropsychological testing.  Each technique has merit for diagnostic 
utility but are more successful as complementary diagnostic tools, rather than individual tests 
(Cragar, Berry et al. 2002). 
 In the current study, the differential diagnosis of an apparent seizure disorder was 
conducted by the neurologists in the Janeway Neurology Clinic.  Several steps are involved in 
ruling out causes of alternate pathology with similar presentation, such as a cardiac arrhythmia, 
syncope, migraine, etc.  The diagnoses were made utilizing thorough clinical work up, family 
history, observation, EEG, MRI, and electrocardiogram (ECG) when deemed appropriate in 
cases of diagnostic uncertainty. 
 
1.7.1 Phenocopies 
A phenocopy is an individual whose phenotype appears the same as another but the 
underlying etiology of the phenotype is different between them – usually one has a genetic cause 
of the phenotype, and the other, a non-genetic (environmental) cause.  The possibility of 
phenocopies must be considered when diagnosing patients, particularly family members of 
affected patients that are affected by hearsay.  When collecting data from study subjects, 
investigators are typically very thorough in determining that the correct diagnosis has been made.  
Medical and seizure history data are reviewed in additional to a complete clinical work up.  
Ideally, when conducting family studies, the same level of thoroughness should be employed 
when determining the correct diagnosis for family members.  Unfortunately, this is often not the 
case due to restricted access to medical records, unavailability of technical diagnostic testing, or 
lack of resources.  Thus, it is not unusual, depending on the phenotype and its frequency in the 
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general populace, for phenocopies to be present in family studies.  The phenocopy rate is 
difficult to determine as it can often only be detected after the underlying genotype is established 
in the family. 
Furthermore, each type of epilepsy may have phenocopies that are in fact, alternate types 
of epilepsy, benign seizures (such as febrile seizures), or seizure-associated disorders (such as 
neuronal ceroid lipofuscinosis).  With much similarity between different seizure types, care must 
be taken to establish the correct diagnosis.  Reducing the number of phenocopies present in 
family studies investigating the genetic etiology of disease is imperative to improving the quality 
of the outcomes of such studies. 
 
1.8 Epileptic encephalopathies 
An epileptic encephalopathy occurs when an epileptiform brain wave pattern impairs 
brain function.  Certain types of seizures and epilepsy syndromes commonly cause an epileptic 
encephalopathy.  These particular epilepsy syndromes are referred to as epileptic 
encephalopathies.  In an epileptic encephalopathy, the epileptic activity itself contributes to 
cognitive and behavioral problems, beyond what is expected from the underlying cause.  An 
epileptic encephalopathy can cause progressive academic, behavioral, and motor problems.  
Depending on the frequency and severity of the seizures, abundance of epileptiform activity and 
medications used to inhibit these seizures, patients with epileptic encephalopathies display a 
wide range of cognitive and behavioral problems.  The most common epileptic encephalopathies 
typically begin in infancy and are defined by very frequent or severe seizures that contribute to a 
progressive disturbance of cerebral function.  These syndromes include Dravet syndrome (also 
known as SMEI), Ohtahara syndrome (OS) and West syndrome (also known as Infantile 
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Spasms).  Dravet and West syndrome are described above with the other childhood idiopathic 
epilepsy syndromes.  However, OS has not been exclusively characterized as an idiopathic 
epilepsy due to the underlying cortical malformation identified in many cases.  OS is a 
progressive epileptic encephalopathy which is characterized by early onset intractable tonic 
spasms within the first three months of life and affected infants have a burst suppression pattern 
on EEG (high voltage activity alternating with nearly flat suppression phases).  These clinical 
findings in infancy evolve into West Syndrome between three and six months of age, with 
continuing epileptic encephalopathy between the ages of one and three years.  It is an extremely 
debilitating progressive neurological disorder, involving intractable seizures and severe mental 
retardation.  No single cause has been identified, although structural brain abnormalities are a 
major cause for this condition.  Due to the underlying etiology attributed to a cortical 
malformation in many cases, OS has not been exclusively characterized as an idiopathic 
(genetic) epilepsy.  Further research into the etiology of OS must be undertaken before it can be 
fully understood where this disorder should fall within the current classification system (Noh, 
Jane Tavyev Asher et al. 2012). 
 
1.9 Literature review 
Few population-based studies of the familial basis of childhood epilepsy have been 
undertaken.  Two previous epidemiological studies of childhood epilepsy in northern Sweden 
and Hong Kong found that 9.6% and 9.7% of patients had a first degree relative with a history of 
epilepsy, respectively and an Estonian study found that 14.8% of patients had a family history of 
epilepsy amongst first and second degree relatives (Sidenvall, Forsgren et al. 1996; Beilmann, 
Napa et al. 1999; Beilmann, Napa et al. 1999; Kwong, Chak et al. 2001).  In a population-based 
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Danish twin registry, the concordance rates of epilepsy in 11 900 twin pairs was found to be 
significantly higher in monozygotic twins than dizygotic twins (0.37 vs 0.08, P < 0.01) 
(Kjeldsen, Kyvik et al. 2001).  Though several previous studies have included family history data 
(Sidenvall, Forsgren et al. 1993; Sidenvall, Forsgren et al. 1996; Beilmann, Napa et al. 1999; 
Beilmann, Napa et al. 1999; Freitag, May et al. 2001; Kwong, Chak et al. 2001; Mullins, 
O'Sullivan S et al. 2007), there are no previous reports giving detailed family histories in a 
population-based study.  
 
1.9.1 Twin studies of epilepsy 
Twin studies are one of the strongest study designs used in determining the genetic 
contribution to disease, including various forms of idiopathic epilepsy of childhood.  In 2006, the 
results of an international, multicenter, collaborative twin study examining the etiology of benign 
rolandic epilepsy (BRE), were published in Epilepsia.  BRE is a common childhood epilepsy 
syndrome that had previously been considered to be a genetic idiopathic partial epilepsy.  The 
investigators reviewed twin registries from Australia, Denmark, the United States, and Norway 
(1952 twin pairs with a seizure history), to identify subjects with classic BRE and examine 
concordance rates.  Of the eighteen twin pairs identified of whom at least one twin was 
diagnosed with BRE, all were discordant (pairwise concordance rate was 0.0).  This data 
challenges the hypothesis that BRE is a genetic disorder and suggests that non-inherited factors 
are of major importance in the etiology of BRE and the mode of inheritance of BRE is much 
more complicated than initially believed (Vadlamudi, Kjeldsen et al. 2006).  However, the 
limited number of twin pairs available reporting symptoms of BRE, lends questionability to the 
generalizability of the study results.  A much larger sample of twins was enrolled in a 
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multicenter, population-based study which involved 47 626 twin pairs from the United States, 
Norway and Denmark.  This study showed higher concordance rates of seizures between 
monozygotic pairs when compared to dizygotic pairs, across all subpopulation groups of 
different ages and populations (Kjeldsen, Corey et al. 2005).  The latter study was more powerful 
due solely to the much larger sample size and the results are much more concordant with the vast 
body of literature supporting the important role of genetics in the development of epilepsy. 
 
1.9.2 Population-based studies of epilepsy 
Population-based studies allow researchers to obtain thorough epidemiologic data, 
implement and evaluate interventions, and provide care that is tailored to that population.  Such 
studies improve the ability of the health care system to provide effective and efficient 
interventions that are consistent with the needs of the target population.  Several population-
based studies of epilepsy have been reported from various regions of the world over the last two 
decades (Callenbach, Geerts et al. 1998; Beilmann, Napa et al. 1999; Hesdorffer, Logroscino et 
al. 2011; Bhalla, Chea et al. 2012).  The outcomes of interest were primarily epidemiological 
measures including incidence, prevalence, risk and classification of seizure types and epileptic 
syndromes.  The current section presents the results of these studies chronologically and as 
relevant to the context of this thesis.  
A longitudinal population-based study investigating the prevalence of epilepsy in 
Rochester, Minnesota determined that the age-adjusted prevalence per 1000 individuals, 
increased steadily from 2.7 in 1940 to 6.8 in 1980.  Due to the vast improvements in neurological 
diagnostics during this time period, this marked increase could be somewhat attributable to the 
subsequent increase in diagnoses and ascertainment.  This study also determined the prevalence 
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of epilepsy for a specific date in each of five decennial census years.  At each of the five 
prevalence dates, for all prevalence cases, 60% had epilepsy manifest by partial seizures and 
40% were generalized.  Prevalence was higher for males than females for all.  In terms of 
epilepsy duration and onset, of all prevalent cases in 1980, over 50% had epilepsy less than 10 
years and had their first diagnosis in the first 20 years of life (Hauser, Annegers et al. 1991; 
Hauser, Annegers et al. 1993).  In 2011, another publication from the same group in Rochester, 
Minnesota used retrospective data to assess the cumulative incidence and lifetime risk of 
developing epilepsy.  The authors used incident cases of epilepsy occurring between 1960 and 
1979 to calculate the lifetime risk to age 50 years is 1.6% and to age 80 is 3.0%.  Cumulative 
incidence was 1.7% to age 50 and 3.4% to age 80 (Hesdorffer, Logroscino et al. 2011).  This 
long-term study presented important information in determining epilepsy incidence and 
prevalence utilizing data from multiple decades.  However, it provided no information on 
etiology and thus the number of idiopathic cases could not be derived for comparison to our 
study of the Newfoundland population. 
A Dutch study of epilepsy in childhood followed 462 children with recurrent unprovoked 
seizures prospectively from 1988 to 1992 (Callenbach, Geerts et al. 1998).  The purpose of the 
study was to examine the familial occurrence of epilepsy in children with newly diagnosed, 
multiple, unprovoked seizures.  Seizures and epilepsy syndromes of probands were classified 
according to the ILAE classification system.  Probands with at least one first-degree relative with 
epilepsy were selected.  Seizures and syndromes of their relatives were classified via interviews.   
The results of seizure classifications demonstrated that 42% of probands had partial seizures, 
57% had generalized seizures, and 1% had undetermined localization.  The 47 (10.2%) children 
with at least one first-degree relative with epilepsy, less frequently had partial epilepsy (23%) 
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and more often had generalized epilepsy (77%), as compared with the total group of probands.  
Eighty-three percent (83%) of first-degree relatives with idiopathic or cryptogenic epilepsy had 
the same seizure type as the proband.  This study concluded that in 10% of children with newly 
diagnosed epilepsy, the condition is familial.  These children more frequently have generalized 
epilepsy syndromes as compared with children with a negative family history.  These findings 
confirm the role of genetic factors in the pathogenesis of epilepsy (Callenbach, Geerts et al. 
1998).  This study provided comparable data from a population-based study.  However, the 
criteria used in this study for inclusion in the “familial” group stated only that patients had at 
least one first degree relative with epilepsy.  It provided no further information on pedigrees, 
possible inheritance patterns or the number of affected relatives.  Thus, the proportion of families 
with inheritance patterns compatible with autosomal dominance was not provided. 
In 1999, a team of researchers in Estonia reported a longitudinal, population-based study 
ascertaining all cases from every available source of medical care in seven counties of Estonia to 
determine the prevalence and phenotypic data of childhood epilepsy.  Only cases of patients aged 
one month to 19 years with active epilepsy (defined as at least one seizure during the last five 
years, regardless of treatment) were included.  The study concluded that the prevalence of 
childhood epilepsy was 5.8 per 1000, which was comparable to other Western countries.  
Generalized seizures were the predominating seizure type, and the primary cause was perinatal 
factors, including infections, drugs, and birth trauma (Beilmann, Napa et al. 1999).  The 
strongest design element of this study was the longitudinal population-based approach which 
typically provides a broad picture of the epidemiological data for the given catchment area.  
However, since this study examined all cases of epilepsy, it provides no breakdown of epilepsy 
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by etiology.  Therefore, it is difficult to draw comparisons to the incidence of genetic cases of 
childhood epilepsy in the study population of this thesis. 
In a community-based study from Connecticut, of children with newly diagnosed 
epilepsy, diagnostic neuroimaging was examined for its efficacy in the evaluation of seizures and 
epilepsy.  There is limited information about the current use of neuroimaging in the initial 
evaluation of pediatric epilepsy and about its yield during the initial diagnosis of epilepsy.  The 
study investigators describe the patterns in the use and yield of diagnostic imaging in children 
with newly diagnosed epilepsy.  Children were recruited when first diagnosed with epilepsy by 
participating physicians.  Definitions for etiology and underlying epilepsy syndromes followed 
those published by the ILAE.  Of 613 children, 488 (79.6%) had imaging: 388 (63. 3%) had 
magnetic resonance imaging, 197 (32.1%) had computed tomography scans, and 97 (15.8%) had 
both.  Half of children with idiopathic generalized epilepsy had imaging studies compared with 
70% to 100% of children with other forms of epilepsy, depending on the specific type.  
Etiologically relevant abnormalities were found in 62 (12.7% of those imaged).  Fourteen of 
these children had otherwise completely normal presentations and histories.  Their abnormalities 
included tuberous sclerosis (N = 4), tumors (N = 2), an arteriovenous malformation later 
diagnosed as a tumor, a cavernous angioma, cerebral malformations (N = 3), and other 
abnormalities (N = 5).  Thirteen of the 14 had partial seizures and 12 had focal EEG findings.  
Only one had neither.  The study concluded that in children with newly diagnosed epilepsy, 
neuroimaging reveals a small but significant number of serious abnormalities not previously 
suspected.  Most of these children have partial seizures or focal EEG abnormalities.  
Neuroimaging should be considered during the evaluation of children with newly diagnosed 
epilepsy, especially for those with neurologic deficits or partial seizures or focal EEG 
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abnormalities that are not part of an idiopathic localization-related epilepsy syndrome (Berg, 
Testa et al. 2000).  Since neuroimaging is conducted for all children referred to the Janeway 
Neurology clinic in Newfoundland, this study was not referenced for testing indications, but 
rather for comparison of imaging results.  The neuroimaging result data in the Connecticut study 
was thorough and provided specific information on the proportion of rare abnormalities which is 
useful for evaluating against the imaging data of the current study. 
In a 2004 study conducted by the ILAE, 483 epileptic children attending a pediatric 
epilepsy clinic in a children’s hospital in Bombay, India were classified according to the ILAE 
classification of epileptic seizures and epileptic syndromes.  The predominant seizures were 
partial (53.6%), generalized (40.3%), and unclassifiable (6%).  With respect to epileptic 
syndromes, 55.3% were partial, 27% were generalized, 13.5% were undetermined, and 4.1% 
were special syndromes.  Although these results were similar in many respects to those of other 
reported studies, some differences were observed in the incidence of partial and generalized 
epileptic syndromes and their subgroups (idiopathic, symptomatic, and cryptogenic).  The 
authors attributed these differences to differing age limits, methods of case ascertainment and 
inclusion criteria, genetic and environmental factors, variable interpretation of clinical and EEG 
features, and lack of facilities for investigation in developing countries.  Despite various 
limitations, the investigators were able to classify most cases, and thus concluded that the ILAE 
classification can be used in developing countries so that comparisons can be made with other 
studies (Okuma 2004).  This study used stringent criteria for diagnostic evaluation and was a 
useful proof of principle for the utility of the ILAE classification criteria that was employed in 
the study presented in this thesis.  
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The first population-based incidence study of epilepsy to describe syndrome 
classification from the outset was an Icelandic study published in 2005, which determined the 
annual incidence of a first unprovoked seizure to be 56.8 per 100 000 person-years and 33.3 per 
100 000 person-years for epilepsy (recurrent unprovoked seizures).  Idiopathic epilepsy 
syndromes were identified as the cause of 14% of cases (Olafsson, Ludvigsson et al. 2005).  
These findings were consistent with incidence studies from other developed countries.  The 
population-based incidence data was directly comparable to that which we calculated for the 
current Newfoundland study.  Also, the proportion of idiopathic epilepsy cases provides a frame 
of reference for the data presented herein, but without age-related data, it is difficult to draw 
comparisons to the childhood-based approach taken in the current study. 
A 2012 population-based, case control study in Prey Vemg, Cambodia identified 96 cases 
of epilepsy and matched 192 healthy controls.  The purpose of this study was to identify 
attributable risk factors and determine measures of impact.  Among this population, attributable 
risk to family history (defined as an affected family member of any degree) was 15%, other 
underlying disorders aside from seizures was 20% and eventful pregnancy / perinatal factors was 
21%.  This study also calculated the odds ratio of factors associated with epilepsy.  Family 
history, in any degree relative, in cases versus controls gave an odds ratio of 2.9 (p = 0.0018)  
(Bhalla, Chea et al. 2012).  As a measure of the association between the exposure and the 
outcome, odds ratio allows us to deduce that the odds of epilepsy cases having an affected family 
member is 2.9 times greater than the odds for controls.  Although the outcome measures of this 
study differ from those which we were interested in for the Newfoundland study, it is of interest 
how they defined “family history”.  Using the broad definition of a seizure history in any degree 
relative can lend to selection bias whereby cases with distant relatives could be classified as 
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having inherited forms of epilepsy when in fact the relative’s seizure history is attributable to a 
different cause (phenocopy).  The study made no attempt to adjust for this by further classifying 
cases with a family history into subcategories and therefore the results are difficult to generalize 
to other populations.   
  
1.10 Genetic basis of epilepsy 
Epilepsies are classified based on etiology as idiopathic, symptomatic or cryptogenic.  
Symptomatic and cryptogenic epilepsies result from known or suspected underlying disorders of 
the central nervous system, while in IE there is believed to be no underlying cause other than a 
hereditary predisposition.  Approximately 40% to 60% of all cases are idiopathic and are 
presumed to have a predominantly genetic basis (Annegers, Rocca et al. 1996; Weissbecker, 
Elston et al. 1999; Andrade and Minassian 2007; Pandolfo 2012).  The remainder are 
symptomatic, resulting from an underlying structural or metabolic cause, or cryptogenic, in 
which an underlying cause is suspected but not identified (ILAE 1989).  
Family studies have shown that first degree relatives of an affected individual have a 2.5 
to 4 fold greater risk of being affected than the general population, and twin studies have shown 
more than 40% monozygotic concordance rates (Annegers, Rocca et al. 1996; Weissbecker, 
Elston et al. 1999).  Most cases of IE follow complex inheritance, involving the interaction of 
several genes and unknown environmental factors (Greenberg 1992; Berkovic and Mulley 1996; 
Berkovic, Howell et al. 1998; Berkovic, Mulley et al. 2006).  Less frequently, IE can result from 
a single gene and follow a Mendelian pattern of inheritance.  While a genetic contribution to the 
etiology of epilepsy is estimated to be present in about 40-60% of cases, Mendelian idiopathic 
epilepsies are individually rare, and are thought to account for no more than 1% of heritable 
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cases of epilepsy (Johnson, Robinson et al. 2011)(Gardiner 2000; Robinson and Gardiner 2004).  
These rare Mendelian cases are clinically and genetically heterogeneous with 18 causal genes 
(KCNQ2, KCNQ3, KCND2, KCNT1, CHRNA4, CHRNA2, CHRNB2, SCN1B, SCN1A, SCN2A, 
SCN2B, GABRG2, GABRD, GABRA1, CLCN2A, CACNB4, LGI1and EFHC1) identified to date 
(Berkovic, Mulley et al. 2006; Steinlein 2008; Baulac and Baulac 2009; Pandolfo 2012).  All but 
two of the causative genes identified in IE encode components of neuronal ion channels (voltage-
gated sodium, potassium, and chloride channels) or neurotransmitter receptors (acetylcholine 
nicotinic receptor and GABAA receptor).  A neuronal ion channel gene mutation was previously 
identified in the Province of Newfoundland and Labrador; a missense mutation in exon 6 of a 
potassium channel gene (KCNQ2) was previously shown to be associated with Benign Familial 
Neonatal Convulsions in a Newfoundland family (Singh, Charlier et al. 1998). 
The first non-ion channel gene associated with Mendelian epilepsy, LGI1 (leucine-rich 
glioma inactivated 1), was identified as a cause of autosomal dominant partial epilepsy with 
auditory features (ADPEAF).  A study at Columbia University (USA), conducted physical 
mapping of 10q24, genotyping, and candidate gene sequencing to identify LGI1 as the site of 
pathogenic mutations (four protein truncating variants and one missense variant) in five families 
with this rare form of epilepsy (Kalachikov, Evgrafov et al. 2002).  The second such gene is 
EFCH1 (EF-hand domain (C-terminal) containing 1) which has been associated with autosomal 
dominant juvenile myoclonic epilepsy (Suzuki, Delgado-Escueta et al. 2004).  Table 1 provides a 
summary of all the genes that have been identified in IE, along with their chromosome position, 
associated phenotype, and typical mode of inheritance for each phenotype.  The vast majority of 
the genes implicated to date have been identified in families with autosomal dominant IE.   
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1.10.1 Modes of inheritance 
The genetic basis for epilepsy has primarily been studied in the context of clinically 
heterogeneous and genetically homogeneous families showing autosomal dominant inheritance.  
The characteristic clinical heterogeneity and genetic homogeneity is associated with the 
phenomena of one genetic variant causing disease and segregating in multiple family members, 
but the clinical manifestations can vary widely by individual.  However, the vast majority of 
cases of IE likely follow some form of complex (polygenic) inheritance pattern.  Although, in 
rare cases, the disorder can arise from a mutation in a single gene which segregates within 
families (monogenic inheritance) (Michelucci, Pasini et al. 2012).  There is also limited evidence 
of other, non-Mendelian modes of inheritance including digenic and mitochondrial inheritance.   
Digenic inheritance refers to mutations in two distinct genes interacting to cause a genetic 
phenotype or disease.  This type of inheritance can be considered the simplest form of complex 
inheritance.  A genetic linkage study of a French family with Temporal Lobe Epilepsy (TLE) 
reported evidence of digenic inheritance implicating chromosomes 18qter and 1q24-31.  
Haplotype analysis strengthened the hypothesis that two genes segregated with the disease in this 
family.  However, no causative gene mutations were identified in these regions (Baulac, Picard 
et al. 2001).  Linkage studies, such as this one, are an excellent tool to direct and supplement 
further sequencing studies; however, on their own, often lack sufficient strength to establish 
pathogenicity within chromosomal regions. 
Mitochondrial inheritance refers to the process by which mitochondrial DNA (mtDNA) is 
inherited by offspring from the mother (maternally inherited).  This single parent (uniparental) 
pattern of mtDNA inheritance occurs because mitochondria are inherited only in maternal ova 
and not in sperm.  Therefore, the pattern of inheritance associated with alterations in mtDNA 
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will indicate both males and females being affected, but always being transmitted maternally.  
An affected male does not pass on his mitochondria to his children, so all his children will be 
unaffected.   
Defective mitochondria have been implicated in numerous neurodegenerative diseases 
particularly Parkinson’s disease and Alzheimer’s disease.  The role of mitochondria in the 
maintenance of neurons is well established especially in terms of autophagy (Ghavami, Yeganeh 
et al. 2012).  Proper mitochondrial function is imperative for the survival of neurons as these 
cells are sensitive to the accumulation of damaged cellular components (e.g. membranes) that 
occur over time.  Improperly functioning mitochondria are sometimes caused by mutated nuclear 
genes like DJ-1, PINK1 and PARKIN – all of which have been implicated in Parkinson’s disease.  
As well, cytochrome c, an important mitochondrial protein encoded by a nuclear gene, plays an 
important role in autophagy-mediated cell death.  This protein, in conjunction with lysosomes, 
mediate efficient apoptosis without which aggregation and accumulation of cellular wastes occur 
which is especially toxic to neurons.  That being said, there is not a great deal of evidence to 
date, linking neurodegeneration to the etiology of epilepsy.  In some circumstances neuronal 
damage can occur due to epileptic seizures in the cases of epileptic encephalopathies.  There 
have also been some examples of mutated mitochondrial genes causing epilepsy.  Since the 
mitochondria are in high demand in the central nervous system and muscle, due to the high 
demand for energy in these tissues, it is reasonable to speculate that mutations in mitochondrial 
DNA could result in mitochondrial diseases of the brain.  In fact, there are a group of 
mitochondrial encephalomyopathies (Goto, Nonaka et al. 1990).  Epilepsy may be the presenting 
or a late onset feature of this group.  Common mitochondrial epileptic syndromes include 
MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) and 
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MERRF (myoclonic epilepsy with ragged red fibers) syndromes.  MELAS syndrome is 
genetically heterogeneous but is caused by mutations in MT-TL1 (transfer RNA mitochondrial 
leucine 1 gene) in 80% of cases.  The remaining known mutations are in other mitochondrial 
genes.  MERRF, a syndrome characterized by myoclonus, epilepsy, ataxia, muscle weakness, 
hearing loss, and elevated serum lactate and pyruvate levels, is caused by a single point mutation 
in MTTK (transfer RNA mitochondrial lysine gene) in 80-90% of cases.  Also, a very recent 
report (Almalki, Alston et al. 2013) has linked a missense mutation in the mitochondrial gene 
FARS2, which encodes phenylalanine-tRNA synthetase, with an epileptic phenotype.  They 
showed that mutations in a single patient caused early-onset epilepsy and isolated complex-IV 
deficiency in muscle.  Therefore, mitochondrial involvement has been shown to be important in 
neurodegenerative disease and in conditions where epilepsy is part of a larger spectrum of 
clinical manifestations.  The importance of the mitochondrial genome in “non-syndromic” 
epilepsy has yet to be determined, however. 
 Futhermore, a recent Finnish study identified a novel mutation in the mitochondrial DNA 
cytochrome b gene (MTCYB) in epilepsy patients.  The study’s inclusion criteria required 
patients to have two or more maternal relatives with a seizure history but made no distinctions 
based on etiology or type of epilepsy.  Mitochondrial DNA sequencing identified a missense 
mutation, predicted to be deleterious, in five of 79 patients with epilepsy and four out of 403 
population controls (p = 0.0077) (Soini, Moilanen et al. 2013). 
 
1.10.2 Molecular Genetics of Epilepsy: Known epilepsy genes/mutations  
The molecular genetic basis of epilepsy is known to be complex and the number of 
epilepsy-associated genes/mutations is continuing to grow partly due to recent advances in 
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genetic sequencing technologies.  Many epilepsy syndromes are characterized by both locus and 
allelic heterogeneity.  Locus heterogeneity refers to a single disorder caused by mutations in 
multiple genes at different chromosomal loci.  For example, research to date has identified six 
genes which cause a GEFS+ phenotype.  Similarly, allelic heterogeneity refers to a phenomenon 
in which different mutations at the same locus or gene cause a similar phenotype.  Most 
epilepsy-associated genes have this characteristic whereby multiple mutations in the same gene 
have been identified and implicated to cause the same disorder.  For example, dozens of 
mutations in SCN1A have been identified in SMEI patients.  Additionally, pleiotropy, which 
refers to a gene (and mutations in that gene) influencing multiple, seemingly unrelated 
phenotypic traits, is characteristic of some epilepsy-associated genes.  In fact, the first epilepsy-
associated gene identified in humans, CHRNA4, has been shown to harbour a mutation which 
causes autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) in addition to a unique 
biopharmacological profile including reduced inhibition by carbamazepine and increased 
nicotine sensitivity (Hoda, Wanischeck et al. 2009).  Although, the molecular genetic basis of 
epilepsy is undoubtedly complex, many genetic contributors have been identified over the last 
two decades. 
Currently, there are 18 known genes that contribute to the genetic component of 
monogenic epilepsy (Mulley, Scheffer et al. 2003; Meisler and Kearney 2005; Steinlein 2008; 
Pandolfo 2012).  Amongst these 18 genes known to cause monogenic epilepsy, 16 are 
channelopathies and two are nonchannelopathies of unknown function.  Seventeen of these 18 
known monogenic disease genes have been determined by genome-wide linkage analysis from 
multiplex families with pedigrees suggestive of autosomal dominant inheritance.  The final, and 
most recent gene to cause epilepsy when mutated, was identified by linkage analysis in addition 
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to whole-exome sequencing methods.  The family ascertained for the latter study also presented 
with a highly penetrant form of autosomal dominant nocturnal frontal lobe epilepsy (Heron, 
Smith et al. 2013).   
The first epilepsy gene, CHRNA4, was discovered in 1995 (Scheffer, Bhatia et al. 1995; 
Steinlein, Mulley et al. 1995).  Mutations in this acetylcholine receptor subunit gene result in 
ADNFLE.  This phenotype is characterized by partial seizures and this finding led the way to 
identifying several other monogenic genes for partial epilepsy discovered to date (Berkovic and 
Mulley 1996; Steinlein 2008; Pandolfo 2012). 
Two potassium channel receptor subunit genes (KCNQ2 and KCNQ3) have been found to 
harbour mutations in families presenting with Benign Familial Neonatal Convulsions (BFNC).  
KCNQ2 was first identified in an autosomal dominant family residing in Terrenceville, 
Newfoundland in 1998 (Singh, Charlier et al. 1998).  Since this discovery, other studies have 
published six different mutations in the KCNQ2 gene, resulting in BFNC (Yalcin, Caglayan et al. 
2007; Yum, Ko et al. 2010; Fister, Soltirovska-Salamon et al. 2012).  Patients with BFNC 
typically have normal development and seizures that do not persist beyond the age of six months.  
More recently, KCNQ2 has been implicated in a newly emerging phenotype with a much more 
damaging prognosis.  A 2012 article in Annals of Neurology investigated whether KCNQ2 
mutations were present in 80 patients with unexplained neonatal seizures and associated 
psychomotor retardation.  They identified seven different heterozygous KCNQ2 mutations in 8 
patients (10%); six of which arose de novo, one in which the patient’s father was mosaic and had 
a less severe phenotype, and one in which the mother was not a carrier but the father’s DNA was 
unavailable.  In all of these eight patients, seizures began within the first week of life (two 
reportedly began in utero) and generally stopped by three years of age but the children had 
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profound to severe intellectual disability with motor impairment (Weckhuysen, Mandelstam et 
al.). 
Recently another potassium channel gene, KCNT1, was identified to be the causative 
locus in an Australian family with a severe form of ADNFLE associated with major 
comorbidities including psychiatric and behavioral disorders, intellectual disabilities and a 
median number of 30 seizures per night (Derry, Heron et al. 2008; Heron, Smith et al. 2013).  
Further investigation of the KCNT1 gene implicated two additional causative mutations 
segregating in two other families and a de novo mutation in a sporadic case with nocturnal 
frontal lobe epilepsy (NFLE) and psychiatric issues (Heron, Smith et al. 2013).  The wide 
variability of phenotype in the epilepsy syndromes associated with potassium channel receptor 
subunit genes further substantiates the evidence that inherited forms of epilepsy are highly 
diverse and variable in their clinical presentation (clinically heterogeneous). 
Four sodium channel receptor subunits (SCN1A, SCN2A, SCN1B and SCN2B) have been 
found to cause a recently described phenotype known as Generalized Epilepsy with Febrile 
Seizures Plus (GEFS+) (Wallace, Scheffer et al. 2002).  The SCN1B gene is also implicated in 
Severe Myoclonic Epilepsy of Infancy (SMEI).  GEFS+ is characterized by generalized afebrile 
seizures and febrile seizures that persist beyond the normal age range of six months to six years.  
SMEI is characterized by myoclonic seizures (jerking of the limbs, particularly the arms) in 
infancy and tends to present in patients with a family history of GEFS+.  The sodium channel 
mutations resulting in these phenotypes differ in severity.  A stop codon resulting in protein 
truncation and loss of function of that protein is associated with the SMEI phenotype, while 
mutations causing GEFS+ are typically missense mutations (Gardiner 2005).   
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Two gamma-aminobutyric acid (GABA) receptor subunit genes (GABRA1 and GABRG2) 
have been found to be causative for CAE and JME.  One chloride channel receptor subunit gene 
(CLCN2) has been found to cause several idiopathic generalized epilepsy subtypes including 
juvenile myoclonic epilepsy (Cossette, Liu et al. 2002).  Mutations in a calcium channel beta-4 
subunit gene (CACNB4) have also been found to cause juvenile myoclonic epilepsy in a single 
patient, generalized epilepsy in a German family, and episodic ataxia in a French Canadian 
family (Escayg, De Waard et al. 2000). 
The two monogenic epilepsy genes that are non-channelopathies include an EF-hand 
motif gene (EFHC1) which causes JME and Leucine-rich Glioma Inactivated 1 gene (LGI1) 
which causes Autosomal Dominant Partial Epilepsy with Auditory Features (ADPEAF).  The 
exact function of these genes remains unknown (Turnbull, Kumar et al. 2008).  However, it is 
believed that each of the five missense mutations of the EFHC1 gene interfere with calcium 
channel function and mediate apoptotic activity (Medina, Suzuki et al. 2008). 
Studies investigating alternate mechanisms of genetic contributors to the cause of 
epilepsy have also yielded some interesting findings.  As described later, somatic mutations have 
been identified in genes previously associated with epilepsy.  Epigenetic modifications have also 
been implicated in the etiology of epilepsy.  Epigenetics has been defined as a set of self-
perpetuating modifications on histone proteins or directly onto DNA that produce alterations in 
chromatin structure and alterations in patterns of gene expression (Lubin 2012).  Recent evidence 
suggests that dysregulation of epigenetic mechanisms can cause disorders of the central nervous 
system.  Histone modifications including acetylation and phosphorylation alterations have been 
implicated in epilepsy as well as Alzheimer’s.  However, the exact role these modifications play 
in epilepsy development remains unknown (Portela and Esteller 2010).   
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Gene by subtype Chromosomal 
location 
Phenotype associated 
with gene 
Mode of 
inheritance 
Reference 
Voltage-gated sodium 
channel  genes 
    
SCN1A 2q24 GEFS+ 
SMEI 
MAE 
AD 
AD, de novo 
AD 
(Escayg, MacDonald et al. 2000) 
(Claes, Del-Favero et al. 2001) 
(Ebach, Joos et al. 2005) 
SCN1B 19q13.1 GEFS+ 
MAE 
AD 
AD 
(Wallace, Wang et al. 1998) 
(Sun, Zhang et al. 2008) 
SCN2B 11q23 GEFS+ AD (Wallace, Scheffer et al. 2002) 
SCN2A 2q24 GEFS+ 
BFNIS 
SMEI 
AD 
AD 
AD 
(Sun, Zhang et al. 2008) 
(Heron, Crossland et al. 2002) 
(Kamiya, Kaneda et al. 2004) 
Voltage-gated chloride 
channel  genes 
    
CLCN2A 3q26 JME AD (Cossette, Liu et al. 2002) 
Voltage-gated calcium 
channel  genes 
    
CACNB4 2q22-q23 JME AD (Escayg, De Waard et al. 2000) 
Voltage-gated potassium 
channel  genes 
    
KCNQ2 20q13.3 BFNC AD (Singh, Charlier et al. 1998) 
KCNQ3 8q24 BFNC AD (Singh, Westenskow et al. 2003) 
KCND2 7q31 TLE Single patient (Singh, Ogiwara et al. 2006) 
KCNT1 9q34.3 ADNFLE AD (Heron, Smith et al. 2012) 
Neurotransmitter 
receptor genes 
    
GABRG2 5q31.1-q33.1 GEFS+ AD (Baulac, Huberfeld et al. 2001) 
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SMEI 
MAE 
CAE 
AD 
AD 
AD 
(Gennaro, Veggiotti et al. 2003) 
(Sun, Zhang et al. 2008) 
(Wallace, Marini et al. 2001) 
GABRD 1p36.3 GEFS+ AD (Sun, Zhang et al. 2008) 
GABRA1 5q34-q35 JME 
CAE with JME 
AD 
AD 
(Cossette, Liu et al. 2002) 
(Wallace, Marini et al. 2001) 
CHRNA4 20q13.3 ADNFLE AD (Steinlein, Mulley et al. 1995) 
CHRNA2 8p21 ADNFLE AD (Aridon, Marini et al. 2006) 
CHRNB2 1q21 ADNFLE AD (De Fusco, Becchetti et al. 2000) 
Non-channelopathies     
EFHC1 6p12-p11 JME AD (Suzuki, Delgado-Escueta et al. 2004) 
LGI1 10q24 ADPEAF 
Familial lateral TLE 
AD 
AD 
(Kalachikov, Evgrafov et al. 2002) 
(Kalachikov, Evgrafov et al. 2002) 
Alternate mechanisms     
PIK3CA 3q26 Hemimegalencephaly De novo (Poduri, Evrony et al. 2013)  
AKT3 1q43 Hemimegalencephaly De novo (Poduri, Evrony et al. 2013)   
mTOR 1p36 Hemimegalencephaly De novo (Poduri, Evrony et al. 2013)   
CHD2 15q26.1 Epileptic 
encephalopathy 
De novo (Carvill, Heavin et al. 2013)  
SYNGAP1 6p21.32 Epileptic 
encephalopathy 
De novo (Carvill, Heavin et al. 2013)  
TBC1D24 16p13.3 Epileptic 
encephalopathy 
Compound 
heterozygosity 
(Milh, Falace et al. 2013)  
 
Table 1. Genes identified in idiopathic epilepsy. AD, autosomal dominant. 
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1.10.3  Molecular Genetics of GEFS+ 
GEFS+ is genetically heterogeneous with five causative genes identified to date.  The 
most widely reported is SCN1A, which encodes the α1-subunit of a voltage-gated sodium 
channel and accounts for mutations in approximately 11% of previously described GEFS+ 
families (Escayg, MacDonald et al. 2000; Marini, Mei et al. 2007).  Mutations in genes encoding 
the β1 and αII subunits of voltage-gated sodium channels, SCN1B and SCN2A, can also cause 
GEFS+ (Wallace, Wang et al. 1998; Sugawara, Tsurubuchi et al. 2001).  One splicing and six 
missense mutations associated with GEFS+ have been identified in SCN1B (Wallace, Wang et al. 
1998; Audenaert, Claes et al. 2003; Scheffer, Harkin et al. 2007), and one missense mutation in 
the SCN2A gene has been associated with GEFS+ in a single patient (Sugawara, Tsurubuchi et 
al. 2001).  In addition to mutations in subunits of the sodium channel, GEFS+ may also be 
associated with abnormalities in GABA neurotransmission, resulting from mutations in the 
GABRG2 and GABRD genes, which encode subunits of the GABAA, receptor (Baulac, Huberfeld 
et al. 2001; Dibbens, Feng et al. 2004).  Three missense mutations segregating in GEFS+ 
families have been reported in the GABAA receptor, gamma 2  gene (Baulac, Huberfeld et al. 
2001; Harkin, Bowser et al. 2002), while two have been reported in the GABAA receptor, delta 
(GABRD) gene (Dibbens, Feng et al. 2004).  
The most clinically relevant GEFS+ gene, SCN1A, has 26 exons and is highly conserved 
across species (Escayg, MacDonald et al. 2000).  Mutations in SCN1A have been associated with 
a spectrum of epilepsy phenotypes, including severe myoclonic epilepsy of infancy (SMEI), 
GEFS+, and infantile spasms (IS) (Wallace, Hodgson et al. 2003; Harkin, McMahon et al. 2007).  
Of the 155 SCN1A mutations currently reported on the Human Gene Mutation Database 
(http://www.hgmd.cf.ac.uk), the vast majority are associated with SMEI, while 19 missense 
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mutations in the SCN1A gene have been associated with GEFS+ (Meisler and Kearney 2005; 
Mulley, Scheffer et al. 2005; Pineda-Trujillo, Carrizosa et al. 2005).  
Recently, the phenotypic spectrum resulting from SCN1A mutations has been extended to 
include cryptogenic generalized and partial epilepsy, familial hemiplegic migraine, and familial 
sudden unexpected death in epilepsy (SUDEP) (Gargus and Tournay 2007; Harkin, McMahon et 
al. 2007; Hindocha, Nashef et al. 2008).  Studies involving comprehensive clinical data on 
mutation carriers from multiplex families are necessary to determine the natural history and full 
clinical spectrum associated with the GEFS+ phenotype.   
 
1.10.4 Channelopathies and epilepsy 
There are over two dozen conditions caused by mutations in genes encoding channels, 
known as channelopathies, many of which have numerous channel genes causing the disorder, 
such as retinitis pigmentosa and Long QT syndrome (LQTS).  Due to the almost ubiquitous 
distribution of ion channels in human tissues, mutations in the channelopathy genes can cause a 
wide array of clinical manifestations.  Diseases such as asthma, autism, cystic fibrosis, 
nonsyndromic deafness, visual impairment, epilepsy, ataxia and cardiac sudden death have all 
been associated with deleterious variants in ion channel genes.  
The vast majority of epilepsy-related genes are ion channel genes (see Table 1).  Most 
notably, several sodium channel genes (SCN1A, SCN1B, and SCN2A) are known to cause 
epilepsy with a broad range of phenotypes.  While mutations in the acetylcholine receptor genes 
(CHRNA4, CHRNB2, CHRNA2) cause a susceptibility to nocturnal frontal lobe epilepsy, 
characterized by nocturnal seizures occurring mostly during non-REM sleep.  Mutations in 
calcium channel genes (CACNA1A, CACNB4, CACNA1H) have been associated with idiopathic 
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generalized epilepsy, juvenile myoclonic epilepsy, and childhood absence epilepsy.  As well, 
mutations in potassium channel, chloride channel and GABA genes have all been associated with 
epileptic seizures.  
Another well studied group of channelopathies are those related to sudden cardiac death 
(Webster and Berul 2013).  Probably the best known and well-studied of the cardiac 
channelopathies is LQTS.  There are at least 13 known ion channel genes that, when mutated, 
cause LQTS.  Mutations in these genes can predispose the patient to arrhythmias.  Other known 
cardiac channelopathies include short QT syndrome, Brugada syndrome, arrhythmogenic right 
ventricular cardiomyopathy, and catecholaminergic polymorphic ventricular tachycardia.  In 
total there are approximately 40 known channel genes that cause cardiac arrest and/or sudden 
cardiac death.  
Interestingly, in terms of this thesis, an increased mortality rate in epilepsy patients is 
partially caused by sudden unexpected death in epilepsy (SUDEP) which can be the result of 
cardiac arrhythmias in some epileptic patients (Velagapudi, Turagam et al. 2012).  SUDEP 
accounts for 8%–17% of deaths in people with epilepsy and more often occurs in males.  
Although the risk of SUDEP is thought to be multifactorial, one of the contributors is having an 
underlying channel defect.  In particular, mutations in genes that cause LQTS can also result in 
SUDEP.  An analysis of 68 SUDEP cases (Tu, Bagnall et al. 2011) identified six novel variants 
in KCNH2 and SCN5A. A pathogenic link to SUDEP was supported in two of these variants.  
However, subsequent studies have suggested that these variants are polymorphisms that may 
contribute to SUDEP.  As well, there is limited data on the impact of SCN1A in the etiology of 
SUDEP.  These three genes are well known to be responsible for LQTS.  Of course, the risk of 
SUDEP in epilepsy patients, as noted above, is not exclusively determined by having a mutation 
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in a cardiac-related ion channel gene.  The most prominent risk factors include the long-standing 
disease, poor seizure control, and antiepileptic therapy.  Thus, SUDEP is an important 
consideration when clinically following high-risk epileptic patients, particularly with the ability 
to potentially prevent and treat cardiac arrhythmias.    
As further evidence unfolds into the genetic underpinnings of SUDEP, it appears that the 
pathology is primarily multifactorial, and likely the result of multiple genes/mutations interacting 
to produce this devastating outcome.   
 
1.10.5 Alternate genetic mechanisms of epilepsy 
While most genetic conditions are considered to be directly inherited from one’s parent 
and present in all somatic (body) cells, researchers are becoming increasingly aware of alternate 
mechanisms by which mutations can cause diseases, including epilepsy.  For example, somatic 
mutations in three genes (PIK3CA, AKT3, and mTOR) have been shown to cause enlargement of 
one hemisphere of the brain (hemimegalencephaly) which is a malformation highly associated 
with epilepsy.  Such somatic mutations are undetectable in the parents as they arise de novo (a 
latin expression meaning “from the beginning” which refers to a genetic mutation that neither 
parent possessed nor transmitted) (Poduri, Evrony et al. 2013).  There have also been de novo 
mutations identified in CHD2 and SYNGAP1 that have been shown to cause epileptic 
encephalopathies.  Multiple mutations in each of these genes accounted for the etiology in 
approximately 1% of the 500 cases of epileptic encephalopathy in this study.  Interestingly, the 
vast majority of these mutations were highly deleterious (frameshift and nonsense mutations) and 
resulted in multiple seizure types and severe intellectual disability in all cases (Carvill, Heavin et 
al. 2013). 
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Rare cases of compound heterozygosity (e.g. recessive mode of inheritance) causing 
epileptic syndromes have also been reported.  The term compound heterozygosity refers to the 
condition of two different mutations on separate alleles (one inherited from each parent) of the 
same gene causing a disorder.  A 2013 study published in Human Mutation described two 
siblings with early onset epileptic encephalopathies attributed to compound heterozygous 
mutations in TBC1D24.  The patients were born to healthy, unrelated parents and both children 
appeared to be healthy for the first month of life.  Seizure onset and neurological regression 
began at four and five weeks of age and progressed rapidly with moderate to global brain atrophy 
by six months of age.  Functional studies showed that the two TBC1D24 mutations severely 
impair the expression of the TBC1D24 protein, which is critical to the maturation of neuronal 
circuits (Milh, Falace et al. 2013). 
 Somatic mosaicism has also been postulated to be a mechanism of epileptogenesis.  
Somatic mosaicism occurs when the somatic cells of the body are of more than one genotype.  A 
commentary in Brain in 2008 presented the hypothesis that some portion of disorders of the 
central nervous system, such as epilepsy, could be caused by mosaicism generated in brain cells 
and tissues due to X-linked mutations.  The theory was based upon research involving an X-
linked neurological disorder (craniofacial dysplasia) with an inverse expression pattern; whereby 
females were affected and male carriers were unaffected (thus the opposite of the typical 
expression pattern seen in X-linked disorders)  (Lindhout 2008).  This expression pattern has 
also been observed in a rare epilepsy disorder known as epilepsy and mental retardation limited 
to females (EFMR)  (Juberg and Hellman 1971).  It is believed that disorders of the brain may be 
caused by somatic mosaicism because of the brain’s immense interconnectivity which relies on 
the homogeneous make up of neurons and circuitry.  The formation of genetically different tissue 
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within the central nervous system can create synaptic gaps in connectivity and alter the delicate 
excitation/inhibition balance of the brain.  This theory has been demonstrated in mouse models 
but is yet to be proven in humans (Davy, Bush et al. 2006). 
 
 
1.10.6 Chromosomal loci implicated in epilepsy 
Six different chromosomal loci for common generalized epilepsies have been identified.  
These include two separate loci for JME on chromosomes 6p and 15q.  Two separate loci are 
also present for pyknoleptic CAE, namely, CAE that evolves to JME on chromosome 1p and 
CAE with tonic-clonic seizures on chromosome 8q24 (Delgado-Escueta, Medina et al. 1999; 
Steinlein 2008).  Two further putative gene locations have been implicated in idiopathic 
generalized epilepsy, namely tonic-clonic with generalized spike waves on chromosome 3p and 
generalized epilepsy with febrile seizures, JME, and absences on 8q24 (Pandolfo 2012).  Table 2 
provides a summary of all the loci that have been identified to date. 
These chromosomal regions have not been substantiated by follow up studies identifying 
single epilepsy-associated genes with disease-causing mutations. Replication studies are required 
to lend further evidence and/or narrow these chromosomal regions and identify the positional 
candidate genes. 
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Chromosomal locus Phenotype Reference 
6p11 JME (Liu, Delgado-Escueta et al. 1996) 
15q JME (Elmslie, Rees et al. 1997) 
1p CAE evolving to JME (Delgado-Escueta, Medina et al. 1999) 
8q24 CAE with tonic-clonic sz (Fong, Shah et al. 1998) 
3p Tonic-clonic sz (Delgado-Escueta, Medina et al. 1999) 
8q24 Generalized epilepsies (Delgado-Escueta, Medina et al. 1999) 
19q12 BFIS (Striano, Lispi et al. 2006) 
 
Table 2. Chromosomal loci associated with epilepsy phenotypes. JME, Juvenile myoclonic epilepsy; CAE, childhood absence 
epilepsy; BFIS, Benign familial infantile seizures. 
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1.10.7 Approaches to disease gene discovery 
In 2014, there are two major approaches to gene discovery for Mendelian diseases.  
Firstly, and the more traditional approach, is the candidate gene method to gene hunting which is 
ultimately carried out via direct Sanger DNA sequencing of previously disease-associated genes 
or by sequencing genes identified via linkage and/or haplotype analyses.  Thus, a gene can be a 
candidate based on its chromosomal position (a positional candidate), the function of the protein 
for which it codes (a functional candidate), and/or its previous association with the disease of 
interest.  Positional cloning and protein function studies was beyond the scope of the current 
study, thus candidates were primarily identified by their previous associations with epilepsy.  For 
Mendelian conditions, a candidate gene is normally screened for mutations in one or more 
affected patients within a family.  The presence or absence of a possibly pathogenic variant can 
later be tested in both affected and unaffected family members and/or healthy population 
controls.  Healthy controls need to be analyzed to help prove that any variants postulated to be 
disease-causing are not rare non-pathogenic population variants.   
The positional candidate approach often utilizes a statistical method called linkage 
analysis, and in concert with haplotype and segregation analyses.  In order to perform these 
analyses patients and their families must be genotyped to determine if the gene of interest 
segregates on the same haplotype in all affected people within the family.  This method utilizes 
molecular markers present in the genome, which may be Single Nucleotide Polymorphisms 
(SNPs) and/or microsatellites.  Microsatellites are tandem repeating segments of one to six 
nucleotides, present throughout the genome and are used as molecular markers in genetic studies.  
SNPs and/or microsatellites that span the region of interest (which could be the entire genome) 
are selected and primers are designed to anneal to the surrounding sequence.  Polymerase chain 
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reaction (PCR) experiments are then used to amplify these regions.  PCR is a common laboratory 
technique used to amplify a single segment of DNA sequence to generate thousands to millions 
of copies, known as amplicons.  The resulting amplicons are analyzed using a DNA sequencer 
and computer software to determine the number of repeats (for microsatellites) or the specific 
nucleotide (for SNPs) for each family member.  This data is then assembled into haplotypes and 
analyzed on a pedigree to determine if the region of interest segregates with the disease in the 
families.  Haplotype assembly takes advantage of the principals of genetic recombination.  
Chromosomes undergo crossovers during meiosis, which is the process of exchanging genetic 
information, usually between matching regions on homologous chromosomes.  This exchange of 
genetic material is called genetic recombination.  After a crossover event occurs, the newly 
formed chromosome is a recombinant.  Alleles (alternate forms of the same locus) in close 
physical proximity to one another on the same chromosome, generally segregate together in 
blocks known as haplotypes (Keats, Sherman et al. 1991).  Haplotype analysis is a very useful 
tool in defining a critical region within which a disease-causing gene is located. Within a 
haplotype, markers that do not have the same alleles among affected individuals due to 
recombination events can be used to further delineate the critical region containing the gene of 
interest. Thus, by taking advantage of this knowledge it is possible to track traits through 
families in a particular chromosome block, which can be identified by genetic markers that are 
physically adjacent to the disease gene.  In order to determine if the genetic markers and the 
disease-causing mutation are linked, one must determine the phase (which parent passed on 
which allele to the child) and recombination points.  Phase is difficult to determine when parents 
are homozygous for the particular allele.  Such alleles are deemed uninformative for linkage as it 
is impossible to determine which parental copy was inherited.  Alleles for which parents are 
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heterozygous must be utilized in order to determine phase and recombination status.  These 
alleles are the basis of haplotype construction.  Once a region of presumed linkage between a 
disease gene and genetic markers are identified, the subsequent step involves direct Sanger DNA 
sequencing of the coding segments of the genes within the segregating haplotype.   
Over the past decade, the Sanger DNA sequencing method has been the most common 
approach to screening genes for causative variants.  It may be used independently or in 
conjunction with linkage analysis.  This method was introduced in 1977 by Fredrick Sanger and 
has since become the gold standard for generating or confirming sequencing data (Sanger, 
Nicklen et al. 1977).  It involves the incorporation of deoxynucleotide triphosphates (dNTPs) 
with target DNA using primer sequences to determine nucleotide sequences. It is a tried and true 
technique that is considered the gold standard for mutation detection. 
The second and much more recent strategy for disease gene hunting involves the latest 
technology in DNA sequencing methods, called Next Generation Sequencing (NGS).  NGS 
refers to high-throughput DNA sequencing technologies whereby millions to billions of DNA 
strands can be sequenced in parallel, yielding substantially more throughput than Sanger 
sequencing.  This technology has revolutionized how geneticists perform novel gene discovery 
programs and has begun to have clinical applications (Mardis 2008; Glusman 2013).  NGS 
incorporates various platforms to produce high throughput data by way of simultaneous capture.  
The targeted region of interest depends on the platform selected (many platforms have now been 
developed by various companies) but they each utilize massively parallel sequencing strands.  
Multiple fragmented sequencing reads are assembled on the basis of their overlapping regions.  
Choice of platform depends on multiple criteria including price and data requirements.  Whole 
genome sequencing (WGS) captures the entire genome, including untranslated and intergenic 
60 
 
regions.  Whole exome sequencing (WES) captures only the exons and intronic boundaries of 
genes.  Targeted deep sequencing (TDS) allows the user to select one or multiple chromosomal 
regions of interest and target the DNA sequence in only those particular areas.  Thus, if a 
mutation in a specific gene has been previously associated or linked to epilepsy, it would be 
possible to sequence the entire coding and regulatory regions of that particular target gene in 
large samples (potentially thousands) of patients to determine if the same mutation or novel 
mutations in that gene are linked or associated with disease (Ferraro 2012).  Each of these NGS 
methods has led to many breakthroughs in a plethora of genetic diseases (Glusman 2013).  
Epilepsy research has also recently benefited from NGS with the discovery of the KCNT1 gene 
using WES technology (Heron, Smith et al. 2013).  There are also potential clinical applications 
for these technologies in epilepsy research.  With the large number of genes associated with 
inherited and sporadic forms of epilepsy, it may improve cost-effectiveness and efficiency to 
screen epilepsy patients for the known epilepsy genes using NGS technologies.   
These technologies, however, carry their own unique set of limitations and challenges.  
The vast amount of data produced when employing NGS technologies has invoked an entire field 
of study developed to analyze and filter this data.  These technologies can produce lists of 
hundreds of thousands of variants, of which, almost all are incidental findings.  In the case of 
Mendelian disease, the researcher aims to identify one pathogenic variant amongst thousands.  
There are numerous software programs that incorporate bioinformatics data to identify the 
variants of highest biological impact.  The data is reduced to incrementally shorter lists through 
various filtering techniques according to mutation severity, evolutionary conservation, functional 
pathways, and minor allele frequency in comparison populations.  The short-list of potentially 
pathogenic variants must then be tested and confirmed using Sanger sequencing.  Further 
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evidence of pathogenicity of a variant may then be gleaned through familial segregation studies, 
identification of the variant in unrelated patients, functional studies, etc.  Although NGS 
technologies have allowed genetic studies access to the vast amount of information in the human 
genome, the analysis of this data is still in its early phases and further research in this area will 
allow for improved techniques for identifying pathogenic variants. 
 
1.10.7.1    Determining the pathogenicity of sequence variants 
Once sequencing data is generated, the task of determining the pathogenic nature of each 
variant must be diligently undertaken.  In order to separate disease-causing mutations from 
common or rare variants that are not deleterious, various methods of filtering are utilized.  There 
are currently several online DNA variation databases available to determine the frequency of 
variants (e.g. dbSNP, 1000 Genomes, UCSC Genome Browser, Ensembl, NHLBI).  Some of the 
information in these databases consists of entire genome sequences of individuals, including the 
frequencies of alternate alleles at the same chromosomal positions.  These are reported as minor 
allele frequencies (MAFs) and may include ancestry information for comparison purposes.  For 
example, the current study was conducted on a Caucasian population and therefore used the 
MAFs for Caucasian populations as a comparison for previously reported variants.  However, 
probably the most valuable sequence databases are actually in the laboratories of the centers that 
perform a high volume of NGS.  These labs collate the data of all of the samples (anonymously) 
processed there, which is often many more genomes than are available publically.  Furthermore, 
these databases, and locus-specific databases, can be used to determine if the variant is located in 
a coding or non-coding region of the gene, if the variant alters the amino acid for which it codes, 
and if the variant is located in a probable splice site position.  There are also bioinformatic tools 
62 
 
available (e.g. SIFT, PolyPhen, Panther) which aid in determining if a variant may be 
deleterious.  These publically available tools are just one of many instruments that should be 
utilized to determine the pathogenicity of variants.  For many variants, pathogenicity is difficult 
to assess, but with the growing number of genomes being sequenced, there is hope that it will be 
less difficult in the future.  Currently, using segregation data from affected and unaffected family 
members as well as population controls in addition to bioinformatic tools, MAFs and, ultimately, 
data from functional studies of the variants of interest, is all utilized to determine pathogenicity. 
Further to generating segregation data for variants of interest, statistical methods can be 
employed to determine the probability that the segregation of a putative disease allele is 
statistically significant.  A Simplified method for Segregation Analysis (SISA) is used to 
calculate the probability that a genetic variant cosegregates with the disease phenotype in a 
family by chance.  It uses the level of disease expressivity in mutation carriers and non-carriers 
to determine the penetrance and expression of the variant in the family (Moller, Clark et al. 
2010). 
 
 
1.11 Benefits of studying the Newfoundland population 
 The population of Newfoundland and Labrador (NL) is predominantly of English and 
Irish extraction and has grown primarily by natural increase within small, isolated communities, 
resulting in multiple founder populations (Mannion, Memorial University of Newfoundland. 
Institute of Social and Economic Research. et al. 1978; Mannion and Memorial University of 
Newfoundland. Educational Television Centre. 1979; Bear, Nemec et al. 1987; Bear, Nemec et 
al. 1988; Rahman, Jones et al. 2003).  Currently, the population of the province is approximately 
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509 200; about 50% of the population live in rural communities of fewer than 2500 inhabitants 
and approximately half the population (257 223) live in the Avalon Peninsula region 
(http://www.statcan.gc.ca).  The Avalon Peninsula is a predominantly urban region and is the 
location of the province’s capital city, St. John’s (see Figure 4). 
 
 
Figure 4. Map of Newfoundland indicating the most densely populated region and the 
capital city, St. John’s. The Avalon Peninsula is highlighted in yellow. 
The population of NL is genetically isolated, as is indicated by an overabundance of 
several monogenic disorders in which a founder effect (e.g. a genetic mutation which arose in a 
population many generations ago and now is responsible for disease in many individuals) has 
been observed.  A provincial study of Bardet-Biedl Syndrome (BBS), a rare, multi-system 
autosomal recessive disorder, demonstrated that the condition occurred in multiple geographic 
isolates, but the genetic cause differed from region to region.  In fact, six different genes were 
identified, in which 10 different mutations were identified as the cause of this syndrome (Webb, 
St. John’s 
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Dicks et al. 2009).  In autosomal dominant Lynch Syndrome, the genetic cause of this cancer 
syndrome also varied across geographic isolates on the island (Warden, Harnett et al. 2012).  
The population of Newfoundland and Labrador presents a unique opportunity to study 
genetically inherited diseases such as idiopathic epilepsy.  Like other genetic isolates that have 
arisen from a limited founder population, this province represents a valuable resource for 
identifying disease-related genes for monogenic disorders (Bear, Nemec et al. 1987; Bear, 
Nemec et al. 1988).  In comparison to other developed regions, the relative genetic homogeneity 
of the Newfoundland population perpetuates genetic disease in such a manner that potentially 
allows molecular studies to yield more novel gene discoveries for numerous inherited diseases. 
 
1.12 Study Protocol 
The aim of the current study was to determine the clinical and genetic epidemiology of 
childhood IE in Newfoundland and Labrador.  Specifically, this study was designed to determine 
the incidence of IE in the Avalon Peninsula region and the geographic distribution of sporadic 
and familial cases of childhood IE, as well as classify childhood IE in the province by clinical 
manifestations, identify families with IE compatible with likely monogenic inheritance, and to 
determine the underlying genetic etiology in these families. 
 
1.12.1  Study Eligibility: Inclusion/exclusion criteria 
Criteria for inclusion in the study included all children in Newfoundland and Labrador, 
aged 0 to 15 years during the seven-year study inception period from 1999-2006, with a history 
of two or more unprovoked seizures, more than 24 hours apart.  Children with only febrile 
seizures, only one seizure, and/or known underlying seizure-associated disorders were excluded 
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from the study.  Those diagnosed with a seizure-associated disorder (eg. neuronal ceroid 
lipofuscinosis, tuberous sclerosis, etc.) through the course of the study were excluded from 
further follow-up and analysis. 
 
1.13 Thesis statement 
This population-based study of the clinical and genetic epidemiologic characteristics of 
pediatric IE in Newfoundland creates a foundation of knowledge which is directly translated to 
improved patient care and also serves as a pilot for future studies to potentially identify novel 
epilepsy-associated gene(s) in this population. 
 
  
66 
 
 
 
 
 
 
 
 
 
 
Chapter 2  
Methods 
 
  
67 
 
2 Methods 
2.1 Study design and patient ascertainment 
 The current study is a provincial, population-based epidemiological study, designed to 
assess clinical and genetic features of childhood IE.  The study was designed to research and 
measure several variables, both cross-sectionally and prospectively.  Cross-sectional studies were 
employed to analyze the population of all children with IE for the entire province, while the 
prospective analyses utilized a representative subset of the population for one portion of the 
study and the entire population for the remainder of the study.   
To determine the most accurate incidence of childhood IE, only the childhood population 
of the Avalon Peninsula was used.  Within this subset of the NL population, it is estimated, by 
the physicians and staff at the Janeway Neurology Clinic, that the ascertainment of children with 
IE seen at this clinic approaches 100%.  However, for the entire province, the ascertainment is 
approximately 95% (personal communication, Dr. David Buckley).  Therefore, to obtain the 
most complete incidence data, only the Avalon Peninsula population was included in this portion 
of the study. 
 
2.1.1 Cross-sectional analyses 
Cross-sectional studies are a class of research methods that involve the observation of all 
of a population, or a representative subset, at one specific point in time.  For this study, thorough 
medical records and a database of patient information maintained at the Janeway Pediatric 
Neurology Clinic allowed for epidemiologic analysis of the entire NL childhood population 
utilizing these baseline measures.  Data was extracted from the database and medical records to 
compile patient information pertaining to gender, EEG recordings (classified as normal versus 
68 
 
abnormal), neuroimaging results (both MRI and CT scans), primary epilepsy diagnosis, 
classification by primary seizure type, active epilepsy status (occurrence of seizure(s) within the 
last one and five years), and anti-epileptic drug (AED) status.   
 
2.1.2 Prospective study 
Prospective studies follow a group or population of individuals over time to determine 
how certain factors affect outcomes of interest.  The current study was designed to obtain patient 
data over several years to assess the etiology and level of impact of IE in this population of 
Newfoundland children.  Patients were ascertained prospectively (all consecutive IE cases 
presenting to clinic) through the provincial pediatric neurology clinic at the Janeway Child 
Health Centre, the only children’s hospital in the province.  Inclusion criteria were as follows; 
residents of Newfoundland and Labrador, aged 0 to 15 years, with a clinical diagnosis of IE 
made between 1999 and 2006.  IE was defined as two or more unprovoked, asymptomatic 
seizures occurring more than 24 hours apart in accordance with the International League Against 
Epilepsy (Commission 1993).  Diagnoses were confirmed by the pediatric neurologists at the 
Janeway Child Health Centre (DB, MA).  Children with a single unprovoked seizure, febrile 
seizures, or another precipitating or underlying cause discovered throughout the duration of the 
study were excluded from further investigation and removed from analyses.  Children with 
psychomotor delay were not excluded from the study for having an underlying cause as the 
delays may be unrelated to the seizures or could be caused by the seizures themselves (as with 
epileptic encephalopathies). 
Three-hundred ninety-five cases of childhood epilepsy, presenting to the neurology clinic 
between 1997 and 2006, were reviewed, yielding 121 cases (117 families; three with more than 
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one child presenting to clinic) who met eligibility criteria for the study.  Ninety-seven of the 117 
families were contacted and 86 agreed to participate, giving a response rate of 74%.  Three 
attempts were made to reach the remaining 20 families by telephone and/or mail-out consent 
form.  However, they chose not to respond and/or participate.  Ascertainment bias was assessed 
by calculating the rate of familial disease in responders versus non-responders.  The 11 families 
who did not participate in the family study either refused (n=6), relocated (n=3) or had social 
issues preventing participation (n=2).  Figure 5 depicts the study design and ascertainment.  The 
86 participating families provided genealogical data for pedigree construction and answered 
medical and seizure history questionnaires (Appendix B).  When necessary, and after informed 
consent was provided, medical charts were also reviewed for further medical history details.  
Pedigree data was obtained by personal and/or phone interviews with the parent(s) or 
legal guardians to the patients.  I gathered as much family history data as they could provide and, 
as needed, contacted other family members to obtain a more extensive history.  I used this data to 
construct pedigrees, spanning at least three generations, and analyzed the disease segregation 
structure to determine the most probable mode of inheritance.  Pedigree data was then transferred 
to digital format using Cyrilic pedigree drawing software (version 2.1).  These pedigrees were 
then analyzed according to compatible inheritance patterns.  Patients with no known family 
history were classified as sporadic cases.  Patients with a family history in only one first degree 
relative or with affected relatives that were second degree or greater, were classified as having a 
family history of unknown type where the mode of inheritance was inconclusive.  Patients with 
two or more affected first degree relatives, spanning at least two generations of the pedigrees, 
were classified as having a likely autosomal dominant inheritance pattern.  Geographic data was 
used to determine distribution patterns and examine familial clustering.  Blood samples were 
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obtained from 21 families (79 individuals) choosing to participate in the molecular phase of the 
study.  Amongst the families with a positive family history, the mean number of affected 
relatives was calculated for two groups – those who participated in the molecular phase of the 
study and those who did not.   
Patients and their family members were informed of any molecular findings that could 
improve the course of their medical treatment or have implications for genetic counseling.  I 
provided the neurologist and research nurse with a mutation report for all individuals in which a 
pathogenic mutation was identified.  The patients and family members were then notified of their 
result by the neurologist in the clinic and referred to genetic counseling for further follow up. 
The study was approved by the Human Investigations Committee (HIC) of Memorial 
University (Study No. 4.15, see Appendices A and C for HIC application and study consent 
form).   
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Figure 5. Flowchart depicting study design and ascertainment. 
Study design and HIC approval 
Database search: 395 epilepsy 
cases 
Other diagnosis 
after enrollment: 2 
Clinical data 
obtained: 119 cases 
Idiopathic epilepsy 1999-2006: 
121 cases (117 families) 
Contacted: 97 families Unable to contact: 20 families 
11 families did not participate: refusal 
n=6, relocation n=3, social issues n=2 86 families studied 
Chart review 
Positive family history n=55 families Sporadic n=31 families 
Apparent AD n=8 Not AD n=47 
DNA n=14 families DNA n=7 families 
Molecular testing n=21 
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2.2 Epidemiological measures 
A 5-year incidence of pediatric IE for the Avalon Peninsula was calculated 
retrospectively, using population data from Statistics Canada.  This region was chosen because 
all childhood cases of IE presenting to family physicians, clinics and emergency rooms on the 
Avalon Peninsula are referred to the Janeway Neurology Clinic (personal communication, D 
Buckley).  Children living in all other regions of the province are typically treated solely by their 
family physician or may be referred to the nearest health clinic.  The number of new incident 
cases on the Avalon Peninsula, over a 5-year period was divided by the average population of 
children, aged 0-15 years, living in the region during that period.  An incident case of IE was 
defined as a person diagnosed with epilepsy in the previous five years, regardless of antiepileptic 
drug treatment or symptom remission. 
A database maintained by the neurologists and research nurses at the Janeway Pediatric 
Neurology Clinic was used to obtain case status, age at onset, age at diagnosis, seizure type(s), 
medication(s), family history status, and epilepsy syndrome diagnosis.  Epilepsy diagnoses, as 
written in patient charts by the attending neurologist, are coded based on the primary epilepsy 
diagnosis and the data is then entered into the database by a research nurse.  Definitions for 
etiological categories were based on the most recent criteria published by the ILAE Commission 
on Epidemiology and Prognosis (Commission 1993).   
Data on family history, medical history and investigations including neuroimaging (MRI 
and CT brain scans) and EEG reports were obtained from medical chart reviews and interviews 
performed during clinic visits, over the phone, and during in-home visits.  A positive family 
history of IE was defined as the occurrence of epilepsy in at least one first or second degree 
relative of the proband (Mullins, O'Sullivan S et al. 2007).  Positive family history cases were 
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further classified as being compatible with autosomal dominant or other (non-autosomal 
dominant) familial inheritance.  Compatibility with AD inheritance was defined as the presence 
of IE in at least two generations and in at least three relatives, one of whom is a first degree 
relative of the other two.  The remaining cases in the positive family history group that did not 
fulfill the criteria for AD inheritance were classified as having non-AD familial disease.   
 
2.2.1 Informed consent 
For both the family/medical history and DNA extraction phases of this study, informed 
consent was obtained from parents or legal guardians.  When patients were of literacy age, they 
were briefed on the ethical considerations of the study and were also asked to sign informed 
consent forms. 
 
2.3 Molecular method selection  
The molecular approach was a candidate gene screen based on phenotypic features in 
multiplex families with apparent AD inheritance.  Phenotype data was carefully examined, for 
both the probands and family members of these families, and used to select the highest priority 
candidate genes, based on previously published phenotype-genotype associations.  Linkage 
analysis was selected as the initial candidate gene approach to screen family A.  Both affected 
and unaffected relatives were selected for genotyping to enable phasing of polymorphic markers.  
The subsequent gene screening method selected after linkage analysis was direct Sanger 
sequencing of the coding exons and splice sites of candidate genes.   
 
2.3.1 Molecular methods 
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Those families choosing to provide DNA for molecular analysis were all entered into the 
molecular phase of this study (n=21).  Eight candidate genes were selected based on previous 
associations with IE syndromes similar to those in the current study.  The primary consideration 
involved in candidate gene selection and prioritization was the frequency of occurrence of 
associations between the gene and phenotype of interest in previously reported studies.  SCN1A 
was prioritized as it is the most common childhood IE-associated gene.  KCNQ2 was also 
prioritized as it was the only gene to be associated with epilepsy in Newfoundland at the time the 
study was undertaken (Singh, Charlier et al. 1998).  Genomic DNA samples from 21 probands (7 
with a likely AD family history) were sequenced for all 26 exons of SCN1A (NCBI accession no. 
NM_006920) and all 16 exons of KCNQ2 (NCBI accession no. NM_172107).  The largest 
isoforms of each gene were selected.  Blood samples were obtained from affected children and 
their relatives (affected and unaffected) and genomic DNA was extracted from peripheral blood 
using standard salting out methods (see Appendix G) (Miller, Dykes et al. 1988).  Direct 
bidirectional DNA sequencing of the SCN1A gene and the KCNQ2 gene was conducted for 74 
samples from 21 families.  Sequencing traces were analyzed with Mutation Surveyor v.3.20 
software.  Variants predicted to be deleterious based upon online bioinformatic software 
searches, were screened in 190 healthy population control alleles.  DNA samples from probands 
of 20 families were then sequenced for the largest isoforms of the remaining six candidate genes: 
SCN2A (NCBI accession no. NM_021007), SCN1B (NCBI accession no. NM_199037.2), 
KCNQ2 (NCBI accession no. NM_004519.3), GABRA1 (NCBI accession no. NM_000816.3), 
GABRG2 (NCBI accession no. NM_000816.3)  and KCNQ3 (NCBI accession no. 
NM_004519.3) (See Appendix F).  Sequencing primers were custom designed for PCR 
amplification of all coding exons, untranslated regions, and intron-exon boundaries using 
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Primer3 software (http://primer3.sourceforge.net/ and http://frodo.wi.mit.edu/).  Standard PCR 
reactions were optimized and performed for each primer set.  Primer sequences and optimized 
PCR conditions are provided in Appendices C & D.  PCR products were confirmed on 1% 
agarose gel using ethidium bromide.  Products were then purified using a Sephacryl spin column 
purification method.  Purified samples were sequenced using BigDye Terminator v.3.1 Cycle 
Sequencing Kit and run on an ABI 3130xl Sequencer (Applied Biosystems, California, USA).  
Forward and reverse sequencing traces were aligned with reference sequences (from UCSC 
Genome Browser) and inspected manually for quality control and analyzed using Mutation 
Surveyor v.3.20, Sequencing Analysis 5.2, and Sequencher 4.10.1.  All variants were recorded 
and searched online using variant databases (NCBI (http://www.ncbi.nlm.nih.gov/) and Ensembl 
(http://www.ensembl.org/index.html)) to determine allele frequencies and population 
demographics.  The frequencies of rare variants (minor allele frequency of less than five percent) 
were tested against 190 ethnically matched healthy population control alleles.  Several online 
bioinformatics tools (PolyPhen (genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/), and 
PANTHER (http://www.pantherdb.org/)) were used to predict the effects of variants on protein 
function and evolutionary conservation.  Information on specific analysis performed is provided 
in Table 4 (page 92). 
 
2.4 Further investigation of most severely affected family 
2.4.1 Clinical Features of Family A 
Family A (Figure 10) represented the most severely affected family with AD-compatible 
IE, enrolled in the study.  The proband of family A was ascertained from a registry of all 
epilepsy patients treated at the Pediatric Neurology Clinic in the Janeway Child Health Centre 
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(St. John’s, NL, Canada).  The pedigree was extended through family visits and interviews and 
further clinical data was obtained from EEG recordings, standardized seizure and medical 
questionnaires (Appendix B), and medical records.  Epilepsy diagnoses for family members were 
made by pediatric neurologists (DB, MA) using the ILAE classification system (Commission 
1993). Informed consent was obtained from all participants or parents/legal guardians.  
 
2.4.2 Genetic Analysis of Family A 
The predominant phenotype expressed throughout Family A was determined to be 
consistent with the GEFS+ spectrum, via chart reviews and medical/seizure history 
questionnaires of patients and family members.  PubMed was used to search previously 
published families with AD forms of GEFS+ with known mutations.  The most common 
GEFS+-associated gene, SCN1A, was prioritized as the most likely candidate gene to harbor a 
disease-causing mutation.  Genotyping was selected as the first method of genetic analysis to 
determine if SCN1A segregated with the disease throughout Family A.  Sixteen family members 
(10 affected, six unaffected) were genotyped for four microsatellite markers (D2S2330, D2S156, 
D2S399 and D2S382) and two intragenic SNPs spanning the SCN1A gene on chromosome 2q24 
(Figure 11).  Genotyping primer sequences for the four microsatellite markers were extracted 
from UCSC Genome Browser website (http://genome.ucsc.edu/).  The forward microsatellite 
primers were tagged with a florescent blue label known as 6-FAM.  Sequencing primers were 
custom designed to amplify all 26 exons, intron/exon boundaries and 5’ and 3’ untranslated 
regions (UTRs) of SCN1A.  Standard PCR reactions were performed with a reaction volume of 
25ul containing 5ul of 3.75 M betaine, 2.5ul of 10x PCR buffer, 2.5ul of 2mM dNTPs, 0.75ul of 
50mM MgCl2, 0.2ul of 500U Taq Polymerase, 1ul each of 10uM forward and reverse primer, 
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and 1ul of genomic DNA at 100ng/ul.  Touch-down PCR conditions were as follows: denature at 
95°C for 5 min, followed by 5 cycles of 95°C for 30s, annealing at 64°C for 30s (decreasing by 
0.5°C/ cycle), and extension at 72°C for 30s.  This step was followed by 30 cycles of 95°C for 
30s, 54°C for 30s, 72°C for 30s, a final extension at 72°C for 7 min, and held at 4°C.   
Microsatellite samples were prepared for fragment analysis by adding 0.5ul of a labeled 
size standard (GeneScan 500 LIZ Size Standard) to 10ul of diluted (1/10), fluorescently labeled, 
PCR fragments.  Samples were analyzed on an ABI 3130xl (Applied Biosystems) using the 
Fragment Analysis program.  GeneMapper v4.0 software was used to create standard curves with 
peaks corresponding to the base-pair lengths of the microsatellite tandem repeats of each sample.  
Repeat sizes were then measured and recorded.  Blinding of sample identifiers was implemented 
to eliminate interpreter bias. 
Primers designed to surround regions with one or more SNPs spanning the SCN1A gene 
were used to amplify those DNA segments.  The samples were then sequenced using BigDye 
Terminator v.3.1 Cycle Sequencing Kit and run on an ABI 3130xl (Applied Biosystems) using 
the sequencing analysis program.  Sequence traces were inspected manually for quality control 
and analyzed using Mutation Surveyor v.3.20.  The effects of variants were predicted using 
online bioinformatics tools (Ensembl, PolyPhen, SIFT, PANTHER and BDGP: Splice Site 
Prediction by Neural Network).  Further data on specific protocols and analyses are provided in 
Appendices D and E. 
 
2.4.3 Segregation and penetrance calculations in Family A 
Segregation and penetrance of a putative pathogenic variant in Family A were determined 
using a SImplified method for Segregation Analysis (SISA).  This method calculates the 
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probability that cosegregation of the disease and the genetic variant is due to chance using the 
following equation; (1/2) n where n is equal to the number of individuals in the pedigree which 
carry the mutation minus 1.  Penetrance can then be calculated by dividing the number of 
affected variant carriers by the total number of variant carriers (Moller, Clark et al. 2010).  These 
statistical measures of genotype-phenotype association can be used to determine the level of 
significance and confidence we have when postulating that a mutation is pathogenic in a given 
family.  These data, in conjunction with the other types of evidence discussed here, offer 
researchers standardized numeric information on probability of variant and disease association. 
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3 Results 
3.1 Epidemiology 
3.1.1 Incidence 
The mean annual incidence of IE for the population of children (ages 0-15y) living on the 
Avalon region of the province, over a five year period, from January 1, 2000 to December 31, 
2004 was 107 per 100 000.  This represents 74 (41 males, 33 females) newly diagnosed cases in 
a mean population of 13 779 over the 5-year period (www.statcan.gc.ca).  The procedure utilized 
to calculate the incidence was as follows; 
Calculation of a 5-year incidence of pediatric IE on the Avalon Peninsula: 
Numerator: Total number of newly diagnosed cases seen in the pediatric neurology clinic, living 
on the Avalon Peninsula of the province between 2000 and 2004. The Avalon Peninsula is 
divided into census zones 17, 18, 19 and 20. 
Denominator: 5-year averaged at-risk, age-matched population living on the Avalon Peninsula 
between the years 2000 and 2004. 
Calculated Numerator:  
74 new cases  =   mean of 14.8 new cases per year 
 5 year period  
 
Calculated Denominator:  
Mean population of children 0-15 years of age living on the Avalon Peninsula between 2000 and 
2004 = 13779 
14.8   =  0.00107 
13 779  
 
0.00107 x 100 000 = 107 per 100 000 children
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3.1.2 Clinical Data 
Of the 121 patients meeting eligibility criteria, 119 cases of IE with a mean onset age of 
7.3 years (range 0.25 – 15 years), were entered into the study (Figure 5).  Of these 119 cases, 65 
were male (55%), and 54 were female (45%).  Two patients were excluded from the analysis as 
they were found to have an underlying disorder (neuronal ceroid lipofuscinosis) during the study.   
EEG recordings were completed for all 119 patients: 86% (102) were abnormal and 14% 
(17) were normal.  The abnormal findings were of two types; the primary idiopathic patients had 
generalized EEG abnormalities and the partial idiopathic patients had abnormalities consistent 
with benign rolandic EEG findings.  
Neuroimaging (CT and MRI) was conducted in 90% (107) of patients: 97% (103) were 
normal and 3% (4) were abnormal.  Neuroimaging was not conducted in 10% (12) of patients as 
they were definitively diagnosed based on EEG results.  These patients had a primary 
generalized pattern on the EEG and imaging was not indicated.  This pattern is presumed to be 
genetic and imaging would not be useful unless there was some other indication deeming it 
necessary.  The abnormal neuroimaging results (4) were: mild cerebral atrophy (1), arachnoid 
cysts (1), cortical dysplasia (1), and benign parietal lobe lesion (1).  The finding of mild cerebral 
atrophy was considered an incidental finding due to an EEG report strongly consistent with a 
generalized seizure disorder coupled with a strong family history of seizures.  The arachnoid 
cysts (congenital lesions that occur as fluid-filled sacs between the brain and the arachnoid 
membrane) were also classified as an incidental finding by the attending neurologist.  The 
findings of cortical dysplasia and a benign parietal lobe lesion led to a change in diagnoses for 
these patients.  They were classified as having symptomatic epilepsy, not IE, based on follow-up 
EEGs, and therefore were excluded from the analysis.   
82 
 
In terms of epilepsy control, 73% (87) of patients had active epilepsy, defined by the 
ILAE as at least one seizure in the past five years, while 26% (31) had at least one seizure in the 
past year.  Fifty one percent (60) are currently on an antiepileptic drug (AED) regimen. 
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(A) (B)  
(C) (D)  
(E)  
Figure 6. Bar charts depicting various clinical characteristics of the 119 IE patients. 
A) Bar chart depicting number of probands as classified by gender.  Males represent 55% of the total 
proband population. 
B) Bar chart depicting number of probands as classified by EEG recording. Abnormal recordings 
were used by neurologists to further classify patients with a specific epileptic diagnosis. 
C) Bar chart depicting number of probands as classified by neuroimaging (CT/MRI) result. Patients 
for which no neuroimaging data was available were definitively diagnosed by EEG based on a primary 
generalization pattern. 
D) Bar chart depicting number of probands as classified by anti-epileptic drug (AED) status. AED 
status was determined at the time of last assessment. 
E) Bar chart depicting number of probands as classified by primary seizure localization. When 
patients had multiple seizure types, they were assessed based their most common seizure classification.  
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3.1.3  Seizure classification and epilepsy diagnosis 
Probands were classified by both primary seizure localization and epilepsy diagnosis.  
Fifty percent (59) of probands had partial onset seizures, 47% (56) had generalized onset 
seizures, and 3.4% (4) were of unknown origin.  The most frequent epilepsy diagnosis was 
primary generalized epilepsy (PGE), not otherwise specified (18.5%), followed by childhood 
absence epilepsy (CAE) (16%), complex partial seizures originating from the temporal lobe 
(CPS-TLE) (16%), complex partial seizures originating from the parietal, frontal and occipital 
lobes (CPS-Other) (16%), juvenile myoclonic epilepsy (JME) (13%), benign rolandic epilepsy 
(BRE) (11%), epilepsy with unknown origin (6%), generalized epilepsy with febrile seizures 
plus (GEFS+) (2.5%), myoclonic astatic epilepsy (MAE) (1.7%), and juvenile absence epilepsy 
(JAE) (0.8%), respectively.  Childhood absence epilepsy, juvenile myoclonic epilepsy and 
juvenile absence epilepsy are all major subcategories of primary generalized epilepsy.  These 
patients were entered into separate categories to provide further diagnostic data.  Those 
remaining in the primary generalized epilepsy category represent all other primary generalized 
patients, not otherwise specified (Figure 7). 
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Figure 7. Bar chart depicting epilepsy diagnoses in all probands. 
Key: PGE, primary generalized epilepsy, not otherwise specified; CAE, childhood absence epilepsy; CPS-TLE, complex partial 
seizures, temporal lobe epilepsy; CPS-Other, complex partial seizures originating from the parietal, frontal and occipital lobes; JME, 
juvenile myoclonic epilepsy; BRE, benign rolandic epilepsy; Unknown, origin could not be determined; GEFS+, generalized epilepsy 
with febrile seizures plus; MAE, myoclonic astatic epilepsy; JAE, juvenile absence epilepsy. 
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3.1.4 Family history data 
Fifty-five (64%) of the responding probands (N=86) had a positive family history of 
epilepsy, defined as at least one affected first or second degree relative of the proband.  Family 
history was also assessed in non-responders (N=31) by blind chart review and a positive family 
history was reported in 17 (55%) of these.  Causes of epilepsy in familial disease, sporadic cases 
and nonresponders are given in Figure 5.  Multiple causes of epilepsy occur within familial 
disease and sporadic cases (Table 3).  Through pedigree analysis, it was determined that eight 
(9.3%) of the participating probands had family histories compatible with AD inheritance.  
Pedigrees for these eight AD families are shown in Figure 8.  Clinical features of probands and 
clinically assessed affected family members in the eight AD families are provided in Table 3.  
Again, the phenotype differs widely across and within families.  
Of the 55 families with a positive family history of epilepsy, 21 families provided blood 
samples for DNA testing to participate in the molecular phase of the study, while 34 families did 
not provide samples.  These two groups were compared in terms of the number of affected 
relatives in each family.  The mean number of affected relatives in the group of families 
participating in the molecular phase was 6.14 while the mean for the non-participating group of 
families was 3.9.  Comparing the two means using a t statistic yielded a p value of 0.387.  This 
suggests that the two groups are significantly different and that there may have been volunteer 
bias in the molecular phase of the study.   
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Figure 8. Pedigrees of eight families compatible with apparent AD IE.  These pedigrees are 
reduced to include only the informative branches.  Black symbols represent cases clinically 
affected with epilepsy, clear symbols represent no known seizure history and question marks 
represent cases with unknown affection status.  Arrows represent the proband (index case) for 
each family.  Letters above pedigrees identify families and numbers below each symbol identify 
the subjects for reference in Table 3. 
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Table 3. Clinical features of select patients from the eight suspected autosomal dominant 
pedigrees illustrated in Figure 8.  Key: m, male; f, female; y, years; mo, months; Ab, absences; 
GTCS, generalized tonic-clonic seizures; FS, Febrile seizures; SE, status epilepticus; GSW, 
generalized spike wave; DS, diffuse slowing; meds, medications; DD, developmental delay; MR, 
mental retardation; cont., continuing. 
  
Family-ID# 
[sex; age(y)] 
Age of 
onset 
Age of 
remission 
Type of 
seizures/number 
Meds 
Clinical 
classification 
A-1 [m;8] 11mo. Cont. 
FS, Ab, GTCS, SE, 
myoclonus/ many 
Cont. GEFS+, DD 
A-2 [m:5] 1y Cont. 
FS, Ab, GTCS, SE/ 
many 
Cont. GEFS+ 
A-3 [f;5] 1y Cont. 
FS, Ab, GTCS, SE/ 
many 
Cont. GEFS+, DD 
B-1 [m;16] infancy Cont. 
FS, partial sz, 
nocturnal/ many 
Stopped CPS 
B-2 [f;21] 4-5y 5y Unknown/ 2-3 None  
B-3 [f;49] infancy  FS/ few None  
C-1 [f;4] 1y 3y 
Partial sz (secondary 
generalization)/ many 
Stopped 
Partial to 
generalized 
C-2 [f;39] 8y 20y 
Partial sz (secondary 
generalization)/ many 
Cont. 
Partial to 
generalized 
C-3 [f;42] 10y ~25y 
Partial sz (secondary 
generalization)/ many 
Cont. 
Partial to 
generalized 
D-1 [f;18] 16y Cont. GTCS/ 4 Cont. GTCS 
D-2 [m;4] 2y Cont. FS+/ few  FS+ 
D-3 [m;7] 2y 2y Partial/ few None Partial epilepsy 
D-4 [f;44] 14y 18y GTCS/ few Stopped GTCS 
D-5 [f;?] teens Cont. GTCS/ many Cont. GTCS 
E-1 [f;5] 1y Cont. Myoclonus/ many Cont. MAE 
E-2 [f;35] 2-3y 5y Unknown/ several Stopped  
E-3 [f;64] 1y 16y Unknown/ many Stopped  
F-1 [f; 6] 4y Cont. 
Ab, FS, GTCS/ 
several 
Cont. 
Partial to 
GTCS 
F-2 [m;40] 6y 12y FS, GTCS/ 3 Stopped GTCS 
F-3 [m;51] 5y 8y GTCS, SE/ many Stopped GTCS 
F-4 [m;24] 2y 4y FS/ 3 Stopped FS+ 
G-1 [f;15] 2y 15y FS, GTCS/ many Cont. GTCS 
G-2 [m;21] 15y 17y GTCS/ 2 None GTCS 
G-3 [f;42] 5y 31y GTCS/ many Stopped 
Partial to 
GTCS 
H-1 [m;8] 6y 8y Nocturnal partial sz Stopped 
Benign 
Rolandic 
H-2 [f;38] Unknown ~20y Drop attacks Stopped Drop attacks 
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3.1.5 Geographic distribution 
The people of Newfoundland are distributed primarily along the coastline and, until 
recently, have been geographically isolated within the large bays of the province.  The 
geographic distribution of the families and cases in this study is broadly dispersed throughout the 
province, closely in accordance with the distribution of the general population (Figure 9A, B & 
C).  The distribution of families with likely autosomal dominant disease (N=8) is wide, with a 
family in Labrador, Central Newfoundland, the South Coast and at the South East Coast in St. 
Mary’s Bay.  A further three families live in Conception Bay and one in the city of St. John’s 
(Figure 9B).  Similar widespread geographic distribution of familial, non AD, IE (N=43) can be 
seen in Figure 9A.  Likewise, non-familial IE patients (N=35) were randomly distributed across 
the province, though no such patients reside on the western half of the province (Figure 9C). 
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Figure 9A. Geographic distribution of pediatric IE families in the province of 
Newfoundland and Labrador. Numbers outside symbols indicate the number of families 
represented by that symbol.  Cases with a positive family history are represented by red circles. 
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Figure 9B. Geographic distribution of pediatric IE families in the province of 
Newfoundland and Labrador.  Numbers outside symbols indicate the number of families 
represented by that symbol.  Families compatible with AD inheritance are indicated by a black 
dot inside the circle. 
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Figure 9C. Geographic distribution of pediatric IE families in the province of 
Newfoundland and Labrador.  Numbers outside symbols indicate the number of families 
represented by that symbol.  Cases with a negative family history are represented by yellow 
circles. Numbers outside symbols indicate the number of families represented by that symbol.
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3.2 Molecular Genetic Results 
The candidate gene selection method was employed.  The strongest gene candidates were 
selected for sequencing based upon their previous associations with the following phenotypes 
seen in patients in the current study, particularly in those with a family history compatible with 
autosomal dominance; SCN1A was selected based on three patients with GEFS+ and an AD-
compatible family history of disease; SCN1B was selected based on several patients with MAE 
and three patients with GEFS+ with various family history backgrounds; SCN2A was selected 
based on a few patients with probable BFNIS and three patients with GEFS+ with various family 
history backgrounds; GABRA1 was selected based on several patients with both CAE and JME 
with various family history backgrounds; GABRG2 was selected based on three patients with 
GEFS+ and an AD-compatible family history of disease; KCNQ2 was selected based on its 
previous association with BFNC identified in a Newfoundland family in 1998; KCNQ3 was 
selected based on its previous association with BFNC which led to the identification of KCNQ2 
in a Newfoundland family. 
Upon sequencing these genes, a novel causative missense mutation in SCN1A 
(c.1162T>C; p.Tyr388His) was identified in a family with GEFS+ (Family A).  Bioinformatic 
software programs were used to help confirm the pathogenicity of this variant.  Panther 
determined the probability that the variant is deleterious to be 93.9%.  Polyphen predicted the 
variant to be “probably damaging”.  SIFT predicted the amino acid change to be “deleterious”. 
No pathogenic variants in SCN1A, SCN2A, SCN1B, KCNQ2, GABRA1, GABRG2 or 
KCNQ3 were found in any of the remaining 20 families, which included six with presumed AD 
inheritance.  All variants with nomenclature and bioinformatic analyses are listed below in Table 
4. 
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Gene 
Exon/ 
Intron 
Variant 
nomenclature 
rs 
number 
Predicted 
protein 
change 
SIFT PolyPhen 
Allele 
freq 
CAU 
MAF 
SCN1A 
Intron 
1 
c.265-83A>T NA 
NA 
non-coding 
NA NA 
0.07 
(3/42) 
NA 
 
Intron 
6 
c.965-21C>T NA 
NA 
non-coding 
NA NA 
0.07 
(3/42) 
NA 
 Exon 8 c.1162T>C NA 
p.Tyr388His 
non-
synonymous 
deleterious 
probably 
damaging 
0.02 
(1/42) 
NA 
 Exon 9 c.1212A>G 
rs 
7580482 
p.= 
(Val404Val) 
synonymous 
tolerated benign 
0.47 
(20/42) 
0.42 
 
Exon 
13 
c.2167T>C NA 
p.= 
(Val723Val) 
synonymous 
tolerated benign 
0.02 
(1/42) 
NA 
 
Exon 
16 
c.3310G>A NA 
p.Ala1104Thr 
non-
synonymous 
tolerated benign 
0.02 
(1/42) 
NA 
 
Exon 
17 
c.3472G>A NA 
p.Glu1158Lys 
non-
synonymous 
tolerated benign 
0.02 
(1/42) 
NA 
SCN1B 
Intron 
1 
c.40+15G>T 
rs 
72556351 
NA 
non-coding 
NA NA 
0.07 
(3/42) 
0.15 
 
Intron 
4 
c.590+68G>A 
rs1467190
86 
NA 
non-coding 
NA NA 
0.02 
(1/42) 
0.04 
 Exon 6 c.*86A>C 
rs 
2278996 
NA 
non-coding 
NA NA 
0.10 
(4/42) 
0.14 
SCN2A 
Intron 
2 
c.-51-16C>T 
rs 
75551103 
NA 
non-coding 
NA NA 
0.02 
(1/42) 
NA 
 
Intron 
17 
c.3400-71C>T 
rs 
3769951 
NA 
non-coding 
NA NA 
0.36 
(15/42) 
0.30 
 
Intron 
13 
c.2017-89A>G 
rs 
74598858 
NA 
non-coding 
NA NA 
0.05 
(2/42) 
0.07 
 
Exon 
23 
c.4287T>C 
rs1502099
84 
p.= 
(Tyr1429Tyr) 
synonymous 
tolerated benign 
0.02 
(1/42) 
NA 
GABRA1 
Intron 
7 
c.1059+22G>
A 
rs1839738
84 
NA 
non-coding 
NA NA 
0.02 
(1/42) 
NA 
KCNQ2 
Intron 
1 
c.297-170C>T rs2297387 
NA 
non-coding 
NA NA 
0.36 
(15/42) 
0.38 
GABRG2 Exon 5 c.588C>T rs211037 
p.= 
(Asp196Asp) 
synonymous 
tolerated benign 
0.33 
(14/42) 
0.39 
KCNQ3 
Intron 
5 
c.573+25T>C 
rs 
17575971 
NA 
non-coding 
NA NA 
0.02 
(1/42) 
0.08 
 
Table 4. List of sequencing variants identified in functional candidate genes sequenced in 
IE patients.  Allele freq, refers to allele frequency found in study samples; CAU MAF, minor 
allele frequency in Caucasian population (as reported in 1000 Genomes and/or Ensembl Genome 
Browser).  
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3.3 Results of Family A Study 
3.3.1 Clinical Features of Family A 
In the current study, we report a four generation family with autosomal dominant GEFS+ 
with a novel mutation in SCN1A, which extends the phenotypic spectrum associated with GEFS+ 
to include neuropsychiatric issues; ataxia and social anxiety.  The founders of this Newfoundland 
family originate from County Cork, Ireland.  The complete pedigree consists of 97 relatives 
across 5 generations segregating an autosomal dominant form of epilepsy.  The core pedigree 
depicts only the affected branches in this family, which includes 11 individuals diagnosed with 
epilepsy in three successive generations (Figure 10).  Marked clinical heterogeneity between 
affected relatives with a variety of seizure types and neurological deficits was observed through 
review of medical records and EEGs, and also through seizure questionnaires and home visits.  
All clinically affected relatives (n=11) had seizure disorders starting in childhood with a mean 
onset age of 2.1 years (range 0.75 – 5.5 years) (Table 5).  Of these, nine (IV:1, IV:2, IV:3, III:3, 
III:2, II:7, II:9, III:12 and III:16) had generalized tonic-clonic seizures (GTCS) which occurred 
with and without fever, and two (II:2 and IV:5) had febrile seizures only.  Regarding seizure 
presentation, five (IV:1, IV:2, IV:3, II:7 and III:12) had multiple episodes of status epilepticus, 
four (IV:1, IV:2, IV:3 and III:12) had absence seizures, one (IV:1) had myoclonic seizures, and 
one (IV:5) had atonic seizures.  Other neuropsychiatric disorders were also prominent, with five 
(IV:1, IV:2, III:2, III:12 and III:16) individuals presenting intellectual disabilities, three (II:7, II:9 
and III:16) with debilitating psychiatric disease, and two, including the proband (IV:1, III:12), 
with ataxia.  None of the eight spouses had any personal or family history of seizures. 
The proband (IV:1, Figure 10) had his first seizure (afebrile GTCS) at 11 months of age.  
He began having myoclonic seizures at two years and by three years of age was experiencing 
approximately 10 myoclonic seizures per day.  These seizures were controlled with Divalproic 
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Acid and Ethosuximide to a rate of one per 2-3 days.  In addition, he had frequent generalized 
tonic-clonic (GTC) and absence seizures despite treatment with Valproic Acid and 
Ethosuximide, as well as rescue Benzodiazepines.  He has had two episodes of status epilepticus.  
CT head scan at three years of age was normal.  EEG at three years of age showed generalized 
epileptiform discharges, slowing, and polyspike and wave discharges.  EEGs at four, six and 
seven years of age were normal.  Of particular note are his neurologic signs.  At eight years old 
he displayed moderate global developmental delay, ataxia and behavioral concerns.  He repeated 
kindergarten and receives special education support at school (Criteria C*), but has had no 
developmental regression.  He continues to have GTCS approximately once every three to four 
months and remains on Valproic Acid.  His most recent episode of status epilepticus was four 
years ago, at the age of four years. 
The sister of the proband (IV:2) was born at 34+3 weeks gestation (twin A).  Her first 
seizure, a febrile GTCS, occurred at the age of one year two weeks.  She has since had many 
GTC and absence seizures, and has had seven hospital admissions for episodes of status 
epilepticus, lasting 30 to 80 minutes.  EEGs (at one, two and three years of age) and a CT head 
scan (at two years of age) were normal.  She is now five years old, has mild developmental delay 
and GTC and absence seizures (persisting at a rate of approximately one per month) on treatment 
with Topiramate and Valproic Acid.  Kindergarten entry was delayed by one year due to 
developmental delay. 
The brother of the proband (IV:3, twin B) experienced his first seizure at the age of one 
year two weeks.  This was an afebrile partial seizure progressing to a secondary generalized 
tonic-clonic seizure.  He has since had both febrile and afebrile onset generalized seizures.  He 
                                                          
* Criteria C: Special education support provided to children exhibiting moderate global/severe/profound cognitive 
delay. 
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has had two episodes of status epilepticus.  EEGs (at two and three years of age) and a CT head 
scan (at one year of age) were normal.  He is now five years old, shows normal cognitive 
development and his seizures persist at a rate of approximately one per three to six months, 
despite treatment with Valproic Acid.  There have been no reported learning or behavioral issues. 
Individual III-14 was considered to be the only obligate carrier in this family as she had 
an affected parent and child.  She had no history of seizures which was confirmed by medical 
chart review.  However, through interview and medical chart review, it was determined that she 
had neuropsychiatric symptoms including anxiety and depression. 
Of the remaining eight affected individuals, all except two have developed afebrile 
seizures requiring antiepileptic medication.  Three of these individuals with afebrile seizures 
have developmental delay, all of whom have a history of multiple seizures refractory to 
medication.  
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Figure 10. Core pedigree of Newfoundland family showing both typical and novel features of GEFS+ associated with the 
epilepsy-associated haplotype (red) on chromosome 2q24 in the vicinity of SCN1A. Markers are listed on the left and alleles given 
in size (base pairs) or specific nucleotide. The proband is indicated by an arrow. Gender has been masked using diamond symbols to 
protect confidentiality. 
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Table 5. Clinical features of affected members of Family A. 
Key: m, male; f, female; y, years; mo, months; Ab, absence; GTCS, generalized tonic-clonic seizures; FS, Febrile seizures; SE, status 
epilepticus; GSW, generalized spike wave; AEDs, Anti-epileptic drugs; DD, developmental delay; MR, mental retardation; ADHD, 
Attention Deficit Hyperactivity Disorder; cont., continuing. aPatient was treated in a psychiatric unit. bPatient lives with his parents 
and is unable to work due to social anxiety.
Pedigree 
reference 
[sex; age] 
Age of 
onset/ 
remission 
Type of seizures/ 
number 
EEG 
Neuroimaging 
(MRI/CT) 
AEDs 
Intellectual 
disability 
Psychiatric/ 
other 
neurological 
disorders 
Clinical 
classification 
of epilepsy 
IV:1 [m; 8y] 
11 mo./ 
cont. 
Ab, FS, GTCS, SE, 
myoclonus/ >100 
GSW 
MRI- normal 
CT-normal 
Cont. 
Moderate 
DD 
Ataxia GEFS+ 
IV:2 [f; 5y] 1 y/ cont. 
FS, Ab, GTCS, SE/ 
>50 
Bilateral 
epileptiform 
discharges in 
frontal region 
CT-normal Cont. Mild DD None GEFS+ 
IV:3 [m; 5y] 1 y/ cont. 
FS, Ab, GTCS, SE/ 
>50 
Normal CT-normal Cont. None None GEFS+ 
III:3 [m; 32y] 1 y/ 29 y 
FS, GTCS/ many 
 
NA CT-normal Cont. None None GEFS+ 
III:2 [m; 34y] 1 y/ 15 y 
FS, GTCS/ 5-10 
 
Normal CT-normal Stopped 
Learning 
difficulty, 
probable 
ADHD 
None GEFS+ 
II:2 [f; 57y] 
5-6 y/ 
teens 
FS/ 2 
 
NA NA None None None FS 
II:7 [f; 63y] 
Infancy/ 
20-22 y 
GTCS, SE/ >50 
 
NA NA Stopped None 
Anxiety/ 
Depressiona 
GTCS 
II:9 [f; 61y] 
4-5 y/ 23 
y 
FS, GTCS/ 4 
 
NA NA Stopped None 
Social anxiety/ 
depression 
GEFS+ 
III:12 
[f; deceased 
27y] DNA 
not available 
9 mo./ 
27 y 
Ab, FS, GTCS, SE/ 
100s 
GSW, 
Rhythmic and 
paroxysmal 
slowing 
CT-normal Cont. Severe MR Ataxia 
GTCS 
Cause of 
death: multiple 
seizures 
III:16 
[m; 41y] 
5 y/ 20 y 
FS, partial to 
GTCS/ many 
Normal CT-normal Cont. Mild DD Social anxietyb GEFS+ 
IV:5 [f; 4y] 
16 mo./ 22 
mo. 
FS, atonic/ 2 Normal NA None None None 
2 atonic febrile 
seizures 
III:14 [f; 35y] 18y/ cont. None NA NA None None 
Anxiety/ 
Depression 
None 
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3.3.2 Genetic Study of Family A 
Genotyping data from 16 members of Family A (10 affected, six unaffected) consisted of 
base pair repeat sizes for four microstatellite markers (D2S2330, D2S156, D2S399 and D2S382) 
and allele calls for two intragenic SNPs spanning the SCN1A gene on chromosome 2q24.  
Haplotypes were constructed for all 16 family members according to Mendelian inheritance 
rules.  Visual analysis of the haplotypes in this pedigree confirmed co-segregation of epilepsy 
with a haplotype on 2q24 (Figure 10).  Direct sequencing of SCN1A in 16 DNA samples from 
this family (10 affected, six unaffected) revealed 7 sequence variants that co-segregated on the 
epilepsy-associated haplotype (Table 6).  However, only one of these, a c.1162T>C transversion 
in exon 8 of SCN1A (Figure 12), was found in all clinically affected relatives, predicted an amino 
acid substitution in the first domain of the sodium ion channel protein (NaV1.1), and was not 
seen in any population controls (Table 6).  This missense mutation predicts a deleterious 
transition from a highly conserved (Figure 12A) polar neutral residue (Tyrosine) to a polar basic 
residue (Histidine) within the pore region of domain one of the sodium channel protein (Figure 
12B).  Bioinformatics software tools provided supportive evidence that this missense mutation is 
pathogenic and segregation analysis of the pedigree confirmed that it is also highly penetrant.
 A Simplified method for Segregation Analysis (SISA) was used to determine the 
penetrance and expression of the variant in this family (Moller, Clark et al. 2010).  It was 
determined that the probability that cosegregation between the disease phenotype and the genetic 
variant occurs by chance is 0.2%.  Based on expressivity of the mutation within these 16 
members, penetrance was 91%.  Specifically, all 10 affected family members carried the 
mutation and 5 of the 6 unaffected members did not carry the mutation.  The only unaffected 
mutation carrier (III-14) was deemed an obligate carrier due to the fact that she has an affected 
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child.  This low probability of cosegregation by chance and high penetrance indicate that the 
genetic variant has a high likelihood of causing the phenotype and is considered to be an 
autosomally, dominantly inherited trait. 
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Table 6. Sequencing variants identified in SCN1A (NM_006920) in clinically affected subjects.  
aBDGP: Splice Site Prediction by Neural Network was used to determine if variants predict splice sites. bNCBI dbSNP was used to 
determine the allele frequency of previously reported variants. 
  
Exon/Intron 
Variant 
Nomenclature 
Classification Amino Acid Change Segregation of Alleles/ Verification 
Intron 1 c.265-83A>T Noncoding No Does not predict a splice sitea 
Intron 6 c.965-21C>T Noncoding No Does not predict a splice sitea 
Exon 8 
c.1162T>C 
p.Y388H 
Missense p.Tyr388His 
Heterozygous in all affecteds 
Not present in 190 control alleles 
Exon 9 
c.1212A>G 
p.V404V 
rs7580482 
Synonymous p.= (Val404Val) Minor allele frequency = 42%b 
Exon 13 c.2167T>C Synonymous p.= (Val723Val) Not present in all affecteds 
Exon 16 c.3310G>A Missense p.Ala1104Thr Not present in all affecteds 
Exon 17 c.3472G>A Missense p.Glu1158Lys Not present in all affecteds 
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Figure 11. Sequencing traces of exon 8 of SCN1A (only forward direction shown) showing the c.1162T>C transition of the 
proband’s (IV:1, Figure 10) genomic DNA aligned with the reference sequence. The amino acid translations (top) show the 
p.Y388H amino acid substitution. 
Reference sequence 
Sequencing trace 
Amino acid translations 
104 
 
 
 
Figure 12. Conservation of SCN1A in the vicinity of Y388 and location of p.Y388H.  
(A) Weblogo was used to align orthologs from Homo sapiens (NP_008851), Pan troglodytes (XP_515872), Mus musculus 
(NP_061203), Rattus norvegicus (NP_110502), Danio rerio (NP_956426), Drosophila melanogaster (NP_001036280), and Nasonia 
vitripennis (NP_001128389). The tyrosine (Y) residue at position 388 of the SCN1A gene across sodium channel genes is marked by a 
red arrow.  
(B) Y388H (red triangle) results in the substitution of a neutral polar tyrosine residue to a polar basic histidine in the loop between the 
S5 and S6 segments of domain 1 of the SCN1A protein. Segments 5 and 6 (darker blue) form the ion channel pore and segment 4 is 
the voltage sensor.  
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4 Discussion 
4.1 Summary 
 This study characterizes pediatric IE in the context of a historically isolated founder 
population on the island of Newfoundland.  This provincial population-based study endeavoured 
to describe the incidence, genetic epidemiology, and genetic etiology of pediatric IE.  The mean 
annual incidence of IE was discovered to be three times higher than reported rates in comparison 
populations.  The scattered geographic distribution of familial and non-familial cases of IE in 
different isolates throughout the province suggests that the disease is genetically heterogeneous.  
The high clinical variability within and between families lends further evidence to this finding.  
A novel mutation in the SCN1A gene was identified and the associated phenotype was found to 
have some novel features as well.  These findings have been published in Seizure (2009) and 
Epilepsy Research (2011). 
 
4.2 Study design: Translational research 
The current study demonstrates the utility of obtaining thorough and accurate clinical 
data to fuel laboratory research. Consequently, laboratory findings were generated that aided the 
clinical care of patients.  This “bedside-to-bench-to-bedside” approach demonstrates the 
importance of all facets of research interacting to produce patient-tailored care.  I obtained 
comprehensive clinical data from all available patients and family members through multiple 
clinical assessments, interviews, questionnaires, medical chart reviews, EEGs, and 
neuroimaging.  Using this plethora of data, each patient had the best possible epilepsy 
classification.  This data was also used for hypothesis generation.  I generated a list of candidate 
genes, genotyped and/or DNA sequenced patients at these loci, and determined if any pathogenic 
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variants were present.  In the case of Family A, identifying the pathogenic mutation in SCN1A 
had an immediate clinical impact on patient care.  The results of genetic testing were relayed to 
the family via genetic counseling.  Subsequently, several other relatives were also contacted and 
clinically assessed.  The family is now receiving clinical follow-up including genetic counseling.  
Further, an anti-epileptic drug that several family members were taking prior to this study is 
known to exacerbate sodium channel disorders.  Thus, this finding informed better 
pharmacologic management for affected family members through the use of a more appropriate 
and effective AED regimen and the patients have experienced more favorable seizure outcomes 
as a result. 
 
4.2.1 Extensive patient data ascertainment 
The large sibship sizes and close involvement with the provincial neurology program 
enabled collection of extensive family history data, and construction of at least three-generation 
pedigrees for each family.  The pedigree data in this study is more comprehensive than most 
other epidemiological studies of epilepsy which have obtained brief family histories from chart 
review and have not reported pedigrees (Sidenvall, Forsgren et al. 1993; Sidenvall, Forsgren et 
al. 1996; Beilmann, Napa et al. 1999; Freitag, May et al. 2001; Kwong, Chak et al. 2001; 
Mullins, O'Sullivan S et al. 2007).  The relatively high proportion of families with epilepsy 
suggestive of a mutation in a single gene causing disease may be partly due to the rigorous 
collection and analysis of pedigree data.  While this may present challenges in drawing 
comparisons between populations, and limits the generalizability of familial rates in NL to other 
populations, it also allows a more accurate assessment of the genetic contribution to IE than 
previous studies.  
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4.3 Epidemiology 
This study demonstrates that the incidence of pediatric IE in the Avalon Region of 
Newfoundland and Labrador is approximately three-fold higher than the average incidence 
reported in other developed countries (Kotsopoulos, van Merode et al. 2002).  The proportion of 
IE with familial disease is high (55/86, 64%) as compared to a study in the Irish population 
which found that 48% of IE patients had an affected first or second degree relative (Mullins, 
O'Sullivan S et al. 2007).  This was the only other published study to provide data on the 
proportion with familial IE.  The familial rate is high in both responders (64%) and non-
responders (55%), indicating that the familial rate was not dramatically affected by response 
bias.  The proportion of pedigrees suggestive of AD inheritance (8/86, 9.3%) is also high; most 
population-based studies report a few rare cases of AD families with only 1% of IE being 
attributed to a monogenic cause (Gardiner 2000; Robinson and Gardiner 2004).  The incidence 
of IE on the Avalon Peninsula of the province is high and the genetic contribution to the etiology 
of IE, across the province, is also high as compared to population-based studies in other 
developed regions (Kotsopoulos, van Merode et al. 2002; Mullins, O'Sullivan S et al. 2007). 
 
4.4 Geographic Distribution / Founder Effects 
The geographic locations of study subjects/families were mapped to identify patterns and 
look for trends that may be present.  This information is important for multiple reasons.  A 
clustering of cases in a geographical region is highly relevant to genetic studies as it may indicate 
a single mutation (perhaps a founder mutation) is causing the disease in multiple cases/families.  
This would likely be the result of a common ancestor that may or may not be known to the 
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families.  A clustering of cases in a given region could also be attributed to environmental 
factors.  For example, it could be hypothesized that a given exposure could increase the rate of 
de novo mutations causing epilepsy.  Also, geographic distribution of disease is important to 
health care providers and policy makers as it can aid in determining the distribution of health 
services based on the needs of each given area. 
The geographic distribution of both the cases and families in this study, shows little 
clustering.  Families with likely AD disease or familial non-AD disease are dispersed widely 
throughout the province in a manner comparable to the distribution of the general population.  
Despite the high heritability quotient in this population, and the demonstration of founder effects 
in inherited colorectal cancer (Stuckless, Parfrey et al. 2007) and arrhythmogenic right 
ventricular cardiomyopathy type 5 (Merner, Hodgkinson et al. 2008), founder effects likely 
cannot explain the genetic contribution of epilepsy in its entirety.  Although Newfoundland has 
long been regarded as an isolated founder population (Bear, Nemec et al. 1987; Bear, Nemec et 
al. 1988), it has been noted in a study of genome-wide distribution of linkage disequilibrium 
(LD) that the Newfoundland population has relatively low LD as compared to 10 other well-
described population isolates (Service, DeYoung et al. 2006).  Newfoundland is most likely not a 
single genetic isolate but rather a series of isolates scattered around the coast of the island.  Thus, 
it may be more accurate to conclude that the high incidence of IE and familial disease is due to 
the rigorous ascertainment methods more so than founder effects.  The geographic distribution is 
similar to that seen in Bardet-Biedl Syndrome and Lynch Syndrome, both monogenic conditions 
associated with multiple genetic founders, and caused by mutations in multiple different genes, 
which differ across genetic isolates (Webb, Dicks et al. 2009).  
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There are several methodological advantages to studying a genetically isolated 
population, such as that of Newfoundland.  The province’s founder population is characterized 
by genetic homogeneity which yields a high signal to noise ratio for discerning etiology.  In 
addition, more complete ascertainment and accurate phenotypic information can be obtained 
from typical Newfoundland families which tend to be large, cohesive, and have extensive 
knowledge of their family history.  Clinical and genetic investigation of these families will 
provide information pertaining to the phenotypes and genotypes of the families as well as the 
modes of inheritance and clinical expression of IE in the entire Newfoundland and Labrador 
population. 
As genes have been identified in several autosomal dominant epilepsy families in other 
populations, it is likely that families with Mendelian inherited epilepsy disorders are present in 
the Newfoundland and Labrador population.  Further clinical and genetic investigation of these 
families will provide more information pertaining to the phenotypes and genotypes of the 
families as well as the modes of inheritance and clinical expression of IE in the entire 
Newfoundland and Labrador population. 
 
4.5 Summary of Family A Study 
This study reports a comprehensive clinical study of Family A, a family with an 
autosomal dominant history of extended spectrum GEFS+ and a novel missense mutation in 
SCN1A.  The core pedigree of this large multiplex family had 11 individuals with a history of 
seizures over three generations.  A broad spectrum of epilepsy phenotypes was seen across 
family members, with most having forms of generalized epilepsy such as FS+, absences and 
GTCS.  The phenotype prevalent throughout this family is compatible with the GEFS+ spectrum 
111 
 
(Scheffer and Berkovic 1997) and the inheritance pattern in this pedigree is compatible with an 
autosomal dominant mode of inheritance.  It was hypothesized that an AD mutation was 
segregating with the seizure disorder prevalent in this family.  Assuming AD inheritance, there 
was one obligate carrier in which the lack of a seizure history could be explained by incomplete 
penetrance, subclinical expression of features (e.g. unreported nocturnal seizures), unknown 
environmental protective factors, or other complex protective genetic variations yet to be 
identified.  All living family members with a history of seizures have a heterozygous T>C 
transition at nucleotide 1162 of SCN1A which results in a tyrosine to histidine substitution 
(p.Y388H). 
The clinical findings in this study expand the phenotype associated with GEFS+ to 
include a range of other neuropsychiatric deficits, including mood disorders and ataxia, in 
addition to familial epilepsy.  There have been no previous reports of familial ataxia in families 
with GEFS+ as the primary presentation.  In this family, ataxia was observed in two clinically 
affected family members (IV:1 and III:12), which has been previously reported in association 
with mutations in the pore-forming regions of SCN1A in those with an SMEI phenotype (Kanai, 
Hirose et al. 2004).  In addition, there are three affected mutation carriers that presented with 
debilitating psychiatric disease (anxiety and depression) in addition to epilepsy.  Although not 
clinically examined with neuropsychological scales through the scope of this study, medical 
records suggest that these mutation carriers present an expanded GEFS+ phenotype including a 
range of other neuropsychiatric deficits.   
Unfortunately, the occurrence of mood disorders such as depression and anxiety are 
relatively common in the general population, making it difficult to prove that these symptoms 
represent a novel extension of the current GEFS+ phenotype.  Alternatively, ataxia, being much 
112 
 
less common in the general population and previously reported in SMEI patients, is easier to 
accept as a novel phenotypic extension.  Identifying additional GEFS+ individuals and families 
with these symptoms will give credence for them being included in this syndrome.  Additionally, 
once the genetic predispositions for GEFS+ are identified, it may be possible to ascertain specific 
genotype-phenotype relationships between particular mutated genes and/or mutations in mood 
disorders and ataxia.  However, it is also possible that the observations made between GEFS+ 
and the extended phenotype occur by chance and that they just happen to be present in some 
mutation positive family members.  A good example of the importance of deep phenotyping in 
many families with a particular condition is Bardet-Biedl syndrome (BBS).  BBS is a rare 
autosomal recessive multi-system disorder which is more prevalent in Newfoundland (Moore, 
Green et al. 2005).  The cardinal manifestations were originally thought to be retinal dystrophy, 
obesity, mental retardation, polydactyly and hypogenitalism in males.  However, with additional 
studies, particularly from the Newfoundland group (O'Dea, Parfrey et al. 1996), renal 
malformation was identified as a very important cause of morbidity and mortality and was 
subsequently added as a primary criteria.  Additional studies from around the world have also 
added many other secondary characteristics to the BBS phenotype including neurological, 
speech, and language deficits, behavioural traits, facial dysmorphism, and dental anomalies 
(Beales et al., 1999).  What was once a very rare and relatively unknown phenotype became a 
widely investigated syndrome and a very genetically heterogeneous disease.  The breadth of the 
phenotype was not known until decades after this syndrome was intensely investigated during 
the genetics and genomics era.  
Interestingly, mutations in SCN1A have been previously reported to be associated with 
other neuropsychiatric disorders of similar pathology.  Panic disorder and Asperger syndrome 
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were present in two individuals in a GEFS+ family with a missense mutation in SCN1A, and 
variants in the SCN1A and SCN2A genes were observed in six patients with autism (Weiss, 
Escayg et al. 2003; Osaka, Ogiwara et al. 2007).  Heterozygotes for a null allele of another 
sodium channel gene, SCN8A, showed a variety of cognitive defects, including mental 
retardation and behavior disorders (Trudeau, Dalton et al. 2006).  Additionally, a novel missense 
mutation in SCN1A was identified in a family with familial hemiplegic migraine, widening the 
phenotype associated with mutations in this gene (Gargus and Tournay 2007).  
The majority of affected individuals in this family present a more severe phenotype than 
is usual with GEFS+.  Of the ten affected individuals known to have the SCN1A mutation, four 
have developmental delay (IV:1, IV:2, III:2, and III:12), three have debilitating psychiatric 
disease (II:7, II:9, and III:16), and two have ataxia (IV:1 and III:12), in addition to epilepsy.  The 
eleventh affected individual (III:12) in this family had frequent seizures from the age of nine 
months until her death at 27 years of age.  She also had severe mental retardation and her death 
was ruled to be caused by multiple seizures, though it is not known whether or not her symptoms 
were caused by the SCN1A mutation because her DNA was not available.  Despite the relatively 
severe phenotype seen in most affected family members, two mutation carriers have a history of 
febrile seizures only (II:2 and IV:5) and one female obligate carrier (III:14) is non-penetrant for 
epilepsy at 35 years of age, but has a history of depression.  This mutation is highly penetrant 
with 91% of known mutation carriers expressing an epileptic phenotype and 100% of mutation 
carriers displaying some neuropsychiatric spectrum disorder.  The presence of an unaffected 
mutation carrier in this family suggests that environmental factors and/or other genetic modifiers 
may also play a role in the expression of the GEFS+ phenotype. 
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The variable expressivity in this family is compatible with the broad phenotypic spectrum 
previously observed in other GEFS+ families (Scheffer and Berkovic 1997; Singh, Andermann 
et al. 2001; Bonanni, Malcarne et al. 2004; Grant and Vazquez 2005).  GEFS+ has been 
previously associated with wide intrafamilial variability of phenotype which can include 
progressive myoclonic epilepsy and developmental delay, similar to SMEI (Dravet syndrome) 
(Dravet, Bureau et al. 2005).  Interestingly, mutations in the loop region of the SCN1A gene are 
usually associated with an SMEI phenotype, whereas in this family, though the phenotype is 
variable, no individual fulfills the diagnostic criteria for SMEI.  The proband (IV:1) had multiple 
seizure types including myoclonus, in addition to developmental delay, but has not regressed (a 
hallmark characteristic of SMEI) and now has only occasional seizures on a single antiepileptic 
medication. 
 
4.5.1 Genetic Etiology of GEFS+ and Family A 
Mutations causing GEFS+ have been found in SCN1A, SCN1B, and GABRG2 (Wallace, 
Wang et al. 1998; Escayg, MacDonald et al. 2000; Baulac, Huberfeld et al. 2001; Wallace, 
Marini et al. 2001).  Missense mutations in SCN1A are the commonest identified molecular 
abnormalities and are found in about 10% of GEFS+ families (Wallace, Scheffer et al. 2001; 
Marini, Mei et al. 2007).  Approximately 20% of cases of GEFS+ have been associated with a 
genetic cause (Scheffer, Harkin et al. 2005).  The majority have mutations in SCN1A, which tend 
to be clustered in segments S5-S6 of the SCN1A protein that form the functionally critical pore 
region of the sodium channel.  Mutations in SCN1A in the loop between segments S5 and S6 
usually result in an SMEI phenotype (Kanai, Hirose et al. 2004).  To date, there have been three 
other reports of mutations in SCN1A causing GEFS+ located in the loop between S5 and S6, all 
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of which are missense.  The first was identified in 2001 in GEFS+ patients with febrile seizures 
associated with afebrile partial seizures (domain 3, S5-S6; c.4283C>T, p.Val1428Ala) 
(Sugawara, Mazaki-Miyazaki et al. 2001).  The second occurred in a South American family in 
whom an amino acid substitution was located in the pore-forming region in domain four of the 
SCN1A protein (domain 4, S5-S6; c.5226C>A or G, p.Asp1742Glu).  The phenotype was highly 
variable, with some individuals having only febrile seizures, and others having numerous 
seizures and mental retardation (Pineda-Trujillo, Carrizosa et al. 2005).  This is consistent with 
the hypothesis that mutations in the critical pore-forming loop regions of the SCN1A protein can 
result in a more severe GEFS+ phenotype.  However, ascertainment bias is a well-known 
confounder to studies of patients with more severe phenotypes.  The third was identified in a 
single patient for whom no family history was available.  At six years of age the patient has well-
controlled seizures and normal cognitive and neurological development (domain 1, S5-S6; 
c.1130G>A, p.Arg377Gln) (Zucca, Redaelli et al. 2008).  
The pores of the transmembrane protein coded by SCN1A control the passage of sodium 
ions into and out of the cell, and are thereby responsible for maintaining electrochemical balance.  
Mutations resulting in modifications in the pore-forming loop region may result in a significant 
alteration of electrochemical balance and membrane excitability controlled by this sodium 
channel.  Although, the exact mechanism by which this mutation interferes with protein function 
remains elusive, further understanding of the nature and position of GEFS+ mutations will allow 
functional studies to develop and test hypotheses.  Direct electrophysiological studies are 
required in order to determine the exact impact this mutation has on the structure and function of 
the SCN1A protein.  Xenopus (frog) oocytes are commonly used for genetic expression studies 
of ion transport and channel physiology, due to the high degree of evolutionary conservation as 
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compared to human ion channels.  For example, a 2006 study in California used Xenopus 
oocytes to express a novel mutation in the SCN1A protein (Nav1.1 channel) and demonstrate 
that the mutation caused a decrease in channel excitability (Barela, Waddy et al. 2006).  This 
methodology could be applied to further the results of the current study by determining the effect 
of the novel SCN1A mutation on protein expression and channel excitability. 
A biological continuum between neurological diseases, such as epilepsy, and psychiatric 
disease suggests that genes responsible for neuronal signaling may also directly affect emotional 
and cognitive function (Meisler and Kearney 2005).  The phenotype in this family was extended 
to include psychiatric and neurological deficits, based largely on observations and follow-ups 
from home visits.  It is therefore, worth emphasizing the importance of visiting families and 
using open-question format interviews to facilitate the collection of phenotypic data beyond the 
scope of structured interviews and standardized questionnaires.  Increasing reports of the high 
degree of variability in GEFS+ families implies the presence of modifying influences including 
other genes and environmental factors (Ottman, Lee et al. 1996).  It also presents challenges in 
providing affected families with effective genetic counseling and accurate information about 
long-term prognosis.  Further studies with analysis of comprehensive medical data from GEFS+ 
families will help delineate the extent of neuropsychiatric features resulting from mutations in 
SCN1A. 
There is remarkable clinical heterogeneity observed between affected family members 
which is compatible with the spectrum of GEFS+ phenotypes as described by Scheffer and 
Berkovic (Scheffer and Berkovic 1997).  The most likely explanation for the phenotypic 
variability in GEFS+ families is a significant effect from genetic modifiers (none of which have 
yet been identified) and environmental factors.  Although it is known that such factors contribute 
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to susceptibility, it remains unclear how they interact in their influence on disease risk and 
variability (Ottman, Annegers et al. 1996). 
 
4.6 Genetic Etiology of Unsolved Families 
 Despite sequencing seven candidate genes known to be associated with childhood IE 
syndromes matching those recruited for this study, the genetic cause remains elusive in all but 
one family.  The genetically solved family represents 12.5% (1/8) of the families with AD-
compatible IE, enrolled in this study.  The proportion of childhood IE cases for which the genetic 
cause can be explained by epilepsy-associated genes is unknown.  There have been no previous 
population-based studies to investigate this.  The genetic cause in the remaining seven AD 
families is likely still attributable to segregating monogenic disease alleles, yet to be identified.  
This may be due to differences in the genetic pool of previously studied populations and the 
Newfoundland population or it may be that the proportion of genetically explained monogenic 
epilepsies remains low due to the lack of well-ascertained, AD families segregating IE-causing 
mutations.  It should also be considered that the etiology in patients with no family history could 
be attributed to a recessive inheritance pattern.  Since mutation carrier parents would not exhibit 
symptoms, and offspring would only have a 25% chance of being affected, the likelihood of a 
family history in recessive conditions is relatively low.  While there remain no known cases of 
epilepsy resulting from recessive inheritance, it is important to consider that all inheritance 
patterns may not yet be identified.  Further to this point, de novo mutations could be the cause of 
a significant proportion of the cases with no family history.  In this case, parents would be 
unaffected, non-carriers and the offspring would be the only affected, mutation carrier in the 
family.  These mutations could be identified through elimination analysis of next generation 
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sequencing data from the two parents and the affected child.  Any variants in the child that are 
not present in either parent are considered de novo and could provide a short list for potential 
pathogenic mutations. 
Linkage analysis studies and next generation sequencing of these unsolved families fell 
beyond the funding parameters of this study.  These types of analyses are becoming more readily 
accessible and affordable, and would be the most prudent course of action to undertake in further 
studies on these families.  Also, it may be of interest to undertake testing to identify copy number 
variants (CNVs) in the patient population.  CNVs are of particular interest in 
neurodevelopmental disorders such as developmental delay, intellectual disability, autism, and 
epilepsy.  While there are only a few studies of the role of CNVs in epilepsy etiology and the 
underlying mechanistic pathways remain largely unknown, it would be of interest to determine 
any CNV patterns in a population-based study such as this one.  A recent study of a cohort of 
102 epilepsy patients identified 10 CNVs that were believed to be clinically relevant, including 
two rare deletions in novel pathogenic genetic loci (Bartnik et al, 2012).  Future studies on the 
patient sample in the current study could employ array Comparative Genome Hybridization 
(CGH) to detect variations in the number of copies (duplications/deletions) of genomic 
segments. 
 
4.7 Limitations 
4.7.1 Challenges in genetic studies 
When trying to identify pathogenic mutations using results from affected and unaffected 
patients, we are making two large assumptions; (1) that there are no non-penetrant mutation 
carriers amongst the unaffected subjects and (2) that all of the affected patients in a family share 
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a common mutation, thus there are no phenocopies (an individual whose phenotype for a given 
trait is identical to another individual whose phenotype is determined by the genotype of 
interest).  Thus, these assumptions must be made tentatively, and the researcher must skeptically 
analyze the data, keeping in mind that these assumptions may not be true in all cases. 
Using both affected and unaffected relatives for molecular analysis makes the assumption 
that unaffected relatives are non-carriers of the mutation and not that they are non-penetrant.  
Given that this is an early-onset disease, DNA samples from older relatives were used whenever 
possible, in an attempt to control for age of onset.  However, most AD genetic disorders, 
including epilepsy, demonstrate some degree of non-penetrance.  Many monogenic diseases have 
varied levels of penetrance depending on the mutated gene, the type of mutation, the genetic 
background of the family, and environmental factors.  This must be taken into consideration 
when analyzing molecular data, particularly of unaffected subjects.  An alternate model of 
assessing pathogenicity of a variant identified through sequencing would be to take an “affected 
only” approach.  Those individuals unaffected would not be included in the analyses.  This will 
address the issue of non-penetrance.  Thus reducing the probability of including mutation carriers 
that are, as yet, unaffected.  Obviously, this also reduces the “power” that one has to evaluate a 
potential pathogenic variant.  
These approaches both incur the inherent limitation of potentially including phenocopies 
with the affected individuals.  This reiterates the importance of obtaining the most thorough 
clinical data possible from all study subjects.  In doing so, it aids in eliminating misdiagnoses 
and/or missing a diagnosis.  Thus, particularly in complicated phenotypes like epilepsy, the 
clinical workup is instrumental to the success of a genetic study. 
4.7.2 Limitations of candidate gene testing 
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This study was limited to the current knowledge of the genetic basis of IE.  As this was a 
pilot project for further genetic investigations, only screening of genes previously associated 
with the IE phenotypes in the study subjects was performed.  It is likely that many more IE-
associated genes will be identified in the future.  Furthermore, all IE related genes were not 
screened, thus it is possible that some of the previously described IE genes, not (yet) associated 
with the phenotypes of the patients described herein, could be causing the phenotype in these 
subjects.  It is not uncommon for different mutations, in the same gene, to cause slightly different 
phenotypes.  Such a phenomenon has been identified in the RET gene and dystrophin gene 
(DMD) which cause Hirschsprung disease and Duchenne muscular dystrophy, respectively 
(Edery, Lyonnet et al. 1994; Fehmann and Goke 1994; Piko, Vancso et al. 2009), among others.  
Thus, selecting only the candidate genes that are known to cause the phenotypes in the study 
subjects could limit the discovery of new phenotypes being associated with known genes.   
Obviously, another limitation of candidate gene analysis is that it does not lend directly to 
novel gene discovery.  Traditionally, it has been an important step to rule out known genes 
before further monetary and human resource efforts are placed into identifying novel genes.  
Further molecular genetic analysis, such as next generation sequencing, was beyond the 
budgetary scope of this project and this technology was not available until more recently.  
Since the primary focus of mutation identification in this study was to Sanger sequence 
the coding regions and intron/exon boundaries of the candidate genes, it is possible that disease-
causing variants may have been missed. There are other types of genetic variations that may be 
causing IE that are not amenable to discovery using the protocol outlined in this study.  For 
example, copy number variants (CNVs), methylation abnormalities, large deletions or insertions 
spanning more than one exon (undetectable through Sanger sequencing in heterozygous form), 
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chromosomal rearrangements (such as translocations), modifier effects of variants in other genes, 
and functional intronic or intergenic variants would all be overlooked with the current protocol.  
These types of genetic variations can be examined with various other investigative approaches; 
however, these analyses were beyond the scope of this study. 
 
4.7.3 X-linked versus autosomal dominant inheritance 
 X-linked inheritance refers to an inheritance pattern that arises when a gene carried on the 
X chromosome is mutated and causes a trait that can be passed on to the next generation.  X-
linked inheritance patterns can be difficult to detect when analyzing pedigrees with only clinical 
data available.  That is, determining inheritance patterns based on pedigree data only, without 
knowing the underlying genotypes, often relies on educated hypotheses and thus is not ideal. 
Unfortunately, sometimes X-linked traits can mimic autosomal traits in some families, 
depending on the pedigree structure. 
When a phenotype is fully penetrant and is X-linked, there are particular patterns of 
inheritance that can be derived from the pedigree.  In conditions that are expressed in a 
heterozygote, all daughters and none of the sons of affected males will be affected; but if any of 
the daughters are unaffected and any son is affected, then the inheritance is autosomal.  
However, the pattern of inheritance on the X-chromosome in females mimics that of autosomes 
because females have two X chromosomes.  Although, as a general rule, rare X-linked 
conditions, manifesting in heterozygotes, are twice as common in females than in males, with the 
caveat that the expression of most conditions is milder in females than in males.  This is because 
males (having an XY genotype) are hemizygous (only one X chromosome is present) and do not 
have a "normal" X chromosome to compensate for their mutated X-chromosome. 
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Therefore, determining the mode of inheritance in families with an incompletely 
penetrant gene, causing a variably expressed phenotype, can sometimes be challenging.  This is 
particularly true in families which are small or which only have a few affected individuals.  In 
families with only a “triad” of affected individuals, whereby one is a first degree relative of the 
other two and they span two generations, there are a few scenarios in which it would be 
impossible to determine if a phenotype was inherited on the X-chromosome or on an autosome.   
For instance, if part of the triad was a mother with an affected offspring, then the mode of 
inheritance could be ambiguous.  Or if the trio contains a father with just one female offspring, 
and she is affected, then it would likely be difficult to determine the mode of inheritance.  
Determining inheritance patterns based on pedigree data without knowing the underlying 
genotypes (e.g. mutation) is often difficult, especially when families are small and/or have a 
small number of affected individuals, and the phenotype in question is incompletely penetrant 
and has variable expressivity.  Unfortunately, this is a common issue when studying genetic 
conditions that do not fall within the category of "simple Mendelian" inheritance.  
Since only clinical data was available at the candidate gene selection phase of this study, 
and one of the purposes of the thesis was to identify the genetic basis of epilepsy in 
Newfoundland, the triad was used as a surrogate for autosomal dominant inheritance.  This 
provided a simple defining criteria, based on clinical information only, that would likely 
encompass all of the truly autosomal dominant epilepsy families in the cohort, but might also 
identify some non-autosomal families too.  Due to the nature of the phenotype and the general 
paucity of genetic data on these study families at the time of the study start, this definition of 
triad was employed. 
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4.7.4 Genetic classification versus clinical classification 
As research advances, we gain a more in-depth understanding into the molecular 
biological basis of disease.  In the case of genetic disorders, over the past two decades, 
researchers have made immense progress into understanding the etiology of many diseases, 
placing medicine at a critical point in history for selecting the most pertinent system of disease 
classification for many disorders.  The level of complexity of genetic etiology varies widely 
across diseases.  Further, the impact of diseases on society, based on its prevalence and severity, 
often determines the amount of research effort dedicated to solving its genetic causes.  Due to the 
complexity of many genetic conditions and the different levels of knowledge we have regarding 
them, some diseases have thus far been more amenable to a genetic classification than others.  
The epilepsy classification system, as set forth by the ILAE, relies on clinical data to categorize 
patients.  An individual is classified as having a certain type of seizure and/or epilepsy syndrome 
based solely upon clinical presentation and findings.  This system does not take into account 
genetic etiology.  The primary advantage of using this clinical classification system is that it 
allows physicians to classify patients at the time of clinical workup and select the most 
appropriate treatment regimen specific to the seizure and/or epilepsy diagnosis.  If classification 
was based upon genetic etiology, the majority of patients would remain unclassified as the 
genetic basis of IE remains unknown for most epilepsy syndromes and subtypes.  Furthermore, 
early treatment is very important for epilepsy patients, particularly in children whose brains are 
still developing.  Seizures which occur during this developmental phase can be potentially 
detrimental and may result in permanent damage.  Delaying classification until a genetic cause is 
identified, assuming it is at all, may result in hesitation by physicians to implement the most 
suitable course of treatment. 
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However, there are also several advantages to using a genetic classification system, as 
indicated by other disorders that have adapted such methodology.  For example, in hereditary 
colorectal cancer in the early 1990s, most high risk families (those with a strong family history) 
were clinically labeled as Hereditary Non-Polyposis Colorectal Cancer (HNPCC).  Now we 
know that this group is largely genetically heterogeneous.  However, scientists have identified 
one significant proportion of HNPCC families with mutations in mismatch repair genes – the 
cause of Lynch syndrome.  Thus these families have been clinically identified as HNPCC but 
after genetic testing are more specifically diagnosed as Lynch syndrome.  This classification has 
repercussions on how the “family” is treated.  Those without the mutation will undergo colon 
cancer screening indicative of the general population while those who are unaffected and 
mutation carriers will be put into a more thorough screening program.  Not only does this genetic 
classification alleviate the burden of doubt in unaffected family members but it also saves money 
for the health care system.  Without the genetic classification, all individuals at risk for cancer in 
the family would have to undergo high risk screening even though approximately half of them 
would not have the relatively highly penetrant mutation.  These are very important 
considerations to health care professionals when determining the implications of selecting a 
clinical or genetic classification system. 
The challenges of implementing a genetic classification system in place of the widely 
used clinical system are illustrated in the example of severe infantile epilepsies.  SMEI has long 
been known to have a genetic etiology with 50% of patients having a family history.  Affected 
relatives of SMEI patients typically have a spectrum of symptoms such as febrile seizures and 
mild generalized epilepsies.  These phenotypes are consistent with those in the GEFS+ spectrum.  
GEFS+ is associated with mutations in SCN1A, SCN1B, SCN2A and GABRG2.  SCN1A 
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mutations have also been identified in a large portion (35-82% depending on the population) of 
SMEI cases; however, the majority of these are de novo mutations (Scheffer 2003).  Although 
these molecular findings reinforce the noted clinical continuum between phenotypes of diseases 
with similar genotypes, they also further complicate the molecular puzzle of SMEI families.  As 
yet, it is not fully understood why children with SMEI and de novo SCN1A mutations have a 
family history of seizures or GEFS+.  It has been postulated that additional familial genes must 
be contributing to the seizure history in family members and these genes interact with the de 
novo SCN1A mutation in the SMEI patients to produce the more severe syndrome.  Until these 
other genetic contributors are understood, an SCN1A mutation provides insufficient diagnostic 
information for a clinician to determine the severity of the patient’s prognosis.  Although 
identification of such a mutation supports a diagnosis of SMEI, it probably does not explain the 
entire picture.  Since the molecular basis of SMEI is not fully understood, and complex 
inheritance is believed to play a role, even in de novo mutations, the diagnostic classification 
must remain a clinical one (Shorvon 2011). 
 
4.7.5  Clinical limitations in case ascertainment 
Epidemiological studies in epilepsy have a number of specific problems involving case 
ascertainment, classification of epilepsy, and selection bias (Sander and Shorvon 1987).  Case 
ascertainment may pose difficulties because of deficiencies in patients’ reporting and in the 
diagnosis of seizures, and inherent methodological problems; the classification of epilepsy is 
often arbitrary and definitions are often variable.  Undetected selection bias may markedly 
influence incidence and prevalence estimates (Stuckless, 2007).  The current study employed 
several methods to circumvent these issues.  These included the use of standardized 
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questionnaires for seizure and family history data, using two neurologists to confirm and agree 
upon diagnoses, using a catchment area (the Avalon Peninsula) which would yield the highest 
case ascertainment, blinding chart reviews, and adhering closely to the most recent ILAE 
classification criteria. 
Furthermore, this study employed the relevant classification criteria at the time of study 
inception and maintained the same parameters throughout in order to reduce selection bias and 
improve the power, precision and accuracy of measuring the outcomes of interest.  Since the 
most pervasive classification system in 2003 was those which were initially set forth in 1981 and 
1989 by the ILAE (with revisions in 1991 and 1993), the diagnostic utility was not entirely 
thorough, lacking the benefits of recent technological advances and genetic discoveries.  Since 
the current study involved a large genetic component, the current state of literature was 
considered in addition to the 1989 ILAE classification system. 
 
4.7.6 Bias and Confounders 
Volunteer bias, also referred to as “self-selection” bias, is inherent in studies such as this 
where patients are allowed to refuse participation without penalty to their regular health care 
provision.  Those who volunteer for the study may differ from those who refuse participation, 
thus affecting the study data.  Research has shown volunteers to be better educated, healthier, 
lead better lifestyles, and have fewer complications given similar interventions than the general 
population (Stuckless S, Parfrey P, 2007).  Conversely, non-response bias occurs when those 
who do not take part in a study differ in important aspects from those who respond.  This may 
lead to overestimation or underestimation of the incidence of seizures in the population.   
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The current study made attempts to control for and measure volunteer bias.  Family 
history of disease was assessed in responders and non-responders by blind chart review.  The two 
groups were found to not be statistically different; thus stratified analysis was not required.  
However, it is difficult to control for all forms of enrolment bias, as was demonstrated in 
calculating the incidence.  In order to determine the incidence of each epilepsy syndrome and 
phenotype, family members were contacted and a questionnaire was administered by telephone.  
If those who were willing to provide data differed from those who refused, then the incidence 
estimates of each phenotype may be biased.  For example, parents of some patients with non-
severe seizures, such as absence seizures, claimed that their child did not have epilepsy and 
consequently refused to answer seizure questionnaires.  Thus incidence data may be skewed in 
favor of the occurrence of tonic-clonic and generalized seizures.  
Recall bias can occur in studies such as this where subjects are required to recall past 
events.  In this case, family members who had witnessed seizures of affected individuals were 
asked to recount these events and a detailed questionnaire was administered to the same 
witnesses for each different type of seizure the patient experienced.  Patients themselves were 
also questioned about their experiences prior to, during (if consciousness was maintained), and 
after their seizures.  In an effort to offset this bias, seizure types were confirmed in patient’s 
hospital charts whenever possible.  However, phenotypic information obtained using 
retrospective chart reviews is unlikely to unveil the detailed clinical information that can be 
obtained by prospective evaluation.  Thus, from the cross-sectional start point of this study, all 
subsequent seizure events were reported to a researcher and recorded according to the ILAE 
questionnaire. 
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4.7.7  Referral bias 
Making an accurate estimate of population-based incidence requires comprehensive 
ascertainment methods.  The greatest caveat to an incidence study such as this one arises when 
family physicians fail to refer children with seizures to a neurologist.  A study in Ontario, 
Canada found that ≤ 20% of children with absence seizures would not be referred to a 
neurologist (Nixon Speechley, Levin et al. 1999).  On the Avalon Peninsula of Newfoundland, 
standard protocol dictates that all children presenting to family physicians and emergency rooms 
with seizures are referred to be followed-up by a neurologist in the Janeway Neurology Clinic.  
In the current study, we have attempted to ascertain virtually all cases of childhood epilepsy from 
the catchment area of the Avalon Peninsula; however, nonreferral rates have not been assessed 
for this area as it is difficult to confirm the actual proportion of primary care physicians in the 
province that follow this route of tertiary referral.  
 
4.7.8 Ascertainment bias 
The greater incidence of IE on the Avalon Peninsula may be due to a true difference 
between the NL population and other published populations but also could be attributed to an 
ascertainment bias.  Children living in close proximity to the Janeway, on the Avalon Peninsula, 
are more likely to be referred to a neurologist than children living in other parts of the province, 
where some children may be treated solely by a family physician.  Thus, comparable populations 
may also have deficits in tertiary referral care whereby children with epilepsy are unreported in 
neurology clinic databases. 
Further, the restrictive inclusion criteria may result in an ascertainment bias toward 
multiple-case families and toward a more severe phenotype.  Smaller families and those with 
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only two affected individuals (or three affected individuals in the same generation) were not 
classified as being compatible with autosomal dominant inheritance leading to a possible over-
representation of families with multiple IE cases included in the study sample for molecular 
analysis. 
Subjects with a family history of seizures compatible with AD inheritance were 
prioritized in the candidate gene selection and screening process.  This methodology is 
commonplace in genetic testing for pilot research projects, particularly in the case of diseases 
such as epilepsy where the vast majority of genes harbouring mutations have been identified in 
such AD families.  However, this methodology invariably results in a sample set subject to 
ascertainment bias.  Further, amongst families with a positive family history, a comparison of the 
number of affected relatives suggests a volunteer bias for the molecular phase of the study.  That 
is, families with a stronger history of disease were more likely to participate in the molecular 
study.  Since the genetic results of this study were not evaluated and generalized in comparison 
to other populations as the epidemiological results were, there was an inherent bias introduced 
via this selection method which was accepted. 
 
4.8 Conclusions 
The results of the current study demonstrate that the incidence of IE is high in 
Newfoundland, and it is associated with a high rate of familial and autosomal dominant disease 
as compared to other population-based studies in developed regions.  It is likely that substantial 
genetic heterogeneity exists as judged by the clinical heterogeneity of disease and the 
distribution of affected families in multiple geographic isolates.  Further work will involve 
molecular genetic studies to identify other causative genes for epilepsy in this population.  A 
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better understanding of the genetic epilepsies at both the clinical and molecular levels will 
improve diagnosis, prognosis and genetic counseling for affected families, and allow the 
development of new strategies for pharmacological control of seizures.  
As genes have been identified in several autosomal dominant epilepsy families in other 
populations, it is likely that other families with monogenic epilepsy syndromes are present in the 
Newfoundland and Labrador population (in addition to the previously identified BFNC and 
GEFS+ families).  Clinical and genetic investigation of these families will provide information 
pertaining to the phenotypes and genotypes of the families as well as the modes of inheritance 
and clinical expression of IE in the entire Newfoundland and Labrador population. 
 
4.9 Future directions of epilepsy research 
As research into the molecular genetic etiology of IE continues, further epilepsy-causing 
genes will undoubtedly be identified.  In family studies of Mendelian epilepsy, disease-causing 
genes are likely to be more rapidly identified through NGS.  Over the past few years, numerous 
disease-causing genes have been identified utilizing NGS technologies that entail DNA 
enrichment, massive parallel sequencing and new data analyses strategies (Metzker 2010).  NGS 
is redefining how we identify disease-causing genes.  In particular, whole exome sequencing 
(WES) has been a very effective approach for determining the genetic cause of Mendelian 
disease, using just a few affected individuals (Hoischen, Gilissen et al. 2010; Ng, Buckingham et 
al. 2010).  NGS is largely replacing the traditional method of positional cloning and candidate 
gene analysis for gene discovery.  Instead, the coding regions (and intron/exon boundaries) of all 
the genes in the genome are sequenced simultaneously.  All the genetic variants in these coding 
regions are identified then the data is systematically filtered and analyzed to sort out the benign 
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and/or common variants from the rare and/or disease-causing mutation(s).  It is believed that 
approximately 80% of cases of Mendelian diseases are caused by mutations that can be detected 
in the exome (including intron/exon boundaries).  Therefore, employing WES to continue the 
search for the causative variants in the remaining families would have a high probability of 
success. 
Although it is well recognized that a single epilepsy gene can cause widely varying 
clinical features in different individuals in the same family, the factors determining these 
differences are currently not well understood.  The close collaboration of clinicians and 
molecular geneticists will continue to provide accurate information on the clinical effects of 
genotypes which are identified in the population, and lead to the identification of genetic markers 
predisposing to specific levels of disease severity and progression.  The analysis of clinical data 
combined with molecular genetic studies will allow delineation of natural history and genotype-
phenotype correlations.  This will lead to an improved understanding of the molecular genetic 
basis of pediatric epilepsy and more accurate prognostic information for families.  
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Appendix B:  Seizure History Questionnaire 
 
Adapted from: Reutens et al, Epilepsia 1992 33(6):1065-1071. 
 
* This questionnaire should be asked to all those reporting seizures, AND, if possible, a 
person who has witnesses the seizures, such as a parent or sibling of the person reporting 
seizures.  
 
History taken from:  
 
 
Name of person to whom this history pertains: 
 
 
DOB: 
 
MCP:  
 
Current Date: 
 
I. How many different types of seizures do you think you have?  
 
 
 
II.  Please describe what happens in each type of seizure. 
 
 
 
III. Do you have blank spells or spells in which you go into a trance-like state?   
           Y / N 
 
IV.  Do you have spells in which you twitch or jerk, especially after just waking up?  
  
           Y / N 
 
Name of person to whom this history pertains:  
 
 
For each seizure type: 
 
Seizure Type:  
 
 
1.0 Do the seizures follow each other in a particular pattern, for example: when 
wakening/ going to sleep/ with flashing lights/ around the time of the menstrual period/ or 
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any other pattern ?          
         Y / N 
If Yes, describe the pattern. 
 
 
 
2.0 Do you have any warning before seizures occur, for example, a smell or taste or 
different feeling, or any other warning?        
         Y / N 
If Yes, describe the warning. 
 
 
 
 
If Yes to Question 2.0:  
2.1  How long does the warning last? 
 
 
2.2  Does the warning ever occur on its own?      
           Y / N 
 
 
3.0 Do you “go blank” or lose awareness of your surroundings during the seizure?  
Y / N 
 
If Yes to Question 3.0:  
3.1 For how long are you blank or “out of it?” 
 
 
3.2 Do you go completely blank (out of it altogether) or retain some awareness of your 
surroundings? 
 
 
3.3 Do you stop what you are doing or continue on automatically, not being aware of your 
surroundings? 
 
 
 
If No to Question 3.0:  
4.0 If No to 3.0: Without losing consciousness, have your legs given way?   
          Y / N 
 
 
4.1  Without losing consciousness, have you dropped to ground?   
          Y / N 
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4.2  Without losing consciousness, have your arms dropped or sagged?   
          Y / N 
 
 
4.3  Without losing consciousness, have you had sudden jumps which may have 
caused you to drop things?        
        Y / N 
 
 
4.4  Without losing consciousness, does your head drop or sag?     
          Y / N 
 
 
5.0  During a seizure, do you experience emotional changes or flashbacks?   
          Y / N 
If Yes, describe them:  
 
 
5.1 During a seizure, do you experience a feeling of being in a dream or in an 
unusually strange or familiar place?         
          Y / N 
If Yes, describe the feeling. 
 
 
If Yes to Question 5.0: 
 
5.2 During a seizure do you experience intense fear?   Y / N 
 
 
During a seizure do you experience rage or anger?    Y / N 
 
 
During a seizure do you experience happiness, or pleasure?   Y / N 
 
 
If Yes to Question 5.2: 
5.3 How long do the emotional changes last? 
 
If Yes to Question 5.0:  
5.4 During a seizure do you experience flashbacks or memories of past events (as 
though you are reliving the past)?        
          Y / N  
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5.5 During a seizure do you experience the sense that everyday surroundings or 
objects are unfamiliar? 
             
          Y / N 
 
 
6.0 During a seizure do you see or hear things that aren’t real?     
          Y / N 
 
If Yes, describe what you see or hear: 
 
 
 
 
If Yes to Question 6.0: 
 
6.2 How long does this sensation last? 
 
 
 
7.0 During a seizure do you experience any unusual smells or tastes?    
          Y / N 
If Yes, describe the smells or tastes. 
 
 
If Yes to Question 7.0: 
 
7.2 How long does this sensation last? 
 
 
 
8.0 During a seizure do you notice any pins and needles, electric shocks, tingling, or other 
changes in sensation?  
             
          Y / N 
If Yes, describe the sensations. 
 
 
 
 
If Yes to Question 8.0: 
8.1 Where does the change in sensation start and how does it spread? 
 
 
8.2 How long does the change in sensation last? 
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9.0 During a seizure do objects or sounds in the room appear distorted or altered? For 
example, do sounds seem nearer or farther away or objects seem shrunken or magnified?  
        Y / N 
 
If Yes, describe the changes. 
 
 
 
 
If Yes to Question 9.0,  
 
9.1 Indicate if auditory or visual. 
 
 
9.2 How long does it last?  
 
 
 
10.0 During a seizure do you feel that everything is in slow motion or sped up?   
          Y / N    
If Yes, describe the feeling. 
 
 
 
11.0 During a seizure do you experience a funny feeling in your tummy?   
          Y / N 
 
 
 
12.0 During a seizure do you experience mouth watering or drooling?   
          Y / N 
 
 
 
13.0 During a seizure do you experience palpitations or a pounding heart?   
          Y / N 
 
 
 
14.0 During the seizure do the eyes roll back or tend to look in a particular direction? 
          Y / N 
 
 
If Yes to Question 14.0:  
 
14.1 Which direction do they turn? 
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14.2 How long does it last? 
 
15.0 During a seizure, does the head turn in a particular direction?    
          Y / N 
 
If Yes to Question 15.0: 
 
15.1 Which direction does it turn? 
 
 
15.2 How long does it last? 
 
 
 
16.0 During a seizure, are the arms held stiff in a particular position?    
          Y / N   
 
If Yes, describe what happens. 
 
 
 
If Yes to Question 16.0: 
 
16.1 Are both arms or is just one arm affected? 
 
 
16.2 Are the arms bent or straight? 
 
 
16.3 How long does it last? 
 
 
 
17.0 During a seizure are the legs held stiff in a particular position?    
          Y / N 
 
If Yes, describe what happens. 
 
 
 
If Yes to Question 17.0: 
 
17.1 Are both legs or is just one leg affected? 
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17.2 Are the legs bent or straight? 
 
 
 
17.3 How long does it last? 
 
 
 
18.0 During the seizure, does breathing stop or does the subject go blue? Y / N 
 
 
 
19.0 Do any jerking or twitching movements of the face, arm, or leg occur during the 
seizure?  
           Y / N 
 
 
If Yes to Question 19.0: 
 
19.1 Which parts of the body do they affect (face or lips/arms/legs)? 
 
 
 
19.2 Does the jerking affect both sides of the body at the same time or only one side at a 
time? 
 
 
 
19.3 Are the jerks infrequent and irregular, or are they repeated and regular?  
 
 
 
19.4 Approximately how long does the jerking last? Give approximate longest and shortest 
times. 
 
 
 
 
20.0 During a seizure, do the eyelids twitch or is there any repeated blinking?  
          Y / N 
 
 
If Yes to Question 20.0: 
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20.1 How long does it last? 
 
 
 
21.0 During a seizure, do any of the following things occur? 
 
21.1 Smacking of the lips         
        Y / N 
 
 
21.2 Licking of the lips          
        Y / N 
 
 
21.3 Chewing           
        Y / N 
 
21.4 Swallowing          
        Y / N 
 
 
21.5 Laughing           
        Y / N 
 
 
21.6 Picking at or fiddling with things        
        Y / N  
 
 
21.7 Walking or making stepping or bicycling movements     
        Y / N 
 
 
21.8 Speaking            
        Y / N 
 
 
If Yes, describe what happens. 
 
 
 
22.0 Do you ever bite your tongue during a seizure?      
        Y / N 
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23.0 Do you ever wet yourself during a seizure?      
        Y / N 
 
  
 
24.0 After a seizure are you confused or drowsy?       
        Y / N 
 
Describe how you feel after a seizure. 
 
 
 
 
If Yes to Question 24.0: 
24.1 How long does the confusion or drowsiness last? 
 
 
25.0 After a seizure, do you have a headache?        
        Y / N 
If Yes, describe it. 
 
 
 
 
If Yes to Question 25.0: 
25.1 Is the headache on one side of the head or does it ache all over? 
 
 
 
26.0 Do seizures have any longer lasting effects on vision, speech, sensation, or muscle 
power?  
             
        Y / N 
If Yes, describe the changes. 
 
 
 
 
If Yes to Question 26.0: 
26.1 How long do these effects last? 
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Appendix C 
Human Investigation Committee Application 
 
October 2003 
 
GENERAL APPLICATION CHECKLIST 
Memorial University Human Investigation Committee 
 
One copy of the completed checklist must be attached to each copy of your application. 
Please ensure all items are marked either X or NA 
 
Short title of proposal: The Clinical and Genetic Epidemiology of Pediatric Epilepsy in 
Newfoundland and Labrador 
 
[X] Latest copy of application form has been used. (October 2003) 
 
[X] All questions have been answered in the space provided on the form or in the number of 
lines allowed 
 
[X] One copy of the application is signed by applicant 
 
[X] Copies of the budget are attached to each copy of the application 
 
[X] Questionnaires, chart audit forms, covering letters are attached to each copy of the 
application. (If standard questionnaires such as the SF36 or EROTC are used, list titles 
where requested and ensure one copy for the primary reviewer is included in the full 
protocol.) 
 
[X] One copy of a current curriculum vitae attached (principal investigator if first time 
applicant to HIC 
 
[X] One copy of full protocol with signature of local investigator, is attached (if relevant) 
Secondary use of data/tissue: One copy of data/tissue request form and one copy of letter 
of approval from data/tissue guardian is attached. 
 
[X] I have read "Guidelines for Preparation of a Standard Consent Form" 
 
[X] Consent document is attached (written consent using HIC template or script for verbal 
consent) to each copy of application 
 
[X] DNA/ tissue consent included, if relevant. 
 
[X] Consent has been assessed at a reading level of _grade 8_(must be less than grade 9). 
 
[X] I have verified that the above information is correct: 
165 
 
 
Name of Principal Investigator(s): Dr. SL Moore Dr. DJ Buckley 
 
HUMAN INVESTIGATION COMMITTEE 
General Application Form 
October 2003 
 
Please complete the application in bold or a font which can be easily distinguished from the 
application form. Applicants are advised to consult Application Guidelines 
 
Forward one copy of the checklist, application, budget, consent form and any other documents 
(questionnaires, scripts, etc.) for screening to the Human Investigation Committee (HIC) Office, 
Room 1755/57, Health Sciences Centre, Phone: 777-6974. Twenty-four copies, submitted in 
sets, will be required by HIC when the application has been screened and allowed to proceed to 
review. 
 
1. Investigators: Dr SJ Moore, Dr DJ Buckley, Dr MF Alam, Ms SJ Penney, Dr P 
Rahman, Dr TL Young, Dr PS Parfrey, K Mahoney 
 
• Principal Investigators: 
 
Last Name, First Name, Title (Dr./ Mr./ Ms./ Mrs.) 
 
Moore, Susan  Dr 
 
Buckley, David Dr 
 
(a) Faculty       [X] Dr Buckley 
(b) Employee of HCCSJ, NCTRF    [  ] 
(c) Undergraduate, graduate, postgraduate student  [  ] 
(c) Other: [please specify]     [X] Dr Moore, Clinical Research 
Associate,        MUN 
 
• Mailing Address: 
 
Internal: Pediatric Neurology 
Janeway Child Health Centre - Dr Buckley 
 
Clinical Epidemiology 
Health Science Centre - Dr Moore 
 
External: 
Street Name & #    300 Prince Philip Drive 
P.O. Box City / Town  St. John’s, NL 
Postal Code   A1B 3V6 
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• Telephone Number:   777 4421 Dr Buckley 
777 7616 Dr Moore 
• Pager Number: 
 
• Email Address: DrBuckley:hcc.bargerm@hccsj.nf.ca; Dr Moore: smoore@mun.ca 
 
• Co-investigators: 
 
Dr MF Alam, Ms SJ Penney, Dr P Rahman, Dr TL Young, Dr PS Parfrey 
 
• Local contact (name and contact information) if principal investigator is external: 
 
• Research Coordinator (if relevant): Ms S Penney or Krista Mahoney 
 
Telephone Number: 777 4172 
 
Email: kmahoney@mun.ca 
 
2. Title of study: 
 
A Study of the Clinical and Genetic Epidemiology of Pediatric Epilepsy in Newfoundland 
and Labrador . 
 
3. Study timeline: 
 
• Proposed start date [at least 4 weeks from date of submission}.' 04/01/2004 
 
• Anticipated completion date: 04/01/2005 
 
• Deadline for ethics approval: 03/01/2004 
 
Indicate below if: 
[  ] course project 
 
4. Setting of study and data sources: 
 
• Setting - Please specify the institutions and/or communities involved: Patients will be 
recruited through the Janeway Child Health Centre Neurology Clinic. 
 
• Check relevant data sources: 
 
(a) Patients [X] 
 
(b) Health Providers [ ] 
 
(c) Clinical Records [X] 
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(d) Pre-existing Dataset [X] The Janeway Neurology Clinic Epilepsy Database will be 
used to ascertain patients. This is run by Ms SJ Penney, Pediatric Neurology 
Research Nurse, Janeway Neurology Clinic, phone #: 7097774172 
 
(e) Residents in Community [ ] 
 
(f) Archived Specimens [ ] 
 
(g) Other: [please specify] 
 
5. Objectives: 
 
• To describe the incidence and clinical epidemiology of pediatric epilepsy over the 
last five years in Newfoundland and Labrador, using a defined sub-population 
on the Avalon Peninsula. This will be achieved using data currently stored on 
the Janeway Neurology Clinic database. 
 
• To describe the genetic epidemiology of idiopathic epilepsy, and identify genes 
involved in idiopathic epilepsy in the province. This part of the study wiII involve 
families from any part of Newfoundland and Labrador. 
 
• To assess whether there is a correlation between genotype and phenotype in 
idiopathic epilepsy, and identify genetic markers of severity and progression. 
 
• To determine whether there are genotypes which are associated with resistance 
to antiepileptic medication in idiopathic epilepsy. 
 
6. Introduction to the study: 
 
The average incidence rate for epilepsy per 100,000 children is reported as 
approximately 40 to 80 (Camfield et ai, 1996; Blom et ai, 1978). Approximately 40% to 
60% of all epilepsy is idiopathic (Weissbecker et ai, 1999). Family studies have shown a risk 
to the sibling of an affected person with epilepsy is approximately 2.5 to 4 fold greater than 
the general population risk (Annegers et ai, 1996; Weissbecker et ai, 1999). The heritability 
of epilepsy has been estimated as 70% to 88% (Kjeldsen et ai, 2001). Most cases of 
idiopathic epilepsy (IE) follow complex inheritance, involving several genes and 
environmental factors (Berkovic et ai, 1990, 1998; Greenberg et ai, 1992). Less often, 
epilepsy can result from a single disease gene. Genes have been identified in several 
autosomal dominant epilepsy families (Baulac et ai, 2001; Beivert et ai, 1998; Charlier et ai, 
1998; Cossette et ai, 2002; Phillips et ai, 1995; Singh et ai, 1998; Steinlein et ai, 1995; 
Sugawara et ai, 2001; Wallace et ai, 1998). Genetic heterogeneity has been shown for all of 
these epilepsy syndromes. Variable expressivity also occurs, implying that modifying genes 
exert an important effect on the phenotype, though these have not yet been identified 
(Scheffer and Berkovic, 1997; Wallace et ai, 1998). Attempts to identify disease genes in the 
majority of cases of IE, which follow complex rather than monogenic inheritance, have 
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been less successful. Several loci have been identified, but these findings have not been 
replicated. Juvenile Myoclonic Epilepsy (JME), one of the commoner IE subtypes, has been 
associated with a locus on 6p (Durner et ai, 1991; Greenberg et ai, 1988; Liu et ai, 1995; 
Weissbecker et ai, 1991) but this was not confirmed by other groups (Elmslie et ai, 1996; 
Whitehouse et ai, 1993). The apparently contradictory evidence from association studies of 
epilepsy implies that ethnic factors and genetic heterogeneity are major confounding 
variables in these studies. 
 
Rationale for the study: 
 
Epilepsy is a common, chronic neurologic condition which creates a significant burden 
for the affected child, their family and society. Idiopathic epilepsy is known to have a 
genetic basis, though little is known about which genes cause the disease in most cases. 
One of the epilepsy genes which causes Benign Neonatal Febrile Convulsions (BNFC) 
was identified through genetic linkage studies on a large Newfoundland kindred (Singh 
et ai, 1998). It is likely that other families, with mendelian inherited epilepsy syndromes 
are present in the population of Newfoundland and Labrador. Clinical and genetic 
studies of these families will provide valuable information not just for the families 
themselves, but also for the wider pediatric epilepsy community. The analysis of 
thorough clinical data combined with molecular genetic studies will allow delineation of 
natural history and genotype-phenotype correlations. This will lead to an improved 
understanding of the molecular genetic basis of pediatric epilepsy, and more accurate 
prognostic information for families. 
 
Molecular genetic.studies of those families with complex inheritance of pediatric 
epilepsy are more likely to be successful in the population of this province than in other 
more admixed populations. The decreased genetic heterogeneity combined with extended 
linkage disequilibrium present in this relatively isolated population increases the power of 
association studies to detect disease loci. These findings would help 
identify the genes which contribute to the majority of cases of pediatric epilepsy, 
inherited in a complex manner, in the province, and improve the understanding of the 
pathogenesis of this common disorder. 
 
7. Blood or other tissue sampling which is part of the study: Not Applicable [ ] 
 
• List samples to be taken from participants, the frequency of sampling and the amount of 
sample. 
 
One blood sample will be taken for DNA extraction: 20ml from adults, l0ml from 
children, and 5ml from infants. 
 
• Will any samples be kept after the completion of this study?  Yes [X]  No[ ] 
 
• Can participants withdraw their blood, tissue or other sample?  Yes [X] No [ ] 
 
• Will any samples now archived by a health care institution be used in the study? 
169 
 
Yes [ ] No [X] 
 
8. Research interventions and/or modes of data collection: 
 
• List any interventions which would not be part of a participant's daily life. 
 
All participants will be asked to: 
 
1. Provide a family history 
 
2. Provide a medical history 
 
In addition, affected children, their parents and some other participants (in families 
showing mendelian inheritance of epilepsy) will be asked to: 
 
3. Provide a blood sample for DNA extraction. 
 
Also, controls recruited from the Health Sciences Centre Blood Collection 
Laboratory will be asked a few questions about their medical history, and asked to provide 
a sample of blood for DNA extraction. 
 
• List questionnaires, information sheets, covering letters, telephone or face to face 
interview scripts/outlines or chart audit forms to be used. Include copies of each with 
each copy of the application; if standard questionnaires are being used - SF36, EROTC, 
etc. [see list on HIC website] include one copy only. 
 
1. Telephone or face to face interview script for initial contact with all parents of 
affected children: Appendix la 
 
2. Cover letter (for parents of affected children): Appendix Ib 
 
3. Cover letter (for relatives other than parents of affected children, contacted during 
Phase 1): Appendix lc 
 
4. Medical Questionnaire (used for all participants): Appendix 2 
 
5. Chart audit form (used only for those participants in families showing mendelian 
inheritance of epilepsy): Appendix 3 
 
6. Standard seizure questionnaire (used for all participants reporting a history of 
seizure): Appendix 4 
 
7. Laboratory Requisition Form (used for all parents of affected children, and other 
relatives from whom DNA is requested): Appendix 6 
 
8. Letter to families showing complex inheritance of epilepsy: Appendix 8 
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9. Letter to families showing Mendelian inheritance of epilepsy: Appendix 9 
 
10. Interview script for initial contact with potential controls in Blood Collection 
Laboratory of the Health Sciences Centre: Appendix 10 
 
11. Medical Questionnaire for controls, recruited from the Blood Collection Laboratory 
at the Health Sciences Centre: Appendix 11 
 
9. Description of study: 
 
For Protocol, see Appendix 5. 
 
The study to identify epilepsy genes will take place in two phases. 
 
First Phase 
The first phase is concerned with data collection and pedigree analysis to identify the inheritance 
pattern in the family. 
 
A medical history will be taken from all participating parents of children with 
idiopathic epilepsy. A medical history will also be taken for siblings of the affected child 
(from the parents), and from the grandparents (for themselves, and all their offspring). If 
available, great-grandparents of the affected child will be asked for a medical history of 
themselves and their offspring. 
 
Blood samples will be taken from the affected child and their parents for DNA extraction. 
Genetic counseling will be provided by the Research Nurse employed for this project, who 
will be trained in this area. 
 
During this time, controls will be recruited from the Blood Collection Laboratory of the 
Health Sciences Centre. They will be asked a short medical questionnaire, and asked for a 
sample of blood for DNA extraction, after genetic counseling. 
 
Second Phase 
The second phase involves molecular genetic analysis of DNA from families. The method of 
genetic analysis for each family will be determined by the results of data collected during 
Phase 1. 
 
Family history data collected during Phase 1 will be analysed, and families will be 
categorised as having complex or Mendelian (for example autosomal dominant or 
recessive) inheritance of epilepsy. Letters will be sent to all participants to inform them of 
the pattern of inheritance of epilepsy in their family. 
 
• Parents of affected children from families with pedigrees suggestive of Mendelian 
inheritance will be contacted again and asked to participate in genetic linkage 
studies to try to identify the disease gene causing epilepsy in the family. At this time, 
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medical histories will also be taken from the affected child's parents' siblings, and 
spouses married into the family. Medical histories will be confirmed by review of 
medical charts. 
 
Blood samples for DNA extraction will be taken from as many relatives as possible. 
When available, results will be given to relatives, with genetic counseling. 
 
• Participants in families showing complex inheritance of epilepsy will not be called 
again. Genetic association studies will be performed on DNA from these 
participants. These will involve comparing patterns of DNA around known epilepsy 
genes in affected children and controls, to determine whether particular epilepsy 
genes are associated with idiopathic epilepsy in this province. 
Note: Phase 2 may be started before Phase 1 is completed, if families showing Mendelian 
inheritance of epilepsy are identified during the course of Phase 1. 
 
10. Sample size: [if measuring statistical differences/equivalencies] 
 
1. Sample size calculation is not relevant for the part of this study which involves genetic linkage 
studies in the families showing Mendelian inheritance of epilepsy. A family with 
multiple affected individuals and several unaffected relatives from whom DNA is available, 
would be eligible for this analysis. 
 
2. For the group of families showing complex inheritance of epilepsy who will be analysed 
using the case control method and single nucleotide polymorphism (SNP) technology, the 
sample size is calculated as follows: 
 
Null Hypothesis: For a particular gene with two alleles, either allele will be transmitted 
randomly to affected offspring. On average, an allele will be transmitted in 50% of cases, so 
expected proportion p=0.5 
 
Alternative Hypothesis: An allele (which predisposes to epilepsy) will be transmitted on 
average in 60% of cases to affected offspring. 
 
In complex inheritance, several different genes each contribute a small predisposition to 
the disorder, so a difference of 10% in the rate of transmission of a predisposing allele from 
parent to affected child would be reasonable to assume. 
 
Thus, the expected proportion of a particular allele in the affected children, p=0.6 
The 95% confidence interval (CI) should not overlap 0.5 (expected proportion for the null 
hypothesis, which would be the expected proportion in the control group), so use a half 
width of the CI for a two-tailed test of .07. 
 
Use the following formula to calculate sample size, N: 
N = p (l-p) x (1.96 / desired half width of cn 
p = expected proportion, for alternative hypothesis, = 0.6 
I-p = 0.4 
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desired half-width of CI = 0.07 
=> = 188 = number of cases of children affected with idiopathic epilepsy from whom 
DNA is available 
 
We will attempt to get parents of probands whenever possible to facilitate linkage 
disequilibrium studies. 
 
11. Participants: 
 
• Describe the participants to be contacted or whose record information will be used. 
 
(a) Adults [X] 
 
(b) Children under 19 [Xl 
 
(c) Persons incompetent to give consent [ ] 
 
(d) Protected or vulnerable populations [ ] 
 
This is a study of pediatric epilepsy, so the affected population are children. 
 
• Number of participants at this site: approximately 400 
 
• Will pregnant women be excluded?   Yes [ ] No [X] 
 
• Is this a part of a national/international study?  Yes [ ] No [X] 
 
 
• Will contact be made with potential participants? Yes [X] No [ ] records only 
 
(a) Attending physician [Xl 
(b) Investigator [Xl [See guidelines} 
(c) Other: Research Nurse or coordinator [X] 
 
1. For parents of children affected with epilepsy (and the children 
themselves if they are old enough to understand) first contact will be 
made by Ms S Penney, Dr Buckley or Dr Alam. If the individual agrees to 
be contacted by a researcher, the Research Nurse will then make contact 
by telephone to explain the study, and information sheets and consent 
forms will be sent by mail. 
 
2. In the case of relatives of the affected child other than the parents, these 
people will not be contacted until the parents have asked them if they are 
happy to be contacted by a researcher about the study. Once it is 
confirmed that they are agreeable to be contacted, the Research Nurse 
will contact them by telephone and send information sheets and consent 
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forms by mail. 
 
In both scenarios detailed above, people to whom the information and consent forms have 
been mailed will be called again by telephone three weeks after mailing if the signed 
consent form has not been received, and any questions will be answered. If the individual 
does not wish to participate at this time, they will not be called again. 
 
Once the signed consent form is received, the individual will be called by telephone and 
interviewed, using questionnaires shown in Appendix 2, and Appendix 4 if appropriate. 
 
During the study, approximately 200 controls will be recruited from adult patients presenting to 
the Blood Collection Department at the Health Sciences Center. These patients will be asked a 
short questionnaire to check they do not have a personal of family history of seizures (Appendix 
11), and asked to provide a sample of blood for DNA extraction. These samples will be used 
anonymously as controls in association studies (see Protocol in Appendix 5). 
 
12. Consent process: 
 
• Who will obtain the consent? Research Nurse, who will be employed for this project, 
Dr S Moore, or K Mahoney 
 
See Section 11. 
 
13. Risks, discomforts and inconveniences: 
 
• There will be inconvenience and minor discomfort associated with having blood samples taken 
for DNA extraction. However, inconvenience will be minimized by using local hospital 
laboratories for this purpose, and if this is too difficult for the individual, a phlebotomist will 
visit their home to take the blood sample. 
 
• There is a risk that a person will be identified as being a carrier of an epilepsy gene, if they are 
in a family showing Mendelian inheritance of epilepsy, and the disease gene is 
identified. These people will be referred to the Newfoundland and Labrador Medical 
Genetics Program for further genetic counseling. 
 
14. Benefits: 
 
• Are there any immediate benefits for participants, including controls?   
No 
 
15. Privacy and confidentiality: 
 
• What steps will be taken to protect privacy and confidentiality of information? 
 
(a) Oath of confidentiality [X ] 
(b) Locked storage [X] 
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(c) Limited access [X] 
(d) Password-protected computer files [X] 
(e) Denominalized files provided by data holder to investigator [ ] 
(f) Coded study number [X] 
(g) Locked room [X] 
(h) Anonymous responses to investigator [ ] 
 
Study codes will be used on all samples sent to laboratories involved in the molecular 
genetic analysis, no identifying information will be provided. 
 
• List below the names of all personnel who can access the identities of study participants: 
Ms S Penney, Dr D Buckley, Dr MF Alam, Dr SJ Moore, Krista Mahoney, Research Nurse. 
 
16. Debriefing: 
 
When the pedigrees have been analysed, a letter will be sent to all families explaining the 
inheritance pattern of epilepsy in their family (Appendix 8 and 9). For those families 
showing mendelian inheritance of epilepsy, molecular results will be given to family 
members, with genetic counseling. 
 
The results of the study will be submitted for peer-reviewed publication in an appropriate 
medical journal, and will be presented at scientific meetings. 
 
17. Payments: 
 
• Do you intend to reimburse participants for expenses incurred? 
Yes [X]  No [  ] Amount [$  ] 
 
18. Budget: Not Applicable [ ] 
 
The budget in this application refers only to Phase 1, since the scope of work required for 
Phase 2 will not be known until data collection has been completed. A further submission 
will be made with a budget for Phase 2 in due course. 
 
Research Nurse 
The research nurse will: 
• take pedigree and medical information from families who have agreed to participate 
• put pedigree information onto computer 
• arrange blood sampling for DNA extraction from those who have consented 
37.5 hours per/week for 1 year ($30.14 per hour) $58,783.24 + 20% benefits = $70,539.89 
 
Expenses for travel, meals, etc. 
 
For participants who travel to the Janeway Child Health Centre especially for 
participation in this research. This does not apply to those participants whose 
appointments for the research study are arranged to co-incide with Neurology Clinic 
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follow-up appointments. 
 
100 people x $15/person $1500 
 
Expenses for phlebotomy services 
For participants who live in remote areas and require a visit by a local phlebotomist 
 
100 people x $30/visit $3,000 
 
Overhead Expenses: 
 
Postage, communications (telephone, fax), office supplies $5400 
 
TOTAL COST $80,439.89 
 
• Source of funding: An application has been made to the Janeway Foundation. Further grant 
applications are being made to other institutions, including CARR, Health Care Foundation, 
Epilepsy Newfoundland and Labrador. 
 
• Will the budget be administered through the University Finance Office? Yes [X] No [ ] 
If no, please specify the person or agency responsible: 
 
19. Potential conflict of interest: 
 
• Is any investigator a shareholder in any company/agency    
funding this study?       Yes [ ] No [X] 
 
• Will any investigator receive direct financial or other benefit?  Yes [ ] No [X] 
 
If yes, please describe:  
 
• Will any investigator receive indirect financial or other benefit?  Yes [ ] No [X] 
 
{share of profits, future royalties, patent rights, et all 
If yes, please describe: 
 
20. Ownership, storage and destruction of data: 
 
• The investigator must be free to publish within 6 months after submitting the 
manuscript to the sponsor for review. Publication of the full study must be assumed no 
longer than 1 year after the completion of the study. In agreement with the Office of 
Research, HIC will assume these terms will be negotiated in any research contract. 
 
• Do you intend to destroy the data collected at the end of the study? Yes [] No [X] 
If no: 
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(a) Please give the anticipated date of destruction: Results of molecular genetic 
testing will not be destroyed. If family members ask for further testing in the 
future, these results may be helpful. DNA will not be destroyed unless the 
individual requests this, since it may be needed for further tests in the future. 
 
(b) In what form will the data be retained, e.g., frozen samples, computer tapes, 
paper? Molecular genetic results will be stored on a password protected 
computer, and in charts which will be stored in locked cabinets. DNA 
samples will be stored in the Medical Genetics Laboratory, Health Sciences 
Centre, St John's. 
 
(c) Where will the data be stored?  
 
Data from the study will be stored in the 
Patient Research Centre. 
In those families showing Mendelian inheritance of epilepsy, molecular genetic 
results will be: 
• sent to the family member. 
• kept in a Clinical Genetics chart, stored in the Genetic Clinic 
• in the case of the affected child, kept in the child's Janeway Neurology Clinic chart 
 
(d) Who will be the data guardian? 
 
Name: Dr S Moore, and, for those individuals who are given molecular 
genetic results, health care professionals in the Janeway Neurology Clinic 
and Genetics Clinic. 
 
Contact information: 
 
• Will any form of identifier - name, postal code, study code, be retained? Yes [X] No [ ] 
 
• If yes, please describe the identifiers to be retained and give the rationale for their retention. 
Identifying details including MCP, date of birth and address, will be retained. This is 
necessary in order to identify the individual to whom a molecular genetic result pertains. 
However, no identifying information will be sent to the laboratories in which the genetic 
analyses are being undertaken. 
 
21. Concurrent submissions or approvals: 
 
Has this proposal been submitted to another REB? No. If already approved, please include one 
copy of approval. 
 
Reminders: 
 
 The use of personnel and/or resources of the Health Care Corporation of St. John's 
requires the approval of the Research Proposal Approval Committee (St. John's) 
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subsequent to HIC approval. Such approvals may also be required by institutions outside 
the HCCSJ and/or by regional health boards. 
 
 Forward one copy of the checklist, application, budget, consent form and any other 
documents (questionnaires, scripts, etc.) for screening to the Human Investigation 
Committee (HIC) Office, Room 1755, Health Sciences Centre, Phone: 777-6974/7719. 
Twenty-four copies, submitted in sets, will be required by HIC when the application 
has been screened and allowed to proceed to review. 
 
 
 
 
 
Signature of principal investigator: 
 
 
Date:          December 1, 2003 
 
 
Signature of undergraduate/graduate/postgraduate student (if applicable): 
 
Krista Mahoney 
 
_____________________________ 
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Appendix D  
Primer Sequences 
 
A) Microsatellite Marker and SNP Primer Sequences 
 
Gene/ primer 
name 
Direction 5' Modification Primer 
SCN1A SNPs    
SCN1A-Ex9-F Forward  acagggtgctatgaccaaca 
SCN1A-Ex9-R Reverse  tcctcatacaaccacctgctc 
SCN1A-Ex15-F Forward  gagacggttagggcagatca 
SCN1A-Ex15-R Reverse  tatacatgtgccatgctggt 
SCN1A-Ex26-F Forward  ccttggagctttagaagaaaca 
SCN1A-Ex26-R Reverse  GGTTGTAATTTGGAATAGGCAGA 
SCN1A 
Microsatellites 
   
D2S2330-F Forward 6-FAM AGTCATCTTATAGAAAATAGCAAGC 
D2S2330-R Reverse  AGTTTTACAACTTAATTNTTGGGTG 
D2S382-F Forward 6-FAM ATGCTAAATCTCAAAGCCAGTCT 
D2S382-R Reverse  CTAATNCTCAATTCAGTGCTCCT 
D2S156-F Forward 6-FAM CCCTCTGTTTGCCTGAAATA 
D2S156-R Reverse  CCAGCCTTGATTGTCACAC 
D2S399-F Forward 6-FAM CAAACATCCTACCTGCACAG 
D2S399-R Reverse  CTCAATGGGAAGTTATTGAATG 
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B) Primer Sequences by Exon 
 
Gene/ primer name Direction Primer 
SCN1A   
NM_006920_Ex1_F Forward tttaaatcctctagctcatgtttca 
NM_006920_Ex1_R Reverse TTGGCATGTGTTGGTGCTAC 
NM_006920_Ex2_F Forward cagtgacagtttgttttcatgg 
NM_006920_Ex2_R Reverse tgaggctaatatgacaaagatgc 
NM_006920_Ex3_F Forward tttgggcttttcaatgttagc 
NM_006920_Ex3_R Reverse tgctgcgtaattttgtctagga 
NM_006920_Ex4_F Forward ctgatggagtgataagaaattgg 
NM_006920_Ex4_R Reverse ttctacaggtaaagcaaacctattc 
NM_006920_Ex5_F Forward aagaagtgattagagtaaaggataggc 
NM_006920_Ex5_R Reverse caagcagagaaggatgctga 
NM_006920_Ex6_F Forward ctccactagcgttgcaaaca 
NM_006920_Ex6_R Reverse ggatatccagcccctcaagt 
NM_006920_Ex7_F Forward aaatacttgtgcctttgaatgaa 
NM_006920_Ex7_R Reverse gttggctgttatcttcagtttctat 
NM_006920_Ex8_F Forward ccaaatctttctgactaggcaat 
NM_006920_Ex8_R Reverse caagtctcgtttcaagttctgc 
NM_006920_Ex10_F Forward aagccatgcaaatacttcagc 
NM_006920_Ex10_R Reverse cacaacagtggttgattcagttg 
NM_006920_Ex11_F Forward tgaatgctgaaatctccttctaca 
NM_006920_Ex11_R Reverse gctggtgcagcaatagtgag 
NM_006920_Ex12_F Forward atctgccatcaccaattgaa 
NM_006920_Ex12_R Reverse tgcactattcccaactcacaa 
NM_006920_Ex13_F Forward aaggttgtctctgtaacaaaaatgtg 
NM_006920_Ex13_R Reverse caggaagcatgaaggatggt 
NM_006920_Ex14_F Forward gaatcattgtgggaaaatagca 
NM_006920_Ex14_R Reverse gctaatggttgtgtggcaaa 
NM_006920_Ex15_F Forward tgaccatttctaggtaaagctcaat 
NM_006920_Ex15_R Reverse tttgacaaaacagtcaccattaaa 
NM_006920_Ex16a_F Forward gaatgggagaacttgagagca 
NM_006920_Ex16a_R Reverse TTTCCCAATTTCTGCTGTATGA 
NM_006920_Ex16b_F Forward TGGATAGGATGCACAAAGGA 
NM_006920_Ex16b_R Reverse tcaaaacatcattaagctgagga 
NM_006920_Ex17_F Forward aaaagggttagcacagacaatga 
NM_006920_Ex17_R Reverse ttgggcagatataatcaaagca 
180 
 
NM_006920_Ex18_F Forward gctagcaagacagagatgagca 
NM_006920_Ex18_R Reverse gggataattaaaaatgcattgga 
NM_006920_Ex19_F Forward ctgccctcctattccaatga 
NM_006920_Ex19_R Reverse tctgtcaacataacatagtggtctga 
NM_006920_Ex20_F Forward aaaggtttactgaaaatgtctgaaca 
NM_006920_Ex20_R Reverse ttgcaagaatttgccattcc 
NM_006920_Ex21_F Forward tggaaagaccagagattactaggg 
NM_006920_Ex21_R Reverse cacccatctgggctcataaa 
NM_006920_Ex22_F Forward tgtctttcaaaaatattcccttttg 
NM_006920_Ex22_R Reverse ttggtcgtttatgctttattcg 
NM_006920_Ex23_F Forward gcacattactgttcaaatggaag 
NM_006920_Ex23_R Reverse ttcttagctttctatagccggaaa 
NM_006920_Ex24_F Forward ttgggggtgtttgtcttcat 
NM_006920_Ex24_R Reverse tggattgtaatggggtgctt 
NM_006920_Ex25_F Forward caaaaatcagggccaatgac 
NM_006920_Ex25_R Reverse tgattgctgggatgatcttg 
NM_006920_Ex26nc1_F Forward CCTATGACCGGGTGACAAAG 
NM_006920_Ex26nc1_R Reverse CCCAGGTGGCATACCTGTTA 
NM_006920_Ex26nc2_F Forward GGGTGCAAACCTGTGATTTT 
NM_006920_Ex26nc2_R Reverse TGACTCCAAACATTTGAATGAA 
NM_006920_Ex26nc3_F Forward GGGTGATAAGTGGAGGTGCT 
NM_006920_Ex26nc3_R Reverse TGAACAATTTCCTTGACTTTACCA 
NM_006920_Ex26nc4_F Forward TGGATGCTATCAATGCATGTTT 
NM_006920_Ex26nc4_R Reverse TTTGGATATGAATCGTGAACCT 
NM_006920_Ex26nc5_F Forward CATGAAAACAAGACTGGGTAGTTG 
NM_006920_Ex26nc5_R Reverse cccttctcccccaatttgta 
   
KCNQ2   
NM_172107_Ex6variant_F Forward gcccttcgtgtgactagagc 
NM_172107_Ex6variant_R Reverse ggtcccacctagggaactgt 
KCNQ2_Ex1_F Forward tccctttccctcttctctcc 
KCNQ2_Ex1_R Reverse tacaatcgctctccggtctc 
KCNQ2_Ex2_F Forward ctatgggggtgccctctg 
KCNQ2_Ex2_R Reverse gcgtcagaggccctgtagta 
KCNQ2_Ex3_F Forward ggtcagcttgcagtttcctt 
KCNQ2_Ex3_R Reverse aacttccagaaggagccagtc 
KCNQ2_Ex4_F Forward tctgcacatcctcctggaac 
KCNQ2_Ex4_R Reverse cactgactccatccctccac 
KCNQ2_Ex5_F Forward tcatggtgttgatgtgatggt 
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KCNQ2_Ex5_R Reverse gccagtgagagcctggtc 
KCNQ2_Ex6_F Forward gcatctgtcccatcccaag 
KCNQ2_Ex6_R Reverse ggtcccacctagggaactgt 
KCNQ2_Ex7_F Forward gggtgtgtgagtctctggagt 
KCNQ2_Ex7_R Reverse cttcacatcctcgctccttc 
KCNQ2_Ex8_F Forward agtgcctggcctacagcat 
KCNQ2_Ex8_R Reverse tgaacaacaaaaagtggggttt 
KCNQ2_Ex9_F Forward agaaccagcccttgtgctaa 
KCNQ2_Ex9_R Reverse ccggtcacagttccagaca 
KCNQ2_Ex10_F Forward gtgcaagcagagggaggt 
KCNQ2_Ex10_R Reverse actgtcctggcgtgtcttct 
KCNQ2_Ex11_F Forward tgacccatgggactgtgg 
KCNQ2_Ex11_R Reverse acacaaggccctcacatctc 
KCNQ2_Ex12_F Forward gcagagtgacttctctccctgt 
KCNQ2_Ex12_R Reverse gttcccactccaagagcaag 
KCNQ2_Ex13_F Forward gctctgtctagccggtgtg 
KCNQ2_Ex13_R Reverse gctctgtccagcaccatga 
KCNQ2_Ex14_F Forward ccgaggtctcagaggtgcta 
KCNQ2_Ex14_R Reverse acacaacagaagctgacagagg 
KCNQ2_Ex15_F Forward ctagacccaggggcactgt 
KCNQ2_Ex15_R Reverse agagcagctgtcagtggtga 
KCNQ2_Ex16_F Forward tgggtctctcctgtttcctg 
KCNQ2_Ex16_R Reverse GGGGTACAGAGGTCGGAGTC 
   
GABRA1   
GABRA1_Ex1_F Forward cctaccatccgtcaccattc 
GABRA1_Ex1_R Reverse ggtgagagacatacggactgc 
GABRA1_Ex2_F Forward tcaccgcctatttcacatcc 
GABRA1_Ex2_R Reverse cccccgactataacattcctg 
GABRA1_Ex3_F Forward tcagtcagccctggtggt 
GABRA1_Ex3_R Reverse caattttcttcccccgataaa 
GABRA1_Ex4_F Forward gagaaaggatttatttggaaagagg 
GABRA1_Ex4_R Reverse tgtcaccatttttattatttgacca 
GABRA1_Ex5_F Forward ggtgtcagtatgtggtggtga 
GABRA1_Ex5_R Reverse gccaagacttttcaggttgc 
GABRA1_Ex6_F Forward gcaaaaattatgcactgtctgc 
GABRA1_Ex6_R Reverse attccaccatggctcatca 
GABRA1_Ex7_F Forward gctacagttaataacattccacttgt 
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GABRA1_Ex7_R Reverse acgcgtttttctcacagatatag 
GABRA1_Ex8_F Forward tctttcctagcctgccctct 
GABRA1_Ex8_R Reverse gctcaactgatgcccaattt 
GABRA1_Ex9_F Forward ttcccagacctttggtactcat 
GABRA1_Ex9_R Reverse tgagagtggcaattccttga 
GABRA1_Ex10_F Forward tcaagtaggctgtcccatca 
GABRA1_Ex10_R Reverse accacaggccaaaacatctc 
GABRA1_Ex11_F Forward aaaataagggccaccttgct 
GABRA1_Ex11_R Reverse ATCCTGTCTCCAAGCTGCAT 
   
SCN1B   
SCN1B_Ex1_F Forward ggtgcacctagcggatgt 
SCN1B_Ex1_R Reverse caccctcacctccactgc 
SCN1B_Ex2_F Forward atccagtcctgtctgctggt 
SCN1B_Ex2_R Reverse caggtcagcaatcacagcat 
SCN1B_Ex3_F Forward ggggacagaatcagggtca 
SCN1B_Ex3_R Reverse ccactgcctgccatctgt 
SCN1B_Ex4_F Forward aagctcacacagcaagctca 
SCN1B_Ex4_R Reverse ggtctgacgacccctatcct 
SCN1B_Ex5_F Forward tgtgtacctggggtggagac 
SCN1B_Ex5_R Reverse gcaagagagggggaattagg 
SCN1B_Ex6_F Forward cagaggggaaggggattg 
SCN1B_Ex6_R Reverse ggcactaagtggcttcacct 
   
SCN2A   
SCN2A_Ex1_F Forward atgccattttgtagtccctgt 
SCN2A_Ex1_R Reverse agagggaccactttcatttt 
SCN2A_Ex2_F Forward TCCCTCCCTGTTTCTGTAGC 
SCN2A_Ex2_R Reverse GCCCATCCAGCATCTTAGTG 
SCN2A_Ex3_F Forward GCTTTATGTGAATTATAAATGCGG 
SCN2A_Ex3_R Reverse TGTGGCAAGCAATTCGTAAG 
SCN2A_Ex4_F Forward AACTTCATGGTGGTGAAGGC 
SCN2A_Ex4_R Reverse AAATTGAGGAGGTCTCAAGGTG 
SCN2A_Ex5_F Forward GGGACCAACCTGGAAGTGTC 
SCN2A_Ex5_R Reverse TCAAGGCAAGCCACCAAG 
SCN2A_Ex6_F Forward CCAAGGAAGACGTAGATTTCCC 
SCN2A_Ex6_R Reverse AAGCAAAGAATCAAATCCATCC 
SCN2A_Ex7_F Forward TGCTTTCATTCATTTTCACCAG 
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SCN2A_Ex7_R Reverse CAGTCTTCTTAACACATTTCAGTGG 
SCN2A_Ex8_F Forward AGCTTTGCCACCTAAACAGG 
SCN2A_Ex8_R Reverse GAGTGGGACTGGATGAGTGG 
SCN2A_Ex9_F Forward GCCTGTATAAAACAGACATTGGC 
SCN2A_Ex9_R Reverse AACTACCTTGCCACTGACCTC 
SCN2A_Ex10_F Forward TGAATGCCCATTTTACTCTTTG 
SCN2A_Ex10_R Reverse GTGGAAGGCGGTTTTCTCTC 
SCN2A_Ex11_F Forward GTCATCAGAGGGGTGCTTTC 
SCN2A_Ex11_R Reverse GAACAAACTCCCAGCCTTTG 
SCN2A_Ex12_F Forward GTTGTAGGAATGCTTTGGGC 
SCN2A_Ex12_R Reverse TGAGTTATGCACGGATTTTACTG 
SCN2A_Ex13_F Forward TTCCTCCAGCAGATTAACCC 
SCN2A_Ex13_R Reverse TGCTAAACATTTGATGTCAAGATATAC 
SCN2A_Ex14_F Forward AGATACTAAGTTGTTGGACCTAAACC 
SCN2A_Ex14_R Reverse CATTTGGTGGTATGGCAATC 
SCN2A_Ex15_F Forward GACAGTTACCTGTACATTTGCCC 
SCN2A_Ex15_R Reverse AGACAATAGGAAGTGGCCTTG 
SCN2A_Ex16_F Forward TGCATGTTAGAATAAAATAAGGTGTC 
SCN2A_Ex16_R Reverse CTTAACAGGAAGGAAACACGC 
SCN2A_Ex17_F Forward TGCATGTTAGAATAAAATAAGGTGTC 
SCN2A_Ex17_R Reverse CTTAACAGGAAGGAAACACGC 
SCN2A_Ex18_1F Forward TGTGACCCCTGACCTTTACC 
SCN2A_Ex18_1R Reverse CCACAGAAAAGCCAGTTAATAATTTC 
SCN2A_Ex18_2F Forward GTGGGATTGATTTTCAGAAGC 
SCN2A_Ex18_2R Reverse AGATGGTAGACAAATAAACAGACATTT 
SCN2A_Ex19_F Forward AATAATGTAAATGAATCTCCCACC 
SCN2Aex19_R Reverse TGGGTAATATGAGTTGATTGAAGG 
SCN2Aex20_F Forward AACCTTCCAGCCTTAGGCAC 
SCN2Aex20_R Reverse ACTGTGTCAGGCACCATTGC 
SCN2Aex21_F Forward CATTGCATAGAGCAAGGCTG 
SCN2Aex21_R Reverse TGCCAAGTATTATGGGCATC 
SCN2Aex22_F Forward AAAATTCTTAGTTGGAGCTACCAGAG 
SCN2Aex22_R Reverse ACATCCCTGCCAACAATG 
SCN2Aex23_F Forward AAAACATTGCCCCAAAAGTG 
SCN2Aex23_R Reverse ACAGAGTGATTAGAGAAAATCATCC 
SCN2Aex24_F Forward TTCATTCCAGAGATTAAAACATGC 
SCN2Aex24_R Reverse TGCATTTTGGAGGCTAAAGG 
SCN2Aex25_F Forward ATGTGGGAGCCAATTTTCAC 
SCN2Aex25_R Reverse TTCTAGAAATTCGGGCTGTG 
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SCN2Aex26_F Forward TTGTTGCTTTCTTAAAATCAGAAG 
SCN2Aex26_R Reverse GGGAGTTTGGGATGAATGAG 
SCN2Aex27_F Forward GGACCTTCCAGGGTTGAGTC 
SCN2Aex27_R Reverse GATGGGTGTTCCATCACATTC 
   
GABRG2   
GABRG2_Ex1_F Forward ccacgcatgtgttaattcgt 
GABRG2_Ex1_R Reverse aattgtaaagccgcacatcc 
GABRG2_Ex2_F Forward cacaaccctcaagggagaat 
GABRG2_Ex2_R Reverse tccttgctcttgaactacactga 
GABRG2_Ex3_F Forward aactggtaccaaattagttgtgaat 
GABRG2_Ex3_R Reverse ttttgctggcatgtcttttg 
GABRG2_Ex4_F Forward ttggcaaagaaaacaggaatg 
GABRG2_Ex4_R Reverse caaccctgatgcagtcttga 
GABRG2_Ex5_F Forward tgtgttttcaatcagaatgtgaga 
GABRG2_Ex5_R Reverse tttgaaatttgttatgcttctttca 
GABRG2_Ex6_F Forward cctttggtccaagatcctca 
GABRG2_Ex6_R Reverse ttttctgattatcattcattgagagg 
GABRG2_Ex7_F Forward cgggcaaaaatagttttcaa 
GABRG2_Ex7_R Reverse ttgcaggctaaatttaaagca 
GABRG2_Ex8_F Forward gaaactgcccatcagaagtca 
GABRG2_Ex8_R Reverse ctgagccttagcctgcagat 
GABRG2_Ex9_F Forward tttcacttactgtgttttcaaaatg 
GABRG2_Ex9_R Reverse tgcttaaatgtctactcataaaacaaa 
GABRG2_Ex10_F Forward cacattggtgacattgtgga 
GABRG2_Ex10_R Reverse GGGCTTTCACTGTTTTATTTGC 
   
KCNQ3   
KCNQ3_Ex1_F Forward gacaggctgaggctggaac 
KCNQ3_Ex1_R Reverse gcatccatgggtcttaaagc 
KCNQ3_Ex2_F Forward caatgtccagcagaagttgc 
KCNQ3_Ex2_R Reverse caaccagtcagggaggagtg 
KCNQ3_Ex3_F Forward accagcaacagcacaaaatg 
KCNQ3_Ex3_R Reverse gcgtgatttcccagaatagc 
KCNQ3_Ex4_F Forward ccagcaaacagcacctatga 
KCNQ3_Ex4_R Reverse atcaagggtggcagaatgac 
KCNQ3_Ex5_F Forward gaccacagtcacagagctggt 
KCNQ3_Ex5_R Reverse agctgcctggctgaacat 
KCNQ3_Ex6_F Forward caagctgatggagaggctta 
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KCNQ3_Ex6_R Reverse aagatgacactggaaagttgagc 
KCNQ3_Ex7_F Forward gcaattgagccctacagtcc 
KCNQ3_Ex7_R Reverse tgcacacatgcacacataca 
KCNQ3_Ex8_F Forward ggagtccagggcttaaacatt 
KCNQ3_Ex8_R Reverse tgccctgaagagtgttctcc 
KCNQ3_Ex9_F Forward gagagaagctttgcagcaatc 
KCNQ3_Ex9_R Reverse caacagtgtgaccccaaaga 
KCNQ3_Ex10_F Forward ccttggaggagaatgtgtgag 
KCNQ3_Ex10_R Reverse ttaagtgggcaaagggagag 
KCNQ3_Ex11_F Forward gcgtggaaggctttgacc 
KCNQ3_Ex11_R Reverse cccttcccaaagtgcaagat 
KCNQ3_Ex12_F Forward cctgccctggagtttgcta 
KCNQ3_Ex12_R Reverse tgttggcctagacatccaca 
KCNQ3_Ex13_F Forward attccaaacccttatctcattct 
KCNQ3_Ex13_R Reverse cataaaggaccccagcagag 
KCNQ3_Ex14_F Forward ggtgagaacgatggctctgt 
KCNQ3_Ex14_R Reverse cagagtgaaccttcgtcttaaaaa 
KCNQ3_Ex15_F Forward tttcctcccaaccaatagca 
KCNQ3_Ex15_R Reverse CACTTTGTTGTGGTGACATGG 
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Appendix E: PCR protocols and conditions for amplification of seven candidate genes. 
 
PCR conditions for SCN2A 
  All exons except exon 20:       Exon 20       
  Temperature Duration      Temperature Duration    
1 94°C 5 min    1 94°C 10 min    
2 94°C 45 s 
} 
  2 94°C 45 s 
} 
  
3 60°C 45 s 
 
repeat 20 times 3 60°C 45 s repeat 35 times 
  -0.5°C per cycle    4 72°C 45 s   
4 72°C 45 s   5 72°C 10 min    
5 94°C 30 s 
} 
  6 8°C ∞    
6 50°C 45 s repeat 16 times        
7 72°C 45 s          
8 72°C 10 min           
9 8°C ∞               
 
  
PCR protocol for SCN2A 
  x1 
10x buffer 2 µl 
dNTPs (10mM each) 0.25 µl 
F-primer (5µM) 1,3 µl 
R-primer (5µM) 1,3 µl 
H20 13.95 µl 
Taq 0.2 µl 
 =19 µl 
+DNA 50 ng 1 µl 
    =20µl/rxn 
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PCR conditions for SCN1A 
  All exons except exon 1:       Exon 1:       
  Temperature Duration      Temperature Duration    
1 94°C 5 min    1 94°C 10 min    
2 94°C 45 s 
} 
  2 94°C 45 s 
} 
  
3 60°C 45 s 
 
repeat 20 times 3 60°C 45 s repeat 35 times 
  -0.5°C per cycle    4 72°C 45 s   
4 72°C 45 s   5 72°C 10 min    
5 94°C 30 s 
} 
  6 8°C ∞    
6 50°C 45 s repeat 16 times        
7 72°C 45 s          
8 72°C 10 min           
9 8°C ∞               
  
PCR protocol for SCN1A 
  x1 
10x buffer 1.5 µl 
dNTPs (10mM each) 0.375 µl 
F-primer (5µM) 0.5 µl 
R-primer (5µM) 0.5 µl 
H20 9.75 µl 
Taq 0.15 µl 
 =14 µl 
+DNA 50 ng 1 µl 
    =15µl/rxn 
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PCR conditions for SCN1B 
  All exons except exon 1:       Exon 1:       
  Temperature Duration      Temperature Duration    
1 94°C 5 min    1 94°C 10 min    
2 94°C 45 s 
} 
  2 94°C 45 s 
} 
  
3 60°C 45 s 
 
repeat 20 times 3 60°C 45 s repeat 35 times 
  -0.5°C per cycle    4 72°C 45 s   
4 72°C 45 s   5 72°C 10 min    
5 94°C 30 s 
} 
  6 8°C ∞    
6 50°C 45 s repeat 16 times        
7 72°C 45 s          
8 72°C 10 min           
9 8°C ∞               
  
PCR protocol for SCN1B 
  x1 
10x buffer 1.5 µl 
dNTPs (10mM each) 0.375 µl 
F-primer (5µM) 0.5 µl 
R-primer (5µM) 0.5 µl 
H20 9.75 µl 
Taq 0.15 µl 
 =14 µl 
+DNA 50 ng 1 µl 
    =15µl/rxn 
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Appendix F 
Candidate genes represented as exons and introns with relative sizing. Shaded blocks indicate exons and lines between blocks 
indicate introns. Unshaded blocks indicate untranslated regions. Strand and base pair size is also indicated on each diagram. 
 
SCN1A 
 
 
SCN1B 
 
 
SCN2A 
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GABRA1 
 
 
KCNQ2 
 
 
GABRG2 
 
 
KCNQ3 
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Appendix G 
DNA Extraction Method, derived from: 
A simple salting out procedure for extracting DNA from human nucleated cells 
S.A.MWer, D.D.Dykes and H.F.Polesky 
 
This method involves salting out of the cellular proteins by dehydration and precipitation with a 
saturated NaCl solution. 
 
Buffy coats of nucleated cells obtained from anticoagulated blood (ACD or EDTA) were 
resuspended in 15 ml polypropylene centrifugation tubes with 3 ml of nuclei lysis buffer (10 mM 
Tris-HClt 400 mM NaCl and 2 mM Na2EDTA, pH 8.2).  
 
The cell lysates were digested overnight at 37°C with 0.2 ml of 10Z SDS and 0.5 ml of a 
protease K solution (1 mg protease K in 1Z SDS and 2 mM Na2EDTA).  
 
After digestion was complete, 1 ml of saturated NaCl (approximately 6M) was added to each 
tube and shaken vigorously for 15 seconds, followed by centrifugation at 2500 rpm for 15 
minutes.  
 
The precipitated protein pellet was left at the bottom of the tube and the supernatant containing 
the DNA was transferred to another 15 ml polypropylene tube.  
 
Exactly 2 volumes of room temperature absolute ethanol was added and the tubes inverted 
several times until the DNA precipitated.  
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The precipitated DNA strands were removed with a plastic spatula or pipette and transferred to a 
1.5 ml microcentrifuge tube containing 100-200 pi TE buffer (10 mM Tris-HCl, 0.2 mM 
Na2EDTA, pH 7.5).  
 
The DNA was allowed to dissolve 2 hours at 37°C before quantitating.  
 
The 260/280 ratios were consistently 1.8-2.0, demonstrating good deproteinization. 
